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ABSTRACT 
Introduction 
The effects of intravenous lipid emulsions containing fish oil in critically ill patients have not been 
studied widely and show conflicting results. This study compared the effects of a 4-oil lipid 
emulsion (SMOFlipid®) with a 100% soybean-based lipid emulsion in terms of biochemical 
parameters, inflammatory mediators, plasma total phospholipid fatty acid (FA) composition, 
sequential organ failure assessment (SOFA) score, gas exchange and clinical outcomes in patients 
with the systemic inflammatory response syndrome (SIRS) with or without sepsis.   
Design 
Double blind, randomised, single-centre study. 
Method 
Seventy-five patients predicted to need parenteral nutrition (PN) for ≥ five days were randomised 
to receive either a 4-oil lipid emulsion (Study Group (SG)) or a 100% soybean lipid emulsion 
(Control Group (CG)). Isocaloric, isonitrogenous PN was administered continuously. Routine 
biochemical measurements and gas exchange were assessed. SOFA score was calculated and 
plasma cytokines and total phospholipid FA composition was analysed. 
Results 
Both groups were well matched for baseline characteristics, but the SG had a trend to a higher 
mean APACHE II score (13.7 ± 7.5 versus 11.2 ± 8.1, p=0.19). 
The nutritional intakes did not differ, except the SG received fish oil (FO), eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA), and increased amounts of α-tocopherol and reduced 
amounts of phytosterols.  
Triglycerides and Gamma-glutamyl transferase (GGT) levels increased in both groups. Bilirubin 
levels decreased in both groups between day 1 and 3 and then continued to decrease in the SG, 
but increased significantly in the CG after day 3. Concentrations of TNF-α decreased from day 1 to 
day 6 in the SG, whereas they increased in the CG, but the difference was not significant. 
Concentrations of interleukin-1β (IL-1β) and IL-6 decreased in the SG during the intervention and 
increased in the CG after day 3; however the difference was not significant at day 6. IL-10 
concentrations decreased in both groups between day 1 and day 3, but increased from day 3 to 
day 6 in the SG. This difference was not significant (p=0.972). 
Multiple positive changes in plasma total phospholipid FA percentages were demonstrated. 
Plasma EPA showed a significant increase in the SG (p<0.001). The n-6 polyunsaturated fatty acid 
(PUFA):n-3 PUFA ratio decreased in the SG and remained fairly constant in the CG. 
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A significant correlation was found for day 3 EPA intake and improvement in SOFA score. Days on 
mechanical ventilation and ICU LOS were not different between the two groups. 
Conclusion 
The results of this study suggest that PN containing a 4-oil LE with FO at a dose of 0.09 – 0.22g/kg 
in patients with SIRS, with or without sepsis, was associated with multiple changes in the plasma 
total phospholipid FA composition and a tendency to reduce plasma TNF-α and liver enzymes. 
There was no significant difference in terms of SOFA score, length of ICU stay and mortality. 
Additional studies need to be done in this patient population paying particular attention to the 
dose, duration and timing of FO and EPA per day and their effect on clinical outcomes. 
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OPSOMMING 
Inleiding 
Die uitwerking van intraveneuse lipiedemulsies (LE) wat visolie  bevat is nie uitgebreid by krities 
siek pasiënte bestudeer nie en toon teenstrydige resultate. Hierdie studie het die uitwerking van 'n 
4-olie lipiedemulsie (SMOFlipid®) met 'n 100 % sojaboon-gebaseerde lipiedemulsie vergelyk m.b.t. 
biochemiese parameters, inflammatoriese mediators, samestelling van totale fosfolipied- vetsuur 
(VS) in plasma, evaluering van opeenvolgende orgaanversaking (OOV)-telling, gaswisseling en 
kliniese uitkomste by pasiënte met sistemiese inflammatoriese responssindroom (SIRS), met of 
sonder sepsis.   
Ontwerp 
Dubbelblinde, ewekansige, enkel sentrum studie 
Metode 
Vyf-en-sewentig pasiënte by wie daar die behoefte voorspel was vir parenterale voeding (PV) van 
vyf dae, is ewekansig toegewys om óf 'n 4-olie lipiedemulsie (studiegroep (SG)), of 'n 100 % 
sojaboon-lipiedemulsie (kontrolegroep (KG) te ontvang. Isokaloriese, isonitrogene PV is 
deurlopend toegedien. Roetine biochemiese metings en gaswisseling is ondersoek. OOV -telling is 
bereken en plasma sitokiene en totale fosfolipied VS samestelling is ontleed. 
Resultate 
Beide groepe het goed ooreengekom betreffende hul  basislyn eienskappe, maar die SG het 'n 
neiging gehad tot 'n hoër gemiddelde APACHE II - telling (13.7 ± 7.5 teenoor 11.2 ± 8.1, p = 0.19). 
Die voedingsinnames het nie verskil nie, behalwe dat die SG visolie (VO), eikosapentaenoësuur 
(EPA) en dokosaheksaenoësuur (DHA), meer α-tokoferol en minder fitosterole ontvang het.  
Trigliseriede en gamma-glutamieltransferase (GGT) vlakke het by beide groepe toegeneem. 
Bilirubienvlakke het by albei groepe tussen Dag 1 en 3 verlaag en toe aangehou om te daal by die 
SG, maar het beduidend gestyg by die KG na Dag 3. Konsentrasies van TNF-α het van Dag 1 tot Dag 
6 in die SG gedaal, terwyl dit in die KG toegeneem het, maar die verskil was nie beduidend nie. 
Konsentrasies van interleukien-1β (IL-1β) en IL-6 het met die ingryping by die SG gedaal en na Dag 
3 by die KG toegeneem, maar die verskil was nie beduidend op Dag 6 nie. IL-10 konsentrasies het 
by beide groepe tussen Dag 1 en Dag 3 afgeneem, maar toegeneem vanaf Dag 3 tot Dag 6 in die 
SG. Hierdie verskil was nie beduidend nie (p=0.972). 
Veelvuldige positiewe veranderinge in die plasma se totale fosfolipied VS persentasies is 
aangetoon. Plasma EPA het 'n beduidende toename in die SG getoon (P<0.001). Die n-6 poli-
onversadigde VS (POVS): n-3 POVS -verhouding het by die SG afgeneem en het redelik konstant by 
die KG gebly. 
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'n Beduidende korrelasie was aangetoon vir Dag 3 EPA inname en verbetering in OOV-telling. Dae 
op meganiese ventilasie en intensiewesorg eenheid (ISE) LVV het nie verskil tussen die twee 
groepe nie. 
 
Gevolgtrekking 
Die resultate van hierdie studie dui daarop dat PV wat 'n 4-olie LE met VO teen 'n dosis van 0,09 - 
0,22 g/kg by pasiënte met SIRS met of sonder sepsis bevat, verband hou met veelvuldige 
veranderinge in plasma totale fosfolipied vetsuur samestelling en ŉ neiging tot ŉ verlaging in 
plasma TNF-α and lewerensieme. Daar was geen beduidende verskil in terme van die OOV –telling, 
lengte van ISE verblyf asook mortaliteit nie. Bykomende studies moet by hierdie pasiëntpopulasie 
gedoen word, met spesiale aandag aan die dosis, duur en tydsberekening van VO en EPA per dag 
en die uitwerking daarvan op kliniese uitkomste. 
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DEFINITION OF TERMS 
Acute Respiratory 
Distress Syndrome 
Berlin Definition   
 Timing:  Within 1 week of a known clinical insult of new or 
worsening respiratory syndrome 
 Chest imaging:  Bilateral opacities – not fully explained by 
effusions, lobar/lung collapse, or nodules  
 Origin of oedema: Respiratory failure not fully explained by 
cardiac failure or fluid overload. Need objective assessment 
(e.g. echocardiography) to exclude hydrostatic oedema if no 
risk factor present 
 Oxygenation:  
o Mild        200mmHg<PaO2/FiO2 ≤300mmHg with 
PEEP or CPAP ≥5cmH2O 
o Moderate 100mmHg<PaO2/FiO2 ≤200mmHg with 
PEEP  ≥5cmH2O 
o Severe       PaO2/FiO2 ≤100mmHg with PEEP ≥5cmH2O 
(1) 
 APACHE II score  A scoring system for use in ICU patients to assess the severity of 
disease and provide an estimation of in-hospital mortality (2) 
Nutrition Therapy The provision of nutrients via an artificial route, i.e. enteral and/or 
parenteral nutrition (3). Nutrient provision is no longer regarded as 
supportive care in ICU, but rather as therapeutic intervention (4)  
Parenteral Nutrition Provision of nutrients intravenously (5) 
RIFLE criteria Classification scheme for acute renal failure which includes separate 
criteria for creatinine and urine output. RIFLE is Risk of renal 
dysfunction, Injury to the kidney, Failure of kidney function, Loss of 
kidney function and End-stage kidney disease (6). 
Sepsis-3  Sepsis is a life-threatening organ dysfunction caused by a 
dysregulated host response to infection. Organ dysfunction can be 
identified as an acute change in total (SOFA) score ≥ 2 points. 
Septic shock is defined as a subset of sepsis in which particularly 
profound circulatory, cellular, and metabolic abnormalities are 
associated with a greater risk of mortality than with sepsis alone (7)  
Sepsis  The systemic inflammatory response syndrome (SIRS) in the 
presence of infection (8) 
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Septic Shock The presence of severe sepsis and haemodynamic instability despite  
adequate fluid resuscitation  
Severe Sepsis The presence of sepsis / SIRS with one or more organ dysfunction (8) 
SIRS A clinical syndrome that can be caused by a variety of insults, 
including infection, severe trauma, pancreatitis, burn injury and 
ischaemia. It is characterised by fever, tachycardia, tachypnoea, and 
an elevated white cell count as well as organ dysfunction and 
hypotension in severe cases (8) 
SOFA The Sequential/Sepsis-Related Organ Failure Assessment assesses 
the incidence and severity of organ dysfunction in critically ill 
patients (9)  
qSOFA Developed to rapidly identify adults with suspected infection 
following clinical criteria; respiratory rate of ≥22/min, altered 
mentation or systolic blood pressure of ≤100mmHg (7) 
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CHAPTER 1 
INTRODUCTION AND MOTIVATION 
1.1  Significance of the study 
Critical illness is a multisystem process that can result in significant morbidity and mortality. In 
most patients, critical illness is preceded by a physiological deterioration, characterised by a 
catabolic state and intense metabolic changes, resulting in malnutrition and impaired immune 
functions (1). The metabolic response to stress has several clinical consequences, from changes in 
metabolic rate to use of macronutrients as energy sources, stress hyperglycaemia, muscle wasting, 
changes in body composition and behavioural changes (2). 
The inflammatory response to infection or injury is extremely complex. Even though it is a normal 
response following an insult, it can become uncontrolled, leading to additional tissue damage and 
multi-organ failure (MOF) (3). This response is initiated by activation of the innate immune system 
by pro-inflammatory stimuli such as DAMPs (damage-associated molecular patterns) and PAMPs 
(pathogen-associated molecular patterns) (4). The inflammatory process involves the release of 
pro- and anti-inflammatory cytokines. The pro-inflammatory cytokines released, includes the 
following cytokines tumour necrosis factor alpha (TNF-α), interleukin (IL)-1, IL-6 and IL-8, impair 
some of the body’s physiological functions and play pivotal roles in the metabolic changes 
associated with sepsis (2, 5). To balance and control inflammation, coexistent anti-inflammatory 
cytokines, IL-10 and IL-13, are produced in synchrony with pro-inflammatory ones (6). 
Nutritional needs in the critically ill are poorly understood and vary with the phase of critical 
illness. Goals of nutrition therapy focus on attenuating the metabolic response to stress, 
preventing oxidative cellular injury, and favourably modulating the immune response (7). This 
includes providing adequate nutrition therapy, preventing any nutritional deficiencies, preserving 
lean body mass, maintaining glucose control, avoiding metabolic complications, decreasing 
infectious complications, and improving clinical outcomes (8).  
Intravenous lipid emulsions (IVLE) in patients on parenteral nutrition (PN) not only are the main 
source of energy and fatty acids (FA) but remain associated with the development of adverse 
effects. Different types of lipid emulsions (LEs) have different effects on haematological tests and 
metabolic functions, including inflammatory and immune response, coagulation, and cell 
signalling. These effects appear to be based on complex modifications in the composition and 
structure of cell membranes, through eicosanoid and cytokine synthesis and by modulation of 
gene expression. Pro-inflammatory properties of omega-6 polyunsaturated fatty acids (PUFAs) 
have been associated with poor clinical outcomes and have led to the development of newer- 
generation IVLE. There is clinical data suggesting that omega-3 polyunsaturated fatty acids 
(PUFAs), particularly fish oil, have beneficial effects on the immune system and organ function and 
improve clinical outcomes in surgical and acute respiratory distress syndrome (ARDS) patients. In 
addition, there is some promising data on their use in septic patients (9-11). The focus of this 
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research was to compare two different lipid emulsions (LEs) in critically patients requiring 
parenteral nutrition (PN). 
To date there is no study looking at the use of a combination 4-oil lipid emulsion containing fish oil 
(SMOFlipid®) in septic patients. This lipid emulsion’s efficacy and safety have been proved in 
paediatrics and in surgical patients; however there is limited data in septic patients. In South 
Africa, this LE is frequently used in intensive care units (ICUs) and it would thus be beneficial to 
have data showing improved oxygenation, reduced inflammation and improved outcome in this 
group of patients. 
This thesis includes a comprehensive literature review, including a literature review which has 
been published in the South African Journal of Clinical Nutrition, a chapter discussing the 
methodology and an introduction to the results. The main result section is written as two 
manuscripts. The final chapter includes a discussion. Because this document is based on two 
manuscripts, the references are at the end of each chapter.  
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CHAPTER 2 
LITERATURE REVIEW 
This literature review focuses on the administration of different lipid emulsions, in particular 
omega-3 polyunsaturated fatty acids (PUFAs) via the parenteral nutrition route, in critically ill adult 
patients. The clinical consequences associated with critical illness as well as the administration of 
different intravenous lipid emulsions is addressed, focusing on how omega-3 PUFAs can attenuate 
inflammation to improve outcomes and reduce complications associated with the administration 
of parenteral nutrition. 
 
2.1  Sepsis and the critically ill patient 
Sepsis remains a common problem in critically ill patients. The incidence of sepsis is greater than 
500 000 cases per year in the United States. The reported prevalence rates of the systemic 
inflammatory response syndrome (SIRS) in critically ill patients range from 20% to 60%., 
Approximately 40% of patients with sepsis may develop septic shock (12). Severe sepsis and septic 
shock have high mortality rates and are the leading cause of death in ICUs (13). Over the last 
decade, in-hospital mortality following severe sepsis has been reduced. Furthermore, mortality 
from acute lung injury has fallen dramatically (14). However, still more than 10 million people die 
annually of infection, according to the recent report by the Global Burden of Disease (15).  
 
2.1.1  Definitions of sepsis 
Infection induces sepsis, which is a syndrome of physiologic, biochemical and pathologic 
abnormalities (16). A consensus conference in 1991 (17) and 2001 (18) developed definitions for 
SIRS, sepsis, severe sepsis and septic shock (Table 2-1). These definitions have remained largely 
unchanged for more than two decades. 
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Table 2-1: Definition of sepsis (17, 18) 
Diagnosis of SIRS – the presence of two or more of the following:  
 Temperature >38 oC or <36 oC,  
 Heart rate >90 bpm,  
 Respiratory rate > 20 bpm or PaCO2 <32 mmHg, and/or  
 White blood count >12 000/mm3, <4000/mm3)  
 
Sepsis: defined as suspected or proven infection plus SIRS.  
Severe sepsis: defined as sepsis with organ dysfunction (hypotension, hypoxaemia, 
oliguria, metabolic acidosis and/or thrombocytopaenia). 
Septic shock: defined as severe sepsis with hypotension despite adequate fluid 
resuscitation (17,18).  
 
However, in 2014, the European Society of Intensive Care Medicine and the Society of Critical Care 
Medicine convened a task force to re-examine the above definition and proposed a new definition 
of sepsis, termed Sepsis-3 (Table 2-2). The task force recommended the use of Sequential (Sepsis-
related) Organ Failure Assessment (SOFA) scoring to define the organ dysfunction of a potentially 
septic patient. The SOFA score is discussed in more detail in scoring systems. 
Table 2-2: Sepsis-3 Terms and Definitions (16) 
 Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host 
response to infection. 
 Organ dysfunction can be identified as an acute change in total (SOFA) score ≥ 2 points.  
 Septic shock is defined as a subset of sepsis in which particularly profound circulatory, 
cellular, and metabolic abnormalities are associated with a greater risk of mortality than 
with sepsis alone. Clinically identified as: 
o Vasopressor requirement to maintain a mean arterial pressure (MAP) ≥65 mm Hg. 
o Serum lactate level > 2mmol/L in the absence of hypovolaemia.  
 
 
Owing to the complexity of the SOFA score, the use of Sepsis-3 in practice may prove to be 
impractical. Thus, the task force described an easier method, quick SOFA (qSOFA), to facilitate the 
identification of patients potentially at risk of dying of sepsis outside the ICU. The qSOFA only has 
3 components that are each allocated 1 point. A qSOFA score ≥ 2 points to a high probability of 
death or deterioration requiring ICU (19). This is discussed in more detail under the scoring 
systems section. 
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The above definition was not used in this research project as the original protocol was written in 
2012; however the SOFA score was calculated for each patient. 
 
2.1.2  Metabolic response to sepsis and critical illness 
The metabolic response to stress is part of an adaptive response to survive critical illness and 
restore homeostasis as rapidly as possible to survive the injury. Sir David Cuthbertson described 
several phases of the metabolic response over time, including the ‘ebb’ phase and the ‘flow’ 
phase. More recently, the chronic or post-injury phase has been added as a third sequence, 
frequently encountered in the Intensive Care Unit (ICU) (2). The ebb phase occurs several hours 
after the injury, and lasting for 12 to 24 hours, consists of reductions in cardiac output, oxygen 
consumption (VO2), the basal metabolic rate, and glucose tolerance. The flow phase lasts for 3–8 
days, depending on injury severity. It is characterised by increases in cardiac output, respiratory 
rate, VO2, hyperglycaemia, skeletal muscle catabolism, and a negative nitrogen balance (20). The 
post injury or anabolic phase lasts for some weeks, as protein and fat stores are restored and 
weight regained (5).  
The metabolic response to stress involves a neuroendocrine and an inflammatory component. 
Hormones released from the adipose tissue and from the gastrointestinal tract (GIT) can also play 
an important role in this response. The sympathetic nervous system (SNS) is activated when a 
stressor is detected and is involved in the activation of adrenergic receptors resulting in the 
immediate release of norepinephrine and epinephrine into the bloodstream (2). The activation of 
the hypothalamus–pituitary axis results in the release of adrenocorticotropic hormone, thyroid-
stimulating hormone, growth hormone, follicle-stimulating hormone, and luteinising hormone by 
the anterior pituitary gland. The circulating levels of hormones released from peripheral glands are 
decreased in response to this, with the exception of cortisol. Cortisol is a catabolic hormone that 
mobilises energy stores. It promotes gluconeogenesis in the liver, leading to raised blood glucose 
levels (2, 20).   
During the chronic phase, the plasma levels of both pituitary factors and peripheral hormones are 
lowered; however, a peripheral resistance to the effects of growth hormone, insulin, thyroid 
hormone, and cortisol persists. These hormonal alterations affect the energy, protein and fat 
metabolism (2) resulting in negative nitrogen balance, weight loss and hyperglycaemia (5). 
The inflammatory component is partially regulated by the central nervous system via cytokines 
and inflammatory mediators. Inflammation is triggered when innate immune cells detect tissue 
injury or infection. Surveillance mechanisms involve pattern recognition receptors (PRRs) in the 
cytoplasm and on the cell surface. These receptors detect, either directly or indirectly, pathogen-
associated molecular patterns (PAMPs) or host-derived damage-associated molecular patterns 
(DAMPs) released by injured cells and respond by triggering activation of NF-ĸB and other 
transcription factors promoting pro-inflammatory and profibrotic pathways (4). The inflammatory 
process involves the release of pro- and anti-inflammatory cytokines. Anti-inflammatory cytokines 
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act to localise and prevent overexuberant inflammation; it is the loss of this local control that leads 
to SIRS, Multi-Organ Dysfunction Syndrome (MODS), shock, and death (6).  
The pro-inflammatory cytokines released, includes the following cytokines, tumour necrosis factor 
alpha (TNF-α), interleukin (IL)-1, IL-6 and IL-8, impair some of the body’s physiological functions 
and play pivotal roles in the metabolic changes associated with sepsis. They initiate the acute 
phase response, recruit reticulo-endothelial cells (lymphocytes, macrophages and monocytes), 
promote wound repair and induce the production of other cytokines (2,5). To balance and control 
inflammation, coexistent anti-inflammatory cytokines, IL-10 and IL-13, are produced in synchrony 
with pro-inflammatory ones (6). In addition to typical clinical signs of sepsis, like fever and 
lethargy, these cytokines also induce weight loss, proteolysis and lipolysis. They also trigger 
anorexia at the hypothalamic level (2).  
Levels of TNF-α and IL-6, have consistently been shown to correlate with the mortality and poor 
outcome following severe injury and sepsis. Both TNF-α and IL-10 levels are associated with 
mortality (6). Levels of these cytokines were measured during the first 6 days in ICU in this 
research project.   
Adipokines are also released from the different cell types of fat tissue and are being investigated 
as potential contributors to metabolic changes related to sepsis. The role played by hormones 
released by the gut is also under investigation, indicating that circulating levels of ghrelin are 
mostly decreased, while levels of cholecystokinin and peptide YY are increased. These changes 
have been related to anorexia, which is a common behavioural adaptation to stress (2). 
Recently, the term ‘persistent inflammation, immunosuppression, and catabolism syndrome’ 
(PICS) has been used to describe the most recently observed phenotype of chronic multi-organ 
failure (MOF). Patients with PICS experience prolonged low-grade inflammation and catabolism 
with resultant loss of lean body mass (LBM). The PICS paradigm is as follows: following a major 
inflammatory insult (sepsis, trauma, burns, acute pancreatitis, etc) there are simultaneous 
inflammatory (SIRS) and anti-inflammatory (compensatory anti-inflammatory response syndrome) 
responses. In some cases, the SIRS becomes overwhelming, leading to early MOF and death. 
Fortunately, modern ICU care is directed at early recognition of shock and treatment. If patients 
do not die of early MOF, there are two possible pathways. Either their abnormal immunology 
rapidly recovers, immune homeostasis is achieved and they recover, or immunologic dysfunction 
persists and they enter chronic critical illness (CCI), defined as > 14 days in the ICU with organ 
dysfunction. These patients with CCI experience ongoing immunosuppression and inflammation 
associated with a persistent acute phase response (e.g. high C-reactive protein) with ongoing 
protein catabolism. Despite aggressive nutrition intervention, there is a remarkable loss of LBM 
associated with a proportional decrease in functional status and poor wound healing (3). 
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2.1.3  Role of autophagy in sepsis 
Autophagy acts as a survival mechanism under conditions of stress, maintaining cellular integrity 
by regenerating metabolic precursors and clearing subcellular debris. This process contributes to 
basal cellular and tissue homeostasis. Autophagy participates in the turnover of mitochondria and 
other organelles and is involved in the clearance of polyubiquitinated protein aggregates which 
accumulate during stress and disease. Autophagy has also been implicated as a regulator of lipid 
metabolism. It acts primarily as a protective mechanism that may prevent cell death (21).  
During infection, autophagy assists in the immune response by degrading intracellular bacteria 
and viruses. It contributes to the suppression of inflammation, including the down-regulation of 
both interferon and pro-inflammatory cytokines, through the preservation of mitochondrial 
function (21). 
In an animal model, the administration of parenteral nutrition (PN), in particular protein and lipids 
rather than glucose, in the early phase of critical illness evoked a phenotype of autophagy 
deficiency in the liver and skeletal muscle (22) and is thought to increase muscle weakness and 
impair the recovery thereof (23). Current therapeutic targeting of autophagy is limited by an 
incomplete understanding of how the process contributes to pathogenesis, the lack of specificity 
of compounds that can influence autophagy, and the clinical efficacy. An improved understanding 
of the mechanism by which autophagy can prevent pathogenesis may lead to the identification of 
new targets for both diagnostic and therapeutic approaches (21). 
 
2.1.4  Scoring systems 
Various scoring systems have been developed in the ICU to predict patient outcome, comparing 
quality of care and stratification for clinical trials. Even though disease severity scores are not the 
key elements of treatment, they are, however, an essential part of improvement in clinical 
decisions and in identifying patients with unexpected outcomes. Accurate diagnostic criteria and 
consensus definitions have an important role in adult intensive care medicine, providing tools for 
research, benchmarking, performance monitoring and accreditation (24). 
The APACHE II was developed in 1985 and is a severity of disease classification system. It uses a 
points system based upon values of 12 routine physiologic measurements (taking the worst 
measurements during the first 24 h after stabilisation), age and previous health status to provide a 
general measure of severity of disease. An integer score from 0 to 71 is then computed based on 
these measurements: higher scores imply a more severe disease and a higher risk of death (see 
Appendix A: APACHE II score) (24, 25).  
The Sequential (or sepsis-related) Organ Failure Assessment (SOFA) assesses the incidence and 
severity of organ dysfunction in critically ill patients (Table 2-3). It is a simple, effective method to 
describe organ dysfunction and/or failure in critically ill patients. Regular, repeated scoring 
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enables patient disease development and condition to be monitored (26) (Table 2-4). Recently, the 
Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) was published. 
Sepsis-3 emphasised the value of a change of 2 or more points in the SOFA score, which was 
associated with an in-hospital mortality rate greater than 10%. They also introduced quick SOFA 
(qSOFA), where adults out of hospital, in emergency departments or general hospital ward 
settings, with suspected infection, can be rapidly identified as being more likely to have poor 
outcomes typical of sepsis if they have at least 2 of the following clinical criteria: respiratory rate 
of 22/min or greater, altered mentation, or systolic blood pressure of ≤100mmHg (16). 
Table 2-3: Sequential (sepsis-related) Organ Failure Assessment Score (26)  
SOFA Score 0 1 2 3 4 
        
 With respiratory support 
  
Respiration 
PaO2/FiO2 
mmHg 
> 400 ≤ 400 ≤ 300 ≤ 200 ≤ 100 
Coagulation, 
platelets X 
103/mm3 
> 150 ≤ 150 ≤ 100 ≤ 50 ≤ 20 
Liver, bilirubin 
mg/dl (µmol/l) 
<12 (<20) 1.2–1.9 (20–32) 2.0–5.9  
(33–101) 
6.0–11.9 (102–
204) 
>12.0 (>204) 
Cardiovascular, 
hypotension 
No 
hypotension 
MAP < 70mmHg Dopamine ≤5 
or 
Dobutamine 
(any dose) 
Dopamine >5 or 
ephinephrine 
 (adrenaline)     
≤ 0.1 or 
norepinephrine 
≤ 0.1 
(noradrenaline) 
Dopamine >15 
or ephinephrine 
 (adrenaline)     
> 0.1 or 
norepinephrine 
(noradrenaline)
> 0.1 
Central Nervous 
System GCS 
Score 
15 13–14 10–12 6–9 <6 
Renal, 
creatinine mg/dl 
(µmol/l) or urine 
output 
<1.2 (<110) 1.2–1.9 (110–
170) 
2.0–3.4 
(171–299) 
3.5–4.9 (300–
440) or 
<500ml/day 
>5.0 (>440) or 
<200ml/day 
Abbreviations: PaO2/FiO2: ratio of arterial oxygen partial pressure to fractional inspired oxygen, GCS: 
Glascow Coma Scale. 
 
Sepsis results from a dysregulated inflammatory response to infection and leads to organ 
dysfunction, which is associated with high morbidity and mortality. The use of severity scores in 
the ICU, such as the SOFA score mentioned in Sepsis-3, can help predict in-hospital mortality and 
qSOFA can rapidly identify patients likely to have poor outcomes (19). 
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2.1.5  Signs of sepsis 
Diagnosing sepsis relies on assessing a variety of nonspecific signs, symptoms, examination 
findings and laboratory values. A list of signs and symptoms to be considered in clinical practice is 
tabulated below. Owing to the lack of specificity of some variables and the variable time course 
during which some clinical criteria appear, the diagnosis of sepsis is often more apparent in 
retrospect than during the prospective reality of clinical care. Absolute confirmation of the 
diagnosis is not expected in the early phase of the disease. Blood cultures remain an important 
part of the diagnostic strategy in sepsis (19).  
Table 2-4: Clinical signs of sepsis (19, 27) 
General signs and symptoms 
 Rigors, fever or hypothermia 
 Tachypnoea/respiratory alkalosis 
 Positive fluid balance, oedema 
Generalised haematological/inflammatory reactions 
 Increased (sometimes decreased) white blood cell count 
 Increased inflammatory markers (C-reactive protein, procalcitonin, interleukin-6) 
Haemodynamic alterations 
 Hypotension: low mean or systolic arterial pressure 
 Unexplained tachycardia 
 Increased cardiac output 
 Unexplained high cardiac output/low systemic vascular resistance/high SvO2 
 Altered skin perfusion, decreased capillary refill or mottling 
 Decreased urine output 
 Unexplained hyperlactataemia/increased base deficit 
Signs of organ dysfunction 
 Acute lung injury: arterial hypoxaemia 
 Altered mental status 
 Unexplained alterations in renal function 
 Hyperglycaemia or hypoglycaemia 
 Coagulopathy: Elevated prothrombin or partial thromboplastin time or low platelets 
Unexplained alterations in liver enzymes (hyperbilirubinaemia, transaminitis)  
and    function (INR, ammonia)  
Intolerance of feeding (altered gastrointestinal motility, ileus) 
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2.1.6  Consequences of sepsis 
The inflammatory response to infection or injury is extremely complex. Even though it is a normal 
response following an insult, it can become uncontrolled, leading to additional tissue damage and 
multi-organ failure (MOF) (3).  
Data from recent years reveal as much as 40–50% of mortality occurs after the patient leaves the 
ICU within 12 months of an admission and could occur up to two years after an event. The 
survivors of sepsis often have a reduced quality of life (QoL) owing to long-term physical, 
cognitive, and psychosocial morbidity. Many patients that are placed in nursing homes or 
rehabilitation centres may never return home or to a meaningful quality of life (14, 28, 29). 
 
2.1.6.1  Pulmonary function 
The lungs are frequently affected in patients with sepsis either directly as the focus of infection or 
as part of multiple organ dysfunction. Thus, bacterial pneumonia and acute respiratory distress 
syndrome (ARDS) are the conditions in sepsis that most commonly result in patients requiring 
respiratory support (28).  
ARDS is marked by inflammation, increased permeability of alveolar membranes, and cytokine 
activation. Damage to the endothelium, or lining of the capillary, interferes with alveolar gas 
exchange. The damage causes macrophages to release cytokines, including TNF-α, IL-1β and IL-6, 
inflicting more damage on the alveolar endothelium. Protein levels build, pulling fluid into the 
alveolar spaces and causing non-cardiac pulmonary oedema and reduced surfactant level. 
Normally, surfactant decreases surface tension and allows the alveoli to open easily. In ARDS, the 
oedema and reduced surfactant level compromise gas exchange, causing decreased oxygen and 
increased carbon dioxide in the blood. The result is hypoxaemia, pulmonary hypertension, and 
decreased pulmonary compliance. The persistent production of oxygen-free radicals and 
arachidonic acid inflammatory mediators worsen lung inflammation, oedema and diffuse alveolar 
damage. In later stages of ARDS, progressive alveolitis and fibrosis further decrease pulmonary 
function (30, 31).  
Supportive care should include: 
 Prevention of pulmonary failure in sepsis. 
 Closed-loop control of mechanical ventilation to maintain consistent pressure and flow 
waveforms in the face of changing patient conditions (32) and lung protective ventilation in 
patients with ARDS, maintaining low inspiratory driving pressure, with low tidal volumes, 
with limited airway pressure and high levels of positive end-expiratory pressure (33). 
 Implementation of clinical pathways for rescue therapies for severe hypoxia (28). 
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ARDS patients have a severely compromised nutritional status and nutrition therapy should be 
started as soon as possible (31). Patients with ARDS often require PN with lipid emulsions (LEs) as 
essential components. Besides energy supply, these LEs might display differential modulatory 
effects on lung integrity and inflammation. LEs have an ability to alter cytokine release , to modify 
leukocyte function, and to influence the generation of lipid mediators that display both pro-and 
anti-inflammatory properties (31, 34). This is discussed in more detail in Section 2.3.4.2.2 of this 
review. 
 
2.1.6.2  Liver function 
Acute liver failure was defined by at least two of the following items: (a) bilirubin level of > 43 
µmol/L (b) serum alanine aminotransferase (ALT) concentration of more than twice the upper 
limit, and (c) prothrombin time of > 1.5 times the control value or an international normalised 
ratio (INR) of > 1 (35). During sepsis, liver dysfunction is one of the multiple organ dysfunction 
syndrome (MODS) components and is usually associated with a poor prognosis. The incidence of 
liver dysfunction remains unclear. The liver plays a pivotal role in regulating a wide range of key 
metabolic, homeostatic, and host-defence activities. Shock and initial tissue hypoperfusion could 
contribute to liver dysfunction. The lack of reliable diagnostic tools militates against detection of 
early liver dysfunction (36). 
The liver has a role in bacterial and endotoxin scavenging, detoxification, and synthesising proteins 
for metabolic, coagulation and immune functions. Liver perfusion, which represents 25% of 
cardiac output, is required to ensure the above functions. The portal venous blood flow regulated 
by the hepatic arterial buffer response, compensates for any reduction in portal blood flow. 
During the course of septic shock, the liver contributes actively to tissue repair and host defence 
through cross-talk between hepatic and blood cells. The hepatic cells will shift their metabolic 
pathway towards up-regulation of the inflammatory response, which is responsible for an increase 
in the synthesis of acute-phase proteins mediated predominantly by IL-6. This shift leads to 
increases in fibrinogen, prothrombin, C-reactive protein, α-1-antitrypsin, and haptoglobin levels, 
whereas the hepatic production of albumin, transferrin and antithrombin is decreased. The up-
regulation of the acute-phase proteins inhibits the protein C pathway and results in profound 
changes in pro-coagulant activity in sepsis. Glucose metabolism is also significantly altered owing 
to increases in glycogenolysis and gluconeogenesis, and increased amino-acid uptake during liver 
hypermetabolism (36). 
The Küpffer cells (KCs) are involved in scavenging bacteria and endotoxin. The liver harbours 
approximately 80% of all macrophages in the human body as resident KCs. In the case of 
underlying liver disease, endotoxin clearance is impaired resulting in a higher susceptibility of the 
host to infection. KCs can produce various pro-inflammatory mediators, including TNF-α, acute-
phase proteins and nitric oxide (NO). KCs also interact with blood cell components (platelets, 
erythrocytes and leukocytes), promoting neutrophil recruitment in the sinusoids and enhancing 
Stellenbosch University  https://scholar.sun.ac.za
12 
 
the pro-inflammatory response. Liver microvascular perfusion can become impaired through the 
adhesion of neutrophils to sinusoidal endothelial cells (SECs) , promoting thrombus formation in 
the sinusoids (36). 
Several cytokines can induce hepatocellular dysfunction. TNF-α is considered to be the main 
cytokine of SIRS development and can directly stimulate hepatocytes to induce IL-6 production. IL-
6 is considered the main cytokine implicated in the liver inflammatory response and is also 
produced by SECs, KCs and hepatocytes after liposaccharide (LPS) stimulation. In combination with 
IL-1 and TNF-α, IL-6 is widely involved in the stimulation of acute-phase protein (APP) production 
(36). Lipid mediators such as platelet-activating factor and arachidonic acid metabolites, 
metabolised from n-6 polyunsaturated fatty acids (PUFA), are pro-inflammatory and can promote 
direct liver injury (37).  
The SOFA score uses bilirubin to determine liver dysfunction over the course of sepsis. Using the 
SOFA score, the French EPISEPSIS (EPIdemiology of SEPSIS) study group reported incidences of 
liver dysfunction (hepatic score of 3 or 4) of 46.6% and 6.3% respectively, in 541 patients with 
severe sepsis during the first 24 hours after admission to the ICU (38). In the same patient 
population, with the same score, the PROWESS (Protein C Worldwide Evaluation in Severe Sepsis) 
trial reported incidences of liver dysfunction (hepatic score of 1 or 2) and liver failure (hepatic 
score of 3 or 4) of 35.6% and 2.75% respectively (39). Both the EPISEPSIS study and PROWESS trial 
found that the persistence or development of liver failure after the onset of severe sepsis was 
strongly associated with poor outcome and a lower 28-day survival rate respectively (36). 
 
2.1.6.3  Gut function 
Gut failure or gastrointestinal (GI) dysfunction frequently occurs in seriously ill patients and is 
responsible for bacterial translocation. This could cause sepsis with the initiation of SIRS and 
MODS and/or death. Delayed gastric emptying, abnormal motility patterns, and impaired 
intestinal barrier integrity, are commonly observed in the ICU. It has been recognised that a 
functional gastrointestinal tract (GIT) is an important factor in clinical outcome of patients in the 
ICU (40).  
Several factors related to critical illness have been reported to be associated with gastric 
dysmotility and feed intolerance, including hyperglycaemia, deranged electrolyte levels, the 
nature of the acute illness, mechanical ventilation, intra-abdominal hypertension, raised 
intracranial pressure, sedatives, cytokine release, and splanchnic hypoperfusion due to shock and 
sepsis  (40, 41). Nguyen et al. assessed the impact of admission diagnosis on gastric emptying (GE) 
in critically ill patients and found the highest occurrence of delayed GE was observed in patients 
with head injuries, burns, mechanical ventilation (MV), multi-system trauma, and sepsis (41). 
Intestinal function is an important determinant in the outcome of patients admitted to ICU and 
the development of GI problems is related to worse outcomes in critically ill patients. Until 2011 
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there was no clear definition of gastrointestinal function in ICU. The ESICM Working Group on 
Abdominal Problems suggested the following definition for acute gastrointestinal injury (AGI) (42).  
Table 2-5:The four grades of severity of AGI (42) 
AGI Grade I Increased risk of developing GI dysfunction or failure. The function of the GI 
tract is partially impaired, e.g. postoperative nausea and/or vomiting, absence 
of bowel sounds. 
AGI Grade II GI dysfunction that requires intervention. The GI tract is unable to perform 
digestion and absorption adequately to satisfy the nutrient and fluid 
requirements of the body, e.g. gastroparesis with high gastric residual volumes 
(GRVs) or reflux, paralysis of the lower GI tract, and diarrhoea.  
AGI Grade III GI failure. Loss of GI function, where restoration of function is not achieved 
despite interventions and the general condition is not improving, e.g. feeding 
intolerance persists, despite treatment, high GRVs, persisting GI paralysis, 
increasing intra-abdominal pressure. 
AGI Grade IV Dramatically manifesting GI failure, a condition that is immediately life-
threatening, e.g. bowel ischaemia with necrosis, GI bleeding leading to 
haemorrhagic shock, abdominal compartment syndrome requiring 
decompression.  
 
Primary AGI is associated with direct injury to the organs of the GI system or a primary disease, 
e.g. peritonitis, pancreatic or hepatic pathology, abdominal trauma or surgery (42). 
Secondary AGI develops as the consequence of a patient’s response to critical illness without 
primary pathology in the GI system, e.g. GI malfunction in patients with pneumonia, non-
abdominal surgery or trauma, post-resuscitation state and cardiac pathology (42). 
Septic shock, with excess nitric oxide (NO) production, can cause a paralytic ileus that can lead to a 
delay in the institution of enteral feeding. Narcotics and muscle relaxants can further worsen GI 
tract motility, interfering with the optimal protein and energy intake in critically ill patients (12). 
 
2.1.6.4  Renal function 
Sepsis is the most frequent contributing factor to the development of acute kidney injury (AKI) in 
critically ill patients. The incidence of AKI in adult ICU settings has been reported by the consensus 
AKI definition criteria by Risk, Injury, Failure, Loss, End-Stage Kidney Disease (RIFLE), Acute Kidney 
Injury Network (AKIN) and, most recently Kidney Disease Improving Global Outcomes (KDIGO), to 
range between 16% and 67% and sepsis accounts for 26% to 50% of patients (43).  
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Septic AKI is associated with greater derangement in haemodynamic and laboratory parameters, 
greater severity of illness and higher need for MV and vasopressor therapy resulting in a higher in-
hospital mortality compared with non-septic AKI. Populations that are at risk of developing sepsis- 
associated AKI are elderly, female patients with baseline comorbidities, specifically chronic renal 
failure, diabetes, heart failure, liver infection and malignancy (43). The causes of AKI are 
multifactorial. The mechanism is complex and most likely involves a decrease in effective 
intravascular volume resulting from systemic hypotension, release of pro-inflammatory cytokines, 
ischaemia-reperfusion injury to the glomerulus, hypoxic or oxidative stress, direct renal 
vasoconstriction and activation of neutrophils by endotoxins and other peptides, which contribute 
to kidney injury. Additional risk factors like nephrotoxic drugs and volume overload with venous 
congestion may further aggravate the situation (28, 43).  
Renal support in sepsis includes early diagnosis, conservative measures and extracorporeal 
therapies. Currently, the major strategies for therapy include optimising renal perfusion by using 
vasopressors and volume resuscitation while avoiding volume overload and interstitial oedema 
(28).  
The RIFLE classification was used in this study to identify patients with AKI. 
 
2.1.6.5  Central nervous system function 
The brain plays a pivotal role in sepsis, acting as both mediator of the immune response and a 
target for the pathologic process. The measurement of brain dysfunction is difficult because there 
are no specific biomarkers of neuronal injury, and bedsides, evaluation of cognitive performance is 
difficult in the ICU. Altered mental status is present in up to 23% of patients with sepsis. When, 
present, sepsis-associated encephalopathy (SAE) is associated with poor prognosis (44). 
The pathophysiology of SAE involves direct cellular damage to the brain, mitochondrial and 
endothelial dysfunction, disturbances in neurotransmission and derangements of calcium 
homeostasis in brain tissue. Cerebral blood flow may also be affected. TNF-α appears to be the 
most significant inflammatory mediator involved in SAE (44).  
 
2.1.6.6  Circulatory function 
Significant derangement in autoregulation of circulation occurs in sepsis. Vasoactive mediators 
cause vasodilatation and increase microvascular permeability at the site of infection. Nitric oxide 
(NO) plays a pivotal role in the vasodilatation of septic shock. The secretion of vasopressin may be 
impaired, resulting in persistent vasodilatation Changes in both systolic and diastolic ventricular 
performance occur in sepsis. Cardiac output often increases to maintain blood pressure in the 
presence of systemic vasodilatation (12, 45). 
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The microcirculation consists of arterioles, terminal arterioles, capillaries, and post-capillary and 
collecting venules. The most important function of the microcirculation is the regulation and 
distribution of flow within the different organs. In septic shock, microcirculatory dysfunction may 
arise as a result of endothelial dysfunction, leukocyte-endothelium interactions, coagulation, 
inflammatory disorders and hemorrheologic abnormalities (46).  
The major cell types constituting microcirculation include endothelial cells lining (ECL) inside of the 
microvessels. These form the interface between the circulating blood and the parenchymal cells 
responsible for organ function. They are critical for the regulation of haemostasis, vasomotor 
control and immunological function. The endothelium forms part of the essential vascular barrier 
for solute transport and osmotic balance. Sepsis is associated with severe endothelial cell 
dysfunction leading to dysregulation of haemostasis and vascular reactivity as well as tissue 
oedema. The glycocalyx is a 0.2 to 0.5 µm-thick gel-like layer lining the luminal membrane of the 
ECL. Glycocalyx shedding occurs in sepsis and other disease states owing to the presence of 
hyperglycaemia, cytokines, oxidants and bacterial endotoxins. The main instigators for glycocalyx 
shedding are thought to be reactive oxygen species (ROS), as well as TNF-α and heparinase. Loss of 
barrier function induced by glycocalyx shedding is associated with the formation of oedema and 
contributes to sepsis-induced organ failure (45). 
 
2.1.7  Nutritional consequences of sepsis 
The metabolic response to stress has several clinical consequences, from changes in metabolic 
rate to use of macronutrients as energy sources, stress hyperglycaemia, muscle wasting, changes 
in body composition and behavioural changes (2). 
During the early post-injury phase, energy expenditure (EE) is usually lower than before injury and 
during the later phases, it increases. Hypermetabolism is induced by signals from stress hormones, 
inflammatory cytokines, and other mediators. To meet the energy demand related to 
hypermetabolism, the body turns to its endogenous energy sources, namely glucose, by 
gluconeogenesis in the liver, and free fatty acids, by lipolysis in the adipocytes. The oxidation of 
carbohydrates (CHO) is increased more during the early phase than the oxidation of lipids and 
proteins. Glucose is the preferred energy substrate. Changes in the metabolism of CHO include the 
rapid utilisation of the glycogen stores, followed by a high level of endogenous glucose production 
from lactate, glycerol and alanine in the liver, kidney and intestine. As the turnover of glucose is 
increased, plasma concentrations of glucose will increase, resulting in stress hyperglycaemia (2, 
20). 
Later on, glucose utilisation is decreased with an increased fat turnover, and loss of muscle and 
visceral protein mass. Endogenous triglycerides (TGs) stored in the adipose tissue and exogenous 
TGs released from chylomicrons and other lipoproteins are avidly hydrolysed to release free fatty 
acids (FFAs) and glycerol into the bloodstream during critical illness, regardless of the amount of 
exogenous lipids provided. FFAs are converted to ketone bodies or re-esterified to TGs and 
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released into the bloodstream as very-low-density lipoproteins (VLDL), which are subject to 
impaired clearance. Plasma FFA levels are increased in critically ill patients over the first few days. 
The metabolism of lipids is increased, although complete oxidation can only be achieved in tissues 
where mitochondria are functional (2, 5, 20).  
A negative nitrogen balance is the result of an increased protein breakdown over protein 
synthesis. This occurs even when reprioritisation leads to an increased overall hepatic protein 
synthesis. The amino acids released during the degradation of proteins will be either re-used by 
the gluconeogenesis organs or oxidised and will provide urea and ammonium as waste products. 
Plasma amino acids generated from increased skeletal muscle proteolysis also contribute to 
glucose production in the liver. Consequently, the skeletal muscles will be rapidly depleted. These 
losses are related to the significant wasting of muscles involved in ICU-acquired muscle weakness 
(2, 47).  
 
2.1.8  Management of sepsis 
Current management aims to control infection, to achieve haemodynamic stabilisation, to 
modulate the immune response and to provide organ and metabolic support, by treating the 
source and providing adequate oxygen delivery, ensuring glucose control and nutrition support 
(27). 
The control of the infection relies on two components: removal of the infected focus and 
appropriate antimicrobial therapy. The infected focus must be identified by repeated clinical 
examination and available imaging techniques, and removed with surgical intervention when 
necessary. All appropriate cultures should be taken before microbial therapy is started (32). 
Prompt and effective treatment of the active infection is essential to the successful treatment of 
sepsis and septic shock (19).  
Haemodynamic stabilisation can be separated into two key components: administration of fluids 
and use of vasoactive agents to counteract vasoplegic shock (27). According to the new Surviving 
Sepsis Guidelines, fluid resuscitation should be initiated as soon as possible. They recommend 
that, in the resuscitation from sepsis-induced hypoperfusion, at least 30ml/kg of intravenous (IV) 
crystalloid fluid be given within the first 3 hours. Additional fluids should be guided by frequent 
assessment of haemodynamic status as well as normalising lactate levels. They suggest that 
dynamic (passive leg raise, variations in systolic and pulse pressure or stoke volume) over static 
variables be used to predict fluid responsiveness where available. They recommend an initial 
target MAP of 65 mm Hg in patients with septic shock requiring vasopressors. Norepinephrine is 
the vasopressor of choice (48).  
Metabolic support with the use of corticosteroids in patients with severe sepsis has been a 
controversial subject in recent years. The Surviving Sepsis Guidelines advise against the use of IV 
hydrocortisone to treat septic shock patients if adequate fluid resuscitation and vasopressor 
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therapy are able to restore haemodynamic stability. If this is not achievable, a dose of 200mg/day 
of IV hydrocortisone is recommended (19, 48).  
Protocolised glucose control may result in improved survival rate. The Surviving Sepsis Guidelines 
recommend a protocolised approach to blood glucose management in ICU patients with sepsis. 
Insulin dosing should commence when two consecutive blood glucose levels are >10mmol/L. This 
approach should target an upper blood glucose level ≤10mmol/L.  Blood glucose values should be 
monitored every 1 to 2 hours until glucose values and insulin infusion rates are stable, then every 
4 hours thereafter (48).  
Nutrition support is important in all critically ill patients. The enteral route is preferable and should 
be commenced once initial resuscitation and adequate perfusion pressure is achieved. Where 
enteral feeding is impossible or not tolerated, parenteral nutrition (either as total or 
supplementary) may safely be administered (49). 
 
2.2  Nutritional therapy in the critically ill patient 
In this literature review, nutrition therapy in general is not discussed. The main focus is on 
parenteral nutrition and the components pertinent to this research. Thus, the focus is on 
intravenous lipid emulsions, particularly fish oil and their immunomodulatory role. As some of the 
parenteral nutrition available in South Africa is compounded by a facility and provides complete 
parenteral nutrition, including glutamine and micronutrients, the immune modulatory roles of 
glutamine and antioxidants are also included. 
Many critically ill patients develop muscle wasting and weakness, with an adverse outcome. This is 
due to the hypercatabolism of critical illness as well as anorexia, gastrointestinal dysfunction and 
resultant decreased feeding intake that accompanies severe illness (50). Recent research indicates 
that critically ill or major surgical patients can lose as much as a kilogram of lean body mass (LBM) 
a day, much of it in the first week of ICU stay. Patients may gain weight back post ICU, but much of 
the weight gain is fat mass, not functional lean muscle mass (14). 
 
2.2.1  Goals of nutrition therapy  
Nutritional needs in the critically ill are poorly understood and vary with the phase of critical 
illness. Goals of nutrition therapy (NT) focus on attenuating the metabolic response to stress, 
preventing oxidative cellular injury, and favourably modulating the immune response (16). This 
includes providing adequate nutrition therapy, preventing any nutritional deficiencies, preserving 
lean body mass, maintaining glucose control, avoiding metabolic complications, decreasing 
infectious complications, and improving clinical outcomes (8).  
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2.2.2  Malnutrition  
The incidence of malnutrition in hospitalised patients on admission is about 15–70%. It has been 
reported that approximately 70% of malnourished patients remain undiagnosed. These patients 
often enter and leave the hospital without receiving any nutritional therapy (51). Critically ill 
patients are at increased risk for the development of malnutrition due to alterations in protein and 
(52) energy metabolism displayed in response to sepsis, burns, major surgery and trauma. 
Malnutrition in critically ill patients includes both underweight and overweight patients, and body 
mass index (BMI) is used to classify these patients. An underweight patient has a BMI <18.5 kg/m2 
and an overweight patient has a BMI between 25 and 29.9 kg/m2. Patients are classified as obese 
if the BMI is between 30 and 39.9 kg/m2, and morbidly obese if the BMI ≥40 kg/m2 (53). It is 
estimated that 25–30% of patients admitted to an ICU have a BMI >30 kg/m2 (54). Malnutrition is 
associated with increased cost of care and poor patient outcomes, including nosocomial 
bloodstream infections, pressure ulcer development and increased mortality (55). 
The risk of malnutrition identified on admission and the worsening of nutritional status during 
hospitalisation have been strongly associated with prolonged length of stay. These patients are 
more likely to be readmitted and their cost of treatment 20% higher than the average patient (55). 
In 2015, the European Society of Clinical Nutrition and Metabolism (ESPEN) published a consensus 
statement on the diagnostic criteria for malnutrition. See Table 2-6 (56). 
Table 2-6 : Diagnostic criteria for malnutrition(56) 
 BMI <18kg/m2   
or 
 Unintentional weight loss >10% indefinite of time or >5% over the last 3 months 
combined with either 
BMI <20kg/m2  if < 70 years of age, or <22kg/m2  if ≥ 70 years of age or 
fat-free mass index <15  and 17 kg/m2  
 
Alberda et al. examined the relationship between the amount of energy and protein received and 
clinical outcomes, i.e., 60-day mortality and ventilator-free days (VFD) and explored how 
nutritional status prior to ICU admission modifies this relationship. Specifically, patients with a 
poor nutritional status, demonstrated by a low BMI, were more likely to experience adverse 
effects from underfeeding or benefit the most from receiving an increased amount of energy and 
protein. They concluded that critically ill patients with a BMI of <25 or ≥35 kg/m2 had improved 
clinical outcomes with increased energy and protein intakes (57). 
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2.2.3  Nutritional risk assessment 
Nutritional status assessment is performed to classify nutritional status, identify nutritional risk 
and to serve as a baseline for monitoring nutrition support adequacy. Identification of nutritional 
risk indicates the need for nutrition therapy to maintain body functions and to facilitate recovery 
(51). Recently, the NUTrition Risk in the Critically ill (NUTRIC score) was validated for nutritional 
risk assessment and identifies patients that benefit from higher nutritional intake. Patients with a 
low NUTRIC score (0–5) predict low malnutrition risk, and high scores (6–9) identify patients with 
increased ventilation duration and mortality (58). However, in the Brazilian population, the 
NUTRIC score didn’t identify high-risk patients; the average score was only 4; however the overall 
hospital mortality was 38%. Thus the NUTRIC score failed to identify critically ill patients most 
likely to benefit from optimal amounts of macronutrients (59). This score  has not been validated 
in the South African population.  
The Nutritional Risk Screening (NRS) tool 2002 was developed by ESPEN for hospitalised patients 
to help identify which patients would benefit from nutrition support (60). 
Table 2-7: NRS 2002 (61) 
Impaired nutritional status Severity of disease 
Score  Score  
Mild: 1 Weight loss >5% in 3 months or 
food intake below 50–75% of 
normal requirement  
Mild: 1 Hip fracture, chronic patients, in 
particular with acute 
complications: cirrhosis, COPD, 
chronic dialysis, diabetes, 
oncology 
Moderate: 2 Weight loss >5% in 2 months or 
BMI 18.5–20.5 + impaired 
general condition or food intake 
25–60% of normal requirement 
Moderate: 2 Major abdominal surgery, 
stroke, severe pneumonia, 
hepatologic malignancy 
Severe: 3 Weight loss >5% in 1 months or 
BMI <18.5 + impaired general 
condition or food intake 0–25% 
of normal requirement 
Severe: 3 Head injury, bone-marrow 
transplantation, intensive-care 
patients (APACHE >10) 
Score (nutritional status)           + Score (disease severity)           = Total score   
Adjustment for age: if ≥ 70 years: add 1 to total score above 
Age adjusted score  
Abbreviations: BMI: Body Mass Index, APACHE: Acute Physiology and Chronic Health Evaluation, 
COPD: Chronic Obstructive Pulmonary Disease 
Stellenbosch University  https://scholar.sun.ac.za
20 
 
Refeeding syndrome could occur in malnourished and many ICU patients who have been nil per os 
for longer than 24 – 48 hours, when nutritional support is instituted (58). (See Table 2-8.) 
Potentially fatal shifts of fluids and electrolytes occur, especially hypophosphataemia, 
hypomagnesaemia, hypokalaemia, thiamine deficiency and changes in blood glucose, protein and 
fat metabolism. It is important to identify the patients that are at risk and monitor them closely 
(51). 
Table 2-8: Patients at risk from refeeding syndrome (62) 
 Anorexia nervosa 
 Chronic alcoholism 
 Oncology 
 Postoperative 
 Elderly 
 Uncontrolled diabetes mellitus 
 Chronic malnutrition 
o Marasmus 
o Prolonged fasting or low-energy diet 
o High-stress patient underfed for > 7 days 
o Malabsorption syndromes 
 Long-term users of antacids 
 Long-term users of diuretics 
 
2.2.4  Parenteral nutrition 
Parenteral Nutrition (PN) is the intravenous administration of macronutrients and micronutrients 
(63). The timing of initiating PN as well as the amount to be delivered differs depending on which 
guidelines are followed. See Table 2-9 below discussing the differences between the ASPEN, 
Canadian and ESPEN guidelines. The British Association for Parenteral and Enteral Nutrition 
(BAPEN) recommends that PN should be used to prevent or treat malnutrition when the intestine 
is unavailable, or the intestinal function is inadequate. Treatment should be initiated before 
malnutrition has developed and the nutrient prescription should reflect the estimated nutritional 
requirement and patient’s clinical condition. The administration of nutrients in excess of estimated 
need is wasteful and potentially dangerous. These recommendations do not specify the exact 
timing of initiating PN (64). The South African National Parenteral Nutrition Practice Guidelines for 
Adults suggest to start PN as soon as possible post admission, in patients who are not expected to 
tolerate <60 % of their oral or enteral nutrition (EN) by day 3 to 5. They also recommend early 
nutrition intervention and introduction of PN in patients with pre-existing malnutrition (65). 
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Table 2-9: Published recommendations for indications and initiating PN from different societies 
Recommendations ASPEN (66) Canadian (67) ESPEN (68) SA National PN Guidelines 
(65) 
Indications and 
initiation of PN 
Withhold exclusive PN over the 
first 7 days following ICU 
admission if the patient has a 
low nutrition risk (NRS 2002 ≤3 
or NUTRIC score ≤5) and EN is 
not feasible. 
If the patient has a high 
nutrition risk (NRS ≥5 or 
NUTRIC score ≥5) or is severely 
malnourished, and EN is 
contraindicated, PN needs to 
be initiated as soon as possible 
following ICU admission.  
The use of supplemental PN 
(SPN) should be considered 
after 7–10 days in patients with 
either low or high nutrition risk, 
if they are unable to meet 
>60% of energy and protein 
requirements by the enteral 
route alone. 
In critically ill patients 
with an intact GIT, it is 
recommended that PN 
not be used routinely.  
Early PN should be 
considered in 
nutritionally high-risk 
patients, with a relative 
contraindication to early 
EN. 
For critically ill patients 
starting on EN we 
recommend that PN not 
be started at the same 
time as EN.  
There is insufficient data 
to recommend when to 
start PN when patients 
are not tolerating EN. 
Patients should be fed because 
starvation or underfeeding is 
associated with increased 
morbidity and mortality. 
PN should be initiated within 
24–48 hours if ICU patients are 
not expected to be on normal 
nutrition within 3 days and EN is 
contraindicated or they cannot 
tolerate EN.  
All patients receiving less than 
their targeted enteral feeding 
after 2 days should be 
considered for SPN. 
Recommend early nutrition 
intervention and 
introduction of PN in 
patients with pre-existing 
malnutrition. 
Start PN as soon as possible 
post admission, in patients 
who are not expected to 
tolerate <60 % of their oral 
or EN by day 3 to 5.  
 
Abbreviations: PN: Parenteral Nutrition, NRS: Nutritional Risk Screening, NUTRIC: Nutrition Risk in the Critically ill, EN: Enteral Nutrition, ICU: 
Intensive Care Unit, ASPEN: American Society of Parenteral and Enteral Nutrition, ESPEN: European Society of Clinical Nutrition and Metabolism. 
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There are considerable differences in terms of timing of initiating PN and this is particularly owing 
to the differences between the target populations, the levels of evidence considered, the clinical 
recommendations put forward, as well as the different types of parenteral nutrition products 
registered and available for use in the various countries (69). All the guidelines agree when the 
patient is malnourished or at high risk, PN should be initiated as soon as possible following ICU 
admission.  
See Table 2-10 for circumstances where PN is the preferred method of nutritional therapy 
Table 2-10: Indications for PN (63, 65, 70) 
Indications Clinical features 
Prolonged ileus > 3 days 
 
Generalised peritonitis 
Peritoneal metastatic cancer 
Abdominal distension on EN 
‘Frozen abdomen’ with chronic obstructive symptoms 
Acute abdomen 
Short bowel syndrome  Massive small bowel resection leaving <1.5m 
Mesenteric infarction 
Intestinal atresia 
Mechanical bowel 
obstruction 
Intrinsic or extrinsic blockage of intestinal lumen 
Severe malabsorption Radiation injury to the intestine 
High output fistulae (>500ml per 24h) 
Inflammatory bowel disease in acute phase 
Splanchnic ischaemia 
Complications of bariatric surgery 
Time to reach full EN or 
oral intake > 5 days 
Inability to provide sufficient nutrients enterally  
Inability to obtain enteral access 
Malnutrition With a non-functioning GIT 
Hyperemesis gravidarum When nausea & vomiting persists for 5–7 days and EN is not 
possible 
High risk of aspiration Intractable vomiting 
High-dose chemotherapy With severe mucositis 
Need to restrict oral or 
enteral intake 
Severe pancreatitis 
Chylous fistula 
Trauma requiring repeat surgical procedures and lengthy 
period of nil per os status 
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Complete PN in its modern form was invented by Arvid Wretlind and colleagues in Sweden and 
the USA in 1961. This feeding technique enabled patients with compromised GI failure to receive 
nutrition support and ultimately saved the lives of many previously doomed to die. Since the start 
of this new feeding technique, PN has evolved and the way we prescribe it has changed; however 
it has generated numerous contradictory publications. In the 1970s and 1980s the observation of 
extensive loss of lean body mass led to the rationale for feeding large glucose loads, thought to 
suppress endogenous gluconeogenesis, thereby preventing amino acid loss. This was known as 
hyperalimentation and resulted in overfeeding, dextrose intake exceeding the body’s ability to 
oxidise glucose resulting in increased infectious complications, CO2 overproduction, increased O2 
consumption, and increased adrenaline and noradrenaline release, compared with EN. The 
awareness of the importance of controlling blood glucose levels only came to the forefront in 2001 
and changed how patients are managed in the ICU. Today the production of metabolically 
balanced  amino acids, different types of lipid emulsion (LE), lower glucose content with a lower 
NPE:N ratio, micronutrients and trace elements have made PN a safe alternative form of NT where 
EN is contraindicated (63).  
Doig et al. compared early PN in critically ill patients with short-term relative contraindications to 
early EN. A total of 1372 patients were randomised to receive either standard of care 
(commencement of EN or PN in 2.8 days) or early PN commenced within 44 minutes after 
enrolment. Day-60 mortality did not differ significantly. The early PN strategy resulted in 
significantly fewer days of invasive ventilation but no significantly shorter ICU or hospital stay (71). 
In a full economic analysis of this trial, the early PN strategy reduced total cost of acute hospital 
care by US$3150 per patient (72). 
In a meta-analysis of 18 RCTs comparing enteral with parenteral nutrition in ICU patients, no 
overall mortality difference was found, but fewer infections were reported with EN. This effect 
was more pronounced when the PN group received more calories, whereas no effect was seen 
with similar caloric intake, suggesting that overfeeding by PN is associated with more infections 
(73). 
 
2.3  Nutritional requirements 
Despite numerous randomised control trials, observational studies, systematic reviews and 
consensus guidelines on NT in critical illness, many issues remain controversial, including the ideal 
method of assessing energy and protein requirements, as well as optimal nutritional targets.  
2.3.1  Energy  
Accurate determination of energy requirements in the critically ill is difficult. Firstly, resting energy 
expenditure is highly variable during the course of critical illness owing to changes induced by 
shock, sedation, surgical procedures, temperature, ventilation, physiotherapy, mobilisation and 
loss of LBM (63). Secondly, accurate determination of energy targets requires knowledge of pre-
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illness weight and body height, data which is often missing. Thirdly, actual body weight is 
frequently inaccurate owing to fluid accumulation post resuscitation (74), while dry weight is a 
poor indicator of LBM, especially in the obese patient where body weight is increased by excess 
fat mass (63, 75). 
Indirect Calorimetry (IC) remains the gold standard for predicting energy requirements. However, 
this method is fairly expensive, time-consuming and remains unavailable in most ICUs (63, 76). 
Predictive equations are therefore frequently used as surrogates to estimate energy requirements. 
Most of these were developed for use in the healthy population and there is currently no 
consensus as to the most accurate equation for estimating energy requirements in the critically ill 
patient (77). The following equations: Harris–Benedict, Mifflin, Owen, the American College of 
Chest Physicians (ACCP), Ireton-Jones 1992 and 1997, Penn State 1998 and 2003, and Swinamer 
1990 are most commonly used. However, the results from these correlate poorly with those of IC 
(75). The most significant source of error in these equations is the use of estimated, rather than 
measured weight (77). Berger and Pichard suggest that the Toronto equation for major burns and 
the Faisy–Fagon equation for patients on mechanical ventilation were developed specifically for 
critically ill patients and are clinically more accurate than other predictive equations for 
metabolically stable, mechanically ventilated patients (75). 
The last method for determining energy requirements is the use of a fixed daily prescription, 
usually in the range of 20–35kcal/kg (76,77). Despite the greater ease of applying this method at 
the patient’s bedside, accuracy is generally regarded as poor. Accuracy might be improved by 
using metabolically active weight, but currently there is no reliable definition of metabolically 
active weight (77). A number of professional organisations and authors have developed consensus 
guidelines for the determination of nutritional requirements in critical illness (see Table 2-11). 
Additional energy provided by dextrose-containing fluids and lipid-based medications such as 
propofol and citrate dialysis should be accounted for when deriving NT regimens to meet target 
energy goals, to avoid overfeeding (58,66). In a recent publication by Veldsman et al., the non-
nutritional energy sources, mostly from carbohydrate-containing IV fluids, contributed 8% to total 
energy delivery (78).  
Overfeeding can occur easily with PN, especially during the first 2–3 days in the ICU. During this 
initial acute phase of critical illness, endogenous energy sources are utilised to meet total energy 
expenditure. The utilisation of exogenous energy sources is limited, and even administering a large 
amount of energy will not terminate this response. Thus, introducing early full feeding will create 
overfeeding which is associated with poor outcome and increased mortality. Potentially 
deleterious effects of overfeeding early are hyperglycaemia, hyperlipidaemia and hypercapnia, 
resulting in increased infectious complications and liver steatosis (14, 79).  
During the later chronic or recovery phase of critical illness, the body experiences a massive 
increase in metabolic needs, with total energy expenditure increasing as much as ~1.7 fold above 
resting energy expenditure (14). 
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Table 2-11: Published guidelines for nutrient intake in critically ill patients requiring PN 
Society Year Energy (kcal/kg/day) Protein (g/kg/day) 
ACCP (80) 1997 25 - 
CCCPG (67) 2015 No recommendation 
(insufficient evidence) 
No recommendations for protein 
Glutamine: When PN is prescribed to critically ill 
patients, we recommend parenteral 
supplementation with glutamine not be used 
ESPEN (68) 2009 25 if IC not available 
(Grade C) 
1.3–1.5 
(+0.3-0.6 alanyl-glutamine dipeptide) 
(Grade A) 
ASPEN (66) 2016 25 – 30 or predictive 
equations if IC not 
available 
Obesity: 
60–70% of energy 
requirements or  
11–14 (actual BW) 
22–25 (IBW) 
PN:  
20kcal/kg/day or 80% of 
estimated energy needs, 
for first week in ICU 
1.2–2.0 
 
 
Obesity: 
≥ 2 (IBW)    (BMI 30–40) 
≥2.5g (IBW) (BMI ≥40) 
 
 
 
> 1.2 
Glutamine: Parenteral glutamine supplementation 
not be used routinely in the critical care setting 
SA 
National 
DoH PN 
Guidelines 
(65) 
2016 20–25 (acute phase) 
25–30 (recovery phase) 
Obese (BMI>30) 
Hypo-caloric feeding: 
11–14 actual BW 
Eucaloric feeding: 
21 actual BW 
1.3–1.5 
 
Obese (BMI>30) 
≥ 2 (IBW)    (BMI 30–40) 
≥2.5g (IBW) (BMI ≥40) 
 
Evidence grades: B, supported by at least one well-designed randomised controlled trial or other sound 
methodology; C, based on expert opinion or advice. 
Abbreviations: ACCP: American College of Chest Physicians; CCCPG: Canadian Critical Care Practice 
Guidelines; ESPEN: European Society for Clinical Nutrition and Metabolism; ASPEN: American Society of 
Parenteral and Enteral Nutrition; SA National DoH: South African National Department of Health; IC: 
Indirect Calorimetry; IBW: Ideal Body Weight; BMI: Body Mass Index; BW: Body Weight; ICU: Intensive 
Care Unit 
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The Tight Calorie Control Study (TICACOS) investigated whether indirect calorimetry-based feeding 
is superior to equation-based feeding (target 25kcal/kg/day). IC was performed throughout ICU 
stay and was repeated every 48h. Although the primary end point (hospital mortality) was not 
statistically different, morbidity was increased in the IC group, which received approximately 
600kcal/day more. The increased calories provided could likely explain the observed increased 
incidence of pneumonia and prolonged ventilation (50). 
The Early Parenteral Nutrition to supplement insufficient enteral nutrition in ICU patients (EPaNIC) 
trial randomised patients on admission to early (day 2) versus late (day 8) PN and concluded that 
early hypercaloric PN is deleterious (81). Overfeeding leads to increased insulin requirements to 
achieve blood glucose control. The patients in the early PN group in the EPaNIC trial needed nearly 
double the amount of insulin for this purpose, probably reflecting overfeeding that is associated 
with depressed autophagy (63, 75).  
The SPN trial showed that individualised energy supplementation using IC from day 4 in ICU could 
reduce nosocomial infections and should be considered as a strategy to improve clinical outcome 
in patients in the ICU for whom EN is insufficient (82). Grau and colleagues have shown liver 
dysfunction during artificial nutrition support, especially TPN, occurs more frequently if energy 
delivery exceeds 25kcal/kg, and in patients with sepsis (83). 
McCowen and colleagues randomised adult patients requiring PN to either receive hypocaloric PN 
(1000kcal and 70g protein) and standard weight-based regimen PN (25kcal/kg and 1.5g 
protein/kg) for more than five days. They found that the provision of PN to a goal of 25kcal/kg and 
1.5g protein/kg was not associated with more hyperglycaemia or infections, but provided 
significant nutritional benefit in terms of nitrogen balance in comparison with hypocaloric PN (84). 
Whether measured by IC or estimated by predictive equations, energy expenditure should be re-
evaluated more than once per week, and strategies to optimise energy and protein intake should 
be used (66).  
Prolonged underfeeding may result in a cumulative energy and/or protein debt that cannot be 
compensated for later during ICU stay, resulting in increased infections and mortality (85-87). A 
large international survey indicated that ICU practitioners deliver an average of 59% of energy 
requirements, resulting in suboptimal NT (88). 
In conclusion, each patient should be closely monitored for signs and symptoms of overfeeding, as 
well as feeding intolerance, and appropriate measures should be taken to avoid these 
complications. On the other hand, severe underfeeding can also be harmful and justifies 
continuous efforts to optimise nutrient delivery and feeding tolerance (89). 
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2.3.2  Protein  
Critically ill patients can lose as much as a kilogram of LBM a day during the first week of ICU stay. 
It is most pronounced in skeletal muscle, where it is mediated through an increase in muscle 
protein breakdown. This increase in degradation rate is uniformly distributed among cellular 
proteins: contractile and mitochondrial (90). Depletion of muscle mass is associated with impaired 
function and poor outcomes (91). The International Protein Summit in 2016 suggested that high 
doses of protein in the range of 1.2 – 2.5g/kg/day may be required in the setting of the ICU to 
optimise nutrition therapy and reduce mortality. Protein doses in this range may be needed to 
best stimulate new protein synthesis and preserve muscle mass. They recommend that achieving 
protein goals the first week following ICU admission should take precedence over meeting energy 
goals (92). 
Observational studies show higher protein intake is associated with better survival and more 
ventilator-free days (85, 93-95). See Table 2-11 on consensus guidelines for the determination of 
nutritional requirements in critical illness for protein intake recommendations. 
An improvement in quality of life (QoL) linked with protein intake was explored in a recent 
publication by Wei et al. (96) in high-risk ICU patients, who were ventilated for > 8 days. Patients 
receiving low nutritional adequacy over the first ICU week (<50% of predicted calorie and protein 
need) had an increased mortality versus patients receiving high nutritional adequacy (>80% of 
calorie and protein needs). They also demonstrated that for every 25% increase in calorie/protein 
delivery in the first ICU week, there was an improvement in 3-month post-ICU physical QoL scores 
(as measured by the SF-36) with medical ICU patients showing significant improvements in both 3- 
and 6-month SF-36 scores. A recent publication by the Australian and New Zealand Intensive Care 
Society indicated that a 7.8 point change in physical QoL domain scores is considered clinically 
relevant in post-ICU patients. In the Wei study, there was a 10.9 point increase in physical 
functioning and a 13.1 point increase in role-physical measures, thus indicating the post-ICU QoL 
can improve significantly by just a 25% increase in calorie/protein delivery during the first 8 days 
of ICU stay (14, 96). 
Another recent RCT by Ferrie et al. (97) investigated isocaloric nutrition with different amounts of 
a parenteral amino acid solution (1.2g/kg/day versus 0.8g/kg/day)  in 119 critically ill patients 
requiring PN and measured handgrip strength as the primary outcome. The actual amino acid 
delivery was 1.1g/kg/day versus 0.9g/kg/day, averaged over the first 7 days. Grip strength at ICU 
discharge tended to be higher in the high amino acid group. This group showed less fatigue and 
greater forearm and thigh muscle thickness at day 7. At day 3, nitrogen balance was significantly 
improved in the high amino acid group, but this effect disappeared completely at day 7. There was 
no difference between groups in terms of mortality or LOS. They concluded that the higher level of 
amino acids was associated with small improvements in a number of different measures, 
supporting guideline recommendations for ICU patients (97). 
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There are also some negative reports on higher protein intake in ICU patients. In a post hoc 
analysis of the EPaNIC trial, it was suggested that higher protein intake at day 3 was related to 
worse clinical outcome (98). However, this analysis was likely not adjusted for energy intake (103). 
The investigators proposed that early high protein nutrition support was harmful because of 
inhibition of autophagy (98). 
Puthucheary et al. (100) suggest that protein feeding might have adverse effects. However, this 
conclusion was based on two regression analyses, of which one indicated worst outcome and the 
other did not. There was no actual information in this report on intake, but it appears to be low 
(101). 
While autophagy is an important maintenance instrument, it remains to be determined to what 
extent autophagy is suppressed by protein feeding and whether this may affect clinical outcomes. 
While this is an interesting hypothesis, it is unproven and other recent trials refute this concern (3, 
102, 103). 
Caution should be employed when prescribing high protein levels, and monitoring for clinical 
response may be required. The potential harm from excessive protein or amino acids is generally 
from the delivery of protein without adequate energy sources from CHO. Azotaemia will interfere 
with cellular protein synthesis only when the level of serum urea nitrogen becomes excessive. 
Clinically, serum urea nitrogen may be tempered as patients are given renal support therapy prior 
to reaching uraemia-inducing levels. Altered mental status can be observed from excessive amino 
acids, specifically the aromatic amino acids, as there is a deficiency of branch chain amino acids. It 
is the imbalance that causes hepatic encephalopathy in patients with compromised hepatic 
function (104). 
 
2.3.2.1  Glutamine  
Historically, it was difficult to include glutamine into amino acid solutions owing to stability and 
solubility problems. In the early 1990s, glutamine was finally solubilised as the dipeptide form 
glutamine-alanine and glycyl-glutamine. Glutamine is the most abundant free amino acid in the 
body, which constitutes over 60% of muscle free amino acid pool. Classified as a nonessential 
amino acid, glutamine can be produced in the body by conversion of glutamic acid, primarily by 
the skeletal muscle and liver. Glutamine has important physiologic functions, mainly serving as a 
precursor in the synthesis of other amino acids and glucose for energy. See Table 2-12 for all the 
physiologic functions of glutamine (63, 105). 
The concept of conditionally essential amino acids emerged in the early 1990s; these are amino 
acids that are supplied by food and synthesised under normal conditions but which during critical 
illness become deficient because of insufficient supply and increased consumption. Isolation of 
various amino acids led to the possibility of using them separately, potentially as drugs (63). 
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Table 2-12: Physiologic functions of glutamine (106, 107) 
 Precursor of arginine and nicotinamide adenine dinucleotide  
 Antioxidant role; precursor of glutathione and attenuation of induced nitric oxide synthase 
activation after sepsis 
 Oxidative fuel for rapidly proliferating cells, e.g. GIT, Immune system, reticulocytes and 
fibroblasts 
 Anti-inflammatory/immune regulation by attenuating cytokine release and NF-ĸB 
activation 
 Tissue protection:  
o Functions as a signal molecule and enhances stress-induced heat shock protein 
expression 
o Decreases cellular apoptosis 
 Preservation of tissue metabolic function 
o Attenuates insulin resistance 
o Preservation of ATP levels following sepsis 
 
Glutamine is naturally found in dietary protein and becomes conditionally essential under 
conditions of catabolic stress and critical illness. Demands of glutamine in critical illness are met in 
part by skeletal muscle proteolysis. The release of large amounts of glutamine to maintain normal 
concentrations in the plasma result in depletion of glutamine stores. Depletion of glutamine has 
been shown repeatedly to occur in critically ill patients; a low plasma glutamine level in the 
critically ill patient in ICU at the time of admission was found to be an independent predictor of 
mortality (108, 109).  
Well-conducted repletion studies have shown that glutamine administration is beneficial if 
administered, particularly by the parenteral route, along with an optimised NT-improving glucose 
control and achieving reduction of both infectious complications and mortality (110, 111). But 
glutamine alone cannot be provided in standard PN for stability reasons, which increases the risk 
of deficiency (63). 
A meta-analysis on the impact of perioperative glutamine dipeptide-supplemented PN in 
abdominal surgery patients showed a significant decrease in infectious complication rates, a 
reduction in hospital LOS, and a positive effect on nitrogen balance, but no effect on mortality in 
the glutamine group (112). 
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Bollhalder et al. conducted a meta-analysis of parenteral glutamine supplementation in critically ill 
patients and patients undergoing major surgery. The study showed a significant reduction in 
infections and a shorter length of stay, and a non-significant reduction in short-term mortality in 
the glutamine group (113). 
Two large prospective randomised clinical trials caused confusion with regard to the use of 
glutamine in critical illness. The dose of glutamine as well as the timing of administration could 
explain the negative results (63). Andrews et al. enrolled 502 patients with gastrointestinal failure. 
The patients were randomised to receive daily 20.2g glutamine or 500µg selenium, or both, versus 
placebo for up to 7 days. There was no overall effect of glutamine on new infections or on 
mortality, while selenium was associated with less infectious complications if delivered for longer 
than 5 days. Several shortcomings of the study, including a very short administration time and a 
one-size-fits-all prescription of the ready-to-use 3-chamber PN bags, resulted in the delivery of a 
very low glutamine dose for a very short period (114).  
Heyland et al. reports data for 1223 patients receiving the highest doses so far used for glutamine 
(0.78g/kg/day supplied as 0.35g/kg intravenously + 30g enterally per day), about twice the 
recommended doses, in patients with severe organ failure (93% of patients in shock and 33% with 
renal failure) starting within the first 24 hours of admission independently of nutrition. In addition, 
the glutamine group suffered more organ failure, which might explain on its own the higher 
mortality. Only 31% of a subset of patients presented with low baseline glutamine levels 
(<420µmol/l), whereas 15% of these patients had supranormal plasma glutamine values at 
baseline, which were associated with increased mortality. Pharmacological doses of glutamine in 
unstable patients should be avoided (115). 
Subsequent to the above trials, there has been some data published on glutamine-supplemented 
parenteral nutrition still showing benefits. Grintescu et al. studied the influence of parenteral 
glutamine supplementation on glucose homeostasis in 82 critically ill polytrauma patients. They 
found that 63% of patients in the glutamine-supplemented group had no hyperglycaemic episodes 
and only 37% required exogenous insulin, with a mean lower dose than the controls. There was 
also a trend of fewer new infections in the glutamine group vs control group (10 vs 14)  (116). 
Chen et al. conducted a meta-analysis on glutamine therapy in critically ill patients. There was no 
significant difference in hospital and 6-month mortality between the glutamine group and the 
control group. However, in the high dosage subgroup (>0.5g/kg/day), the mortality rate in the 
glutamine group was significantly higher than that of the control group (33.5% vs 28.2%). The 
incidence of nosocomial infections in the glutamine group was significantly lower (117). 
A recent meta-analysis by Stehle et al. (105) on glutamine-supplemented PN in critically ill patients 
confirmed a significant reduction in infectious complications (RR=0.70), ICU LOS (MD – 1.61 days), 
hospital LOS (MD – 2.3 days) and mechanical ventilation duration (MD – 1.56 days). It also lowered 
the hospital mortality rate by 45% but had no effect on ICU mortality. The authors conclude that 
supplementing PN with glutamine dipeptide according to ESPEN clinical guidelines as part of a 
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balanced nutrition regimen, significantly reduces hospital mortality, infectious complication rates 
and hospital LOS, and could also confer economic benefits in this setting (105).  
Various societies have published consensus guidelines on the use of parenteral glutamine in 
critically ill patients. At present, the ESPEN guidelines state that when PN is indicated, the amino 
acid solution should contain 0.2–0.4g/kg/day of L-glutamine (0.3–0.6g/kg/day alanyl-glutamine 
dipeptide). However, the ASPEN guidelines recommend that parenteral glutamine 
supplementation not be used routinely in the critical care setting. According to Heyland and 
Dhaliwal, patients with shock and MOF should not receive glutamine; however for ICU patients 
not in MOF receiving PN, there is still a large body of evidence showing the benefit of IV glutamine 
at 0.35g/kg/day (118).  
See Table 2-11 for the published recommendations on glutamine supplementation.  
 
2.3.3  Carbohydrates 
Carbohydrates (CHOs) are supplied as glucose. Cells such as red blood cells, immune cells and 
renal medullary cells which have no mitochondria are dependent on glucose supply for their 
energy through ATP production. Brain metabolism is also partially dependent on plasma glucose 
concentration: it can use lactate for energy supply when blood glucose decreases gradually (119) . 
Regarding other energy sources, our brain (unlike most of the other peripheral tissues) does not 
utilise fatty acids. Transported in the bloodstream bound to the albumin, fatty acids are unable to 
cross the haematoencephalic barrier (119). However, during long-term starvation, brain 
metabolism adapts to the consumption of ketone bodies (synthesised from the excess of acetyl-
CoA). A full adaption develops approximately within three weeks of starvation. After this period, 
the brain is able to cover up to 50% of its energy expenditure from the oxidation of ketone bodies. 
Brain metabolism accounts for the majority of blood glucose oxidation in the body. It utilises 
around 20% of the total oxygen and 20% of the total glucose consumption (120). In the absence of 
an exogenous supply of glucose, the body can call upon hepatic glycogen stores and can 
synthesise glucose from lactate, lipids and amino acids through gluconeogenesis. Thus, an 
adequate supply of glucose is crucial to prevent wasting of amino acids as substrates for 
gluconeogenesis and thereby preserve body protein and muscle mass (123). 
Glucose represents the only CHO source in PN and should always be infused with PN. The 
minimum glucose requirement for ICU patients is ≥2g/kg/day (65,68) or approximately 60% of 
non-protein energy (NPE) should be supplied as glucose with an intake of 3–3.5g/kg/day. In 
patients with a high risk of hyperglycaemia (critically ill, diabetes, sepsis or steroid therapy) an 
lower initial carbohydrate infusion of 1–2g/kg/day is recommended (121) . 
Insulin resistance in the critically ill means that infusions of large amounts of glucose result in an 
increase in blood glucose levels. It has been documented that the maximum oxidation rate of 
glucose in the stressed patient is 4–7mg/kg/min (119). Hence, in order to decrease the risk of 
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metabolic alterations, the maximum rate of glucose infusion should probably not exceed 
5mg/kg/min (68). 
Excessive administration of glucose should be avoided because of the risk of hyperglycaemia with 
osmotic diuresis and hyperosmolar coma. Hyperglycaemia has pro-inflammatory effects, and 
worsens outcomes in critically ill patients. Target blood glucose levels should be kept between 7 
and <10mmol/L for the general ICU population (66). Hypoglycaemia with PN is typically seen when 
endogenous insulin levels are not adjusted to abrupt withdrawal of dextrose, decreased dose of 
corticosteroids or vasopressors, or recovery from acute illness. It has also been associated with 
increased risk of complications, length of hospitalisation and mortality (122, 123).  
Excess glucose is converted to fatty acids (FA) and stored in adipose tissue or in the liver, resulting 
in steatosis. Furthermore, glucose oxidation is associated with a high production of carbon dioxide 
which could increase respiratory stress (123). 
 
2.3.4  Lipids  
Intravenous lipid emulsions (LEs) provide a source of essential fatty acids (EFAs) and serve as a 
complement to carbohydrates by providing a dense source of NPE in PN. This is known as the Dual 
-Energy system. Lipids provide 9kcal/kg as a source of calories. Thus, fluid volume of PN required 
to achieve adequate caloric intake can be reduced substantially by adding lipids. LEs also have a 
low osmolarity and incorporating them into PN solutions can reduce the overall osmolarity of the 
solution and enable some solutions to be administered peripherally (≤900mOsm/L) or centrally 
(124).  
Fatty acids are classified according to their structure, carbon chain length (short, medium or long), 
degree of saturation (number of double bonds), and the location of double bonds (counted from 
the methyl carbon of the hydrocarbon chain) (10, 124). Fatty acids (FAs) play key roles in 
determining the structural integrity and fluidity of cell membranes and can give rise to several 
important bioactive mediators. They can also regulate the expression of a variety of genes and 
modulate cell signalling pathways, such as those involved in apoptosis, inflammation and cell-
mediated immune responses (124, 125). Changing the FA composition of cells involved in the 
inflammatory response influences their functions. The anti-inflammatory effects of marine n-3 
PUFAs suggest that they may be useful as therapeutic agents in disorders with an inflammatory 
component (126). 
The metabolites of n-3 polyunsaturated fatty acids (PUFAs), primarily from eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA), compete with arachidonic acid (AA) for use of the same 
enzymes, cyclooxygenase and lipoxygenase. As a result, a higher intake of n-3 PUFAs leads to both 
an increase in anti-inflammatory mediators (namely prostaglandins of the 3 series and 
leukotrienes of the 5 series) and a decrease in pro-inflammatory mediators (37, 127). See Figure 2-
1. 
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Omega-6     Omega-3 
  Linoleic acid    Alpha-linolenic acid 
  18:2n-6             18:n-3 
Desaturation     Desaturation 
Elongation     Elongation 
Desaturation     Desaturation 
  Arachidonic acid  Eicosapentaenoic acid 
     20:4n-6       20:5n-3 
       
Elongation           COX & LOX 
  COX & LOX          Docosapentaenoic acid 
       22:5n-3  Anti-inflammatory 
          lipid mediators 
 Pro-inflammatory    Elongation   LTB5, LTC5 & LTE5 
 lipid mediators   Desaturation   TXA3 
 LTB4, LTC4 & LTE4   Beta-oxidation  PGI3 & PGE3 
 TXA2         Resolvins 
 PGI2 & PGE2  
      Docosahexanaenoic acid 
        22:6n-3 
          
            
Figure 2-1: Metabolism of omega-6 and omega-3 PUFAs (adapted from (31, 37, 127) 
COX – Cyclooxygenase, LOX: Lipoxygenase, TXA2: Thromboxane A2 (platelet aggregator, vasoconstrictor), 
PGI2: Prostaglandin I2 (vasodilator, antiaggregator), PGE2 : Prostaglandin E2 (Immunosuppresor)   
 
Difference between Intravenous Lipid Emulsions (IVLEs)  
The first LE that met the criteria for safe use as part of PN in the clinical arena was based on 
soybean oil (SO). This emulsion, named Intralipid®, was developed in 1961 in Sweden by Arvid 
Wretlind after numerous attempts to infuse lipids in humans for therapeutic purposes had failed. 
This was a landmark that triggered the launch of lipid-based PN in Europe and prevented the 
complications of high-dose dextrose infusions that were seen with the use of lipid-free PN in the 
USA.. However a potential disadvantage with SO LEs is their high content of n-6 polyunsaturated 
fatty acids (PUFAs) . The emergence of evidence suggesting that n-6 PUFAs are pro-inflammatory 
and immunosuppressive has led to the development since the mid-1980s of the next-generation 
LEs based on various oil sources (10, 11). See Figure 2-2. 
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Despite sharing several common properties, the oil sources used and the percentages of different 
FAs dictate the key differences between IVLEs. Their differences account for their additional 
benefits or detrimental effects, especially when used for prolonged periods (see Table 2-13 for the 
analysis of LEs). Typically IVLEs are manufactured with 1 of 5 types of oil: soybean, safflower, 
coconut, olive or fish. Each has unique inflammatory properties and may even confer different 
pharmaceutical and therapeutic benefits (125).  
 
Soybean oil 
Soybean oil (SO) lipid emulsions remain the most widely used in many countries because of their 
proven record of safety and tolerability (10,11). SO contains high concentrations of n-6 PUFAs with 
a ratio of LA to ALA of approximately 7:1. LA is metabolised into AA. The eicosanoids generated 
from AA are prostaglandin E2 (PGE2), thromboxane A2 (TXA2) and leukotrienes, including LTB4, 
which act in a pro-inflammatory way (Figure 2-1). The SO is naturally rich in phytosterols and has 
high levels of γ-tocopherol but low amounts of α-tocopherol (bioactive form of vitamin E). The 
phytosterols present in SO are plant sterols thought to contribute to the development of intestinal 
failure-associated liver dysfunction (IFALD). The role of phytosterols in hepatocyte damage has 
been demonstrated by their antagonising effect on the farnesoid X nuclear receptor, which is 
critical in regulating the level of intrahepatic bile acids. In addition, the incorporation of 
phytosterols in erythrocyte membranes accelerates the breakdown of these cells and increases 
the bilirubin load to the liver (125). 
Emulsions with a high content of n-6 PUFAs have been linked to immunosuppressive effects (128, 
129). One study evaluated the effect of lipid intake on the postoperative stress response and cell-
mediated immune function of patients subjected to gastric or colorectal surgery. Higher 
postoperative concentrations of IL-6 and C-reactive protein were seen in patients receiving an SO 
LE compared with those receiving lipid-free PN (130). This is the reason why many centres do not 
administer 100% SO LE to critically ill patients (125). 
 
Safflower oil 
Safflower oil has been used in IVLE alone or in combination with SO in the US since 1980. It was 
developed as an alternative to SO LE. In comparison with SO LE, safflower-based IVLE had higher 
concentrations of LA and less ALA. The use of safflower oil predisposed patients to develop n-3 
PUFA deficiency when used as a sole source of fat in IVLE (125). 
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Coconut oil (MCTs) 
Second-generation LEs consisted of the addition of medium-chain triglycerides (MCTs) to SO. It 
contains a 50/50 mixture. These emulsions reduce the n-6 PUFA content by 50%. MCTs are SFAs 
that are 6–12 carbons long and include caprylic, caproic and myristic acids. They are easily 
metabolised, require little carnitine for mitochondrial entry and lack pro-inflammatory properties, 
both characteristics unique to this fat source. MCTs are also hydrolysed and eliminated from the 
central circulation more quickly than LCTs, which makes them a preferential caloric source. 
Additionally, MCTs are resistant to peroxidation and do not accumulate in the liver. However, MCT 
oils are devoid of EFAs and thus cannot be used as a sole source of fat (9, 125). 
 
Olive oil 
Olive oil (OO) is rich in n-9 FA (oleic acid) a type of MUFA that is not considered essential. OO-
based emulsions were introduced in Europe in the 1990s and are classified as third-generation 
IVLEs. The relatively small amount of LA explains why this oil source requires blending with an oil 
containing EFA, like SO. Olive oil has a lower content of phytosterol than pure SO. One OO-based 
LE is composed of 4 parts OO/1 part SO (ClinoOleic), thus providing 30% of the PUFA content of 
standard SO LE. In comparison to SO, OO is rich in MUFAs that possess fewer pro-inflammatory 
properties and are more resistant to oxidative stress injuries from free radicals (125, 127).  
 
Fish oil 
Fish oil (FO)-based LEs are the most recent developments as alternatives to SO and are known as 
the fourth-generation IVLE. They have been available in Europe and Asia for the past 10 years as a 
supplement to the conventional SO-based LE (Omegaven). More recently, FO has been included in 
a combination emulsion consisting of soybean (30%), MCT (30%), olive oil (25%) and fish oil (15%) 
(SMOFlipid®). Mixing four different oils optimises the fatty acid profile and the n-6:n-3 PUFA ratio 
of 2.5:1 which is in accordance with current recommendations. (131). 
Owing to the high concentrations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 
FO is thought to have anti-inflammatory potential by interfering with the AA pathway and 
producing the anti-inflammatory eicosanoids prostaglandins E3 (PGE3), thromboxanes A3 (TXA3) 
and leukotrienes B5 (LTB5) as well as resolvins, protectins and maresins. FO is also rich in the 
antioxidant α-tocopherol, which is added to prevent the oxidation of its FAs (127, 132).  
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Omega 6: omega 3 polyunsaturated fatty acid ratio 
In an experimental immunocompetence model, Grimm et al. demonstrated that IVLEs show 
varying immunomodulatory effects dependent on the n-6:n-3 PUFA ratio. The optimum immune 
response was maintained by infusion of a lipid emulsion with an n-6:n-3 PUFA  ratio of 2.1:1 (133). 
According to recommendations, new lipid emulsions should be composed of a reduced n-6 PUFA, 
especially linoleic acid, counterbalanced by MCT, MUFA and long-chain n-3 PUFA . Based on 
experimental and clinical studies, the most favourable n-6:n-3 PUFA ratio is proposed to range 
between 2:1 and 4:1 (11, 133-135). 
 
Figure 2-2: Evolution of fat sources in intravenous lipid emulsions and their corresponding 
changes in the inflammatory profile (9, 125, 127) 
1920  1930–1940 1960  1980    1990   Present 
   1st Generation          2nd Generation    3rd Generation        4th Generation 
Castor oil Cotton seed  Soybean oil Soybean + Soybean +   Fish + MCT+ 
  oil  (Intralipid®) MCT oil Olive oil  Soybean + 
      (Lipofundin®) (ClinOleic®)  Olive 
           (SMOFlipid®) 
           Fish Oil 
Japan  US & Europe        (Omegaven®) 
 
 
 
 
 
 
 
 
 
 
 
Pro-inflammatory Anti-inflammatory 
Inflammatory neutral 
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Table 2-13: Characteristics of commercially available intravenous lipid emulsions used In 
reported randomised controlled trials (9, 124, 125, 127, 136, 137) 
Composition 
Abbreviation 
 
Intralipid® 
20% 
SO 
Lipofundin® 
20% 
MCT/LCT 
ClinOleic 
20%® 
OO/SO 
SMOFlipid® 
20% 
SMOF 
Omegaven® 
10% 
FO 
Not available in SA 
Lipoplus® 
20% 
MCT/LCT/FO 
Not available in 
SA 
Oil source % 
Soy bean 
MCT 
Olive 
Fish 
 
100 
0 
0 
0 
 
50 
50 
0 
0 
 
20 
0 
80 
0 
 
30 
30 
25 
15 
 
0 
0 
0 
100 
 
40 
50 
0 
10 
% Fatty acids 
Linoleic  
Arachidonic  
-α-Linolenic  
EPA  
DHA 
 
53 
0.1 
8 
0 
0 
 
50 
0.2 
7 
0 
0 
 
18.7 
0.5 
2.3 
0 
0 
 
21.4 
1.0 
2.5 
3.0-4.7 
2.0-4.4 
 
4.4 
2.1 
1.8 
19.2 
12.1 
 
25.7 
NA 
3.4 
3.5-3.7 
2.5 
n-6 – n-3 
PUFAratio 
7:1 7:1 9:1 2.5:1 1:8 2.7:1 
Phytosterols 
(mg/l)  
348 ± 33 NA 327 ± 8 47.6 0 NA 
Phytosterols 
(mg/l) Xu(142) 
439 ± 5.7 278 ± 5.09 274 ± 2.6 207 NA NA 
α-tocopherol 
(mg/l) 
38 85 ± 20 32 or 180 200 150-296 190 ± 30 
Osmolarity 
(mOsm/L) 
260 380 270 380 308-376 NA 
Abbreviations: SO: Soybean oil; LCT: Long-Chain Triglyceride; MCT: Medium-Chain Triglyceride; 
OO: Olive oil; FO: Fish oil; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid; SMOF: 
soybean, MCT: olive, fish 
 
2.3.4.1  Guidelines on the use of lipids in PN 
Various professional organisations have developed consensus guidelines for prescribing different 
types of lipids in PN (Table 2-14). These guidelines vary in terms of their recommendations 
according to the types of lipids available and registered in the various countries. Up until recently, 
FO-containing lipid emulsions were not available in the US, unless under special concession. 
However, SO/MCT/OO/FO LE (SMOFlipid®) was registered by the FDA in 2016. 
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Table 2-14: Published guidelines for different types of lipids in PN 
Society Year Recommendation 
ESPEN (68) 
(139) 
2009 
 
 
 
 
 
2017 
ICU:  
Lipid emulsions should be an integral part of PN for energy and to ensure 
EFAs provision in long-term ICU patients. 
IVLE (LCT, MCT or mixed emulsions) can be administered safely at a rate of 
0.7g/kg up to 1.5g/kg over 12 to 24 hours. 
Addition of EPA and DHA to lipid emulsions has demonstrable effects on cell 
membranes and inflammatory processes. FO-enriched lipid emulsions 
probably decrease length of stay in critically ill patients. 
Surgery: 
Postoperative PN including omega-3 PUFAs should be considered. 
CCPG (67) 2015 When PN with IVLEs are indicated, consider IVLEs that reduce the load of 
omega-6 fatty acids/soybean oil emulsions. 
Insufficient data to make a recommendation on the type of lipids to be used 
that reduce the omega-6 fatty acid/soybean oil load in critically ill patients 
receiving PN. 
ASPEN (66) 2016 Withhold or limit SO-based IVLE during the first week following initiation of 
PN in the critically ill patient to a maximum of 100g/week. 
Alternative IVLE may provide outcome benefit over soy-based IVLE; 
however we cannot make a recommendation at this time owing to lack of 
availability of these products in the US.  
SA 
National 
DoH PN 
Guidelines 
(65) 
2016 0.7–1.5g/kg/day 
Essential FA: 7–10g/day, equating to 14–20g LCT or 30–40g LCT from 
OO/LCT mix. 
IV FO administration: 0.1–0.2g/kg/day. FO containing LE have been shown 
to be anti-inflammatory and contain less hepatotoxic phytosterols 
Abbreviations: ESPEN: European Society of Clinical Nutrition and Metabolism; CCPG: Canadian 
Clinical Practice Guidelines; ASPEN: American Society of Parenteral and Enteral Nutrition; EFAs: 
Essential Fatty Acids; ICU: Intensive Care Unit; IVLE: Intravenous Lipid Emulsion; LCT: Long-Chain 
Triglyceride; MCT: Medium-Chain Triglyceride; SO: Soybean oil; US: United States; FA: Fatty acids; 
OO: Olive oil; FO: Fish oil. 
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2.3.4.2  Lipid emulsions: Overview of clinical benefit 
Lipid emulsions for PN provide a high amount of calories at a low osmotic load. They are 
composed of plant and/or fish oils containing FA. Their varying FA compositions partly account for 
their differential properties, both under physiological and pathophysiological conditions. 
Parenteral FAs interfere with immunological and inflammatory processes, thereby potentially 
influencing patient outcome. Inadequate or deregulated inflammatory and immune responses 
during acute stress can be responsible for increased complications such as nosocomial infections 
and organ failure. On the other hand, an appropriate and optimal PN may enable a better control 
of inflammatory processes and immune responses and thus improve critically ill patient outcome, 
defined by mortality, organ dysfunction and ICU or hospital LOS (1).  
Adverse events should be carefully assessed with clinical and biological monitoring (TGs, 
inflammatory markers, liver and lung functions). Discrepancies occur between the different clinical 
and experimental study results partly owing to the lack of standardised criteria and because of the 
different PN formulations. Moreover, the clinical relevance of animal models has been largely 
criticised over the past years, as they invariably fail to reproduce the complexity of human illness 
(1). Human studies conducted in adult patient populations, comparing FOLE with other 
comparators, are discussed later in this review. 
 
2.3.4.2.1 Critical illness 
According to the ESPEN definition, a critically ill patient is a patient developing an intensive 
inflammatory response with failure of at least one organ (SOFA Score > 4), necessitating support of 
organ function during an ICU episode expected to be longer than three days (68).  
Septic shock is a systemic inflammatory syndrome leading to profound mononuclear cell 
activation, which can evolve towards MOF and death. Hence, modulating excessive and 
deregulated inflammation by optimising artificial nutrition composition will be of major benefit 
(1). 
The biological effects associated with LE are likely to benefit a majority of patients under 
metabolic stress receiving PN. The potential therapeutic benefits of LE are tabulated below (Table 
2-15). 
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Table 2-15: Potential therapeutic effects of LE (1, 10, 124) 
 Provide sufficient FAs 
 Improve metabolism and limit energy deficit 
 Maintain or increase antioxidant concentrations  
 Limit the contribution of lipid peroxidation to oxidative stress 
 Support the immune function and limit immunosuppression 
 Reduce the incidence of infectious complications 
 Prevent or regulate hyperinflammation  
 
As far back as 1989 Griffin highlighted that reversing the negative nitrogen balance in septic 
patients would probably be impossible to achieve without therapeutic manipulation of cytokine or 
cyclooxygenase inhibitors (140). 
Numerous studies in ICU patients indicate the clinical value of n-3 PUFAs in critically ill patients. 
(See Table 2-16) Mayer et al. (141, 142) showed that n-3 PUFA infusion for 5 days increased free n-
3 PUFAs and reversed the n-6:n-3 PUFA ratio within 24 to 48 hours to an n-3 over n-6 
predominance. Moreover, n-3 PUFAs were incorporated into mononuclear leukocyte membranes, 
with significantly increased EPA and DHA content and significantly increased (EPA+DHA)/AA ratio. 
Serum cytokine levels (TNF-α, IL-1β, IL-6 & IL-8) were decreased by 30% in patients treated with 
FO, whereas they were doubled in those treated with LCTs (n-6 PUFAs). 
In a multicentre study in 661 critically ill patients, Heller et al. demonstrated that IV FO 
administered for ≥3 days improved survival and reduced infection rates, antibiotic requirements, 
and LOS at doses of 0.15 – 0.2g FO/kg/day (143). 
A randomised study conducted by Khor et al., comparing IV FO vs saline in 28 critically ill patients 
with severe sepsis showed a significant score reduction for APACHE II and serum PCT on day 3, 5 
and 7 in the FO group. However, serum TNF-α level, length of stay (LOS) of ICU and hospital stay 
were not significantly different in both groups (13). 
Barbosa et al. studied the effects of FO LE on 25 septic patients for 5 days. The FO group had an 
increase in plasma EPA level. The plasma IL-6 concentration decreased more, and IL-10 
significantly less, in the FO group. There was no difference in days of MV, ICU LOS and mortality. 
The FO group tended to have a shorter hospital LOS which became significant when only surviving 
patients were included (144). Another study conducted in 20 patients with SIRS and 20 patients 
with sepsis showed an increase in TNF-α and IL-6 values on day 7, whereas IL-1 values were 
significantly higher on days 3, 7 and 10 in the MCT/LCT group. Conversely, IL-10 values on days 3 
and 7 were significantly higher in the FO group (145).  
Grecu et al. compared LCT + FO vs LCT in 54 patients with abdominal sepsis for 5 days and showed 
significantly lower reoperation rates, ICU and hospital LOS. The CRP levels were also lower in the 
FO group on day 5, but they found no difference in mortality (146).  
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However, in a study conducted in 166 medical critically ill patients, comparing MCT/LCT LE to 
MCT/LCT plus FO supplementation for more than 6 days, there was no significant difference in 
terms of IL-6 levels and clinical outcomes (infections, duration of MV, ICU LOS and 28-day 
mortality) (147).  
Another study conducted by Hall et al. in 60 critically ill patients with sepsis looked at the effects 
of parenteral n-3 PUFAs (0.2g FO/kg/day) administered as an independent drug additional to 
standard medical care vs standard medical care. The FO-supplemented group had a significant 
decrease in new organ dysfunction (assessed by delta-SOFA and maximum SOFA) and maximum 
CRP. There was no significant reduction in LOS between cohorts and no associated reduction in 28-
day or inpatient mortality; however in the less severe sepsis group there was a statistically 
significant reduction in mortality (148). 
Edmunds et al. compared the effects of different IVLEs on clinical outcomes in critically ill patients 
and showed that compared with lipid-free PN, patients who received FO had a faster time to ICU 
discharge alive. When compared with LCT, patients who received OO or FO had a shorter time to 
termination of MV alive and a shorter time to ICU discharge alive (149). 
Four meta-analyses have looked at different LEs in critically ill patients (150-153). They found no 
difference in mortality but a significant reduction in hospital LOS with IV FO LE. However, two 
meta-analyses showed significant reduction in infection rate in the group receiving FO- 
supplemented PN (150, 152). In addition, Pradelli et al. showed reduced markers of inflammation 
in the FO group, especially IL-6 and a shift towards LTB5 series production (152). He conducted a 
cost-effectiveness analysis on PN regimens containing omega-3 PUFAs in ICU patients. The 
reduction in infection rates and overall LOS translated to a cost saving of between €3972 and 
€4897 per ICU patient (154).  
A recent review published found insufficient high-quality data investigating inflammatory and 
immune markers as well as clinical outcomes to determine the true effect of PN with FO 
containing LE compared with other IVLEs (155). 
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Table 2-16: Clinical studies in septic patients 
Study Patients Duration Lipid Emulsion Effects 
Barbosa 
(144) 
25 septic pts 5 days LCT/MCT/FO 
vs 
MCT/LCT 
FO grp: ↑ EPA, IL-6 ↓ significantly, IL-10 ↓ significantly less. 
D6: PaO2/FiO2 ratio was significantly higher.  
No difference in days on ventilator, ICU & hospital LOS.  
No difference in laboratory measurements. 
Sungurtekin 
(145) 
20 sepsis & 20 
SIRS pts 
7 Days MCT/LCT + FO 
vs 
MCT/LCT 
(FO 0.6g/kg) 
LCT/MCT grp: ↑ liver steatosis on D7 & D10.  
No difference in AST, ALT, GGT or CRP.  
IL-6 & TNF-α ↑ on D7, IL-1 ↑ on D3, 7 & 10 in sepsis grp.  
Serum LDH & TG significantly ↑ on D7 & D10 for SIRS grp 7 only ↑ on D7 in sepsis grp. 
FO grp: IL-10 significantly ↑ on D3 & D7 in sepsis grp. 
Friesecke 
(147) 
116 ICU pts ≥7 days  MCT/LCT+FO 
vs 
MCT/LCT 
FO grp: No effect on inflammation (IL-6) & clinical outcome (infections, MV, ICU LOS & 
28-day mortality). 
Hall (148) 60 critically ill 
pts with sepsis 
14 days 
or until 
discharge 
FO 
supplement 
FO grp: significant ↓ in new organ dysfunction & max CRP. 
No significant ↓ in LOS. 
Edmunds 
(149) 
451 critically ill 
pts 
12 day or 
death 
LCT vs 
MCT/LCT vs 
OO/LCT vs FO 
vs 
LCT/MCT/OO/
FO 
FO or OO grp vs LCT had shorter time to termination of MV & shorter time to ICU 
discharge. 
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Study Patients Duration Lipid Emulsion Effects 
Khor (13) 28 critically ill 
pts with severe 
sepsis 
5 days FO vs saline FO grp: Significant ↓ in APACHE score & PCT on D3, D5 & D7.  
No difference in TNF-α, ICU & hospital LOS and  mortality. 
Mayer (141) 21 septic pts 5 days LCT vs LCT + 
FO (35g/day) 
FO grp: ↓ cytokine secretion. ↑ EPA & DHA after Day 3. n-6:n-3 PUFA ratio=2.5:1 after 
day 3. 
No effect on length of MV & mortality. 
Mayer (142) 10 septic pts 10 days LCT vs LCT + 
FO 
FO grp: ↑ EPA & DHA over AA. ↑ LTB5. Improved neutrophil function. ↓ CRP on D4. 
Improved n-6:n-3 PUFA ratio. 
No effect on length of MV & mortality. 
Heller (143) 661 ICU pts  ≥3 days  FO at different 
doses 
FO grp at 0.1 – 0.2g/kg showed favourable effects on survival, infection rate & LOS.  
↓ antibiotics at 0.15 – 0.2g/kg. 
Grecu (146) 54 pts with 
abdominal 
sepsis 
5 days LCT + FO vs 
LCT 
Significant ↓ reoperation rates, ICU and hospital LOS. CRP lower in FO group on day 5.  
No difference in mortality. 
Grau-
Carmona 
(156) 
159 ICU pts ≥ 5 days MCT/LCT vs 
LCT/MCT/FO 
(FO 0.1g/kg) 
FO grp: Fewer instances of nosocomial infections (21% vs 37.2%).  
Similar clinical outcomes (mortality, hospital LOS, ICU stay, days on MV). 
Abbreviations: Pts: patients; MV: mechanical ventilation; PCT: procalcitonin; ICU: Intensive Care Unit; EPA: eicosapentaenoic acid;  DHA: docosahexaenoic acid; 
AA: arachidonic acid; CRP: C-reactive protein; FO: fish oil; LCT: long-chain triglyceride; MCT: medium-chain triglyceride; OO: olive oil; LTB5: leukotriene B5; AST: 
aspartate aminotransferase; ALT:  alanine aminotransferase; GGT: gamma-glutamyl transferase; IL-6: Interleukin-6; IL-1β: Interleukin-1β;  TNF-α: tumour-necrosis 
factor-alpha; LDH: lactate dehydrogenase; PaO2/FiO2: partial pressure arterial oxygen and fraction of inspired oxygen ratio; n-6:n-3 PUFA: omega-6:omega-3 
polyunsaturated fatty acid ratio. 
I
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2.3.4.2.2 Lipid emulsions in ARDS 
The acute phase of ARDS can be a component of sepsis and septic shock with comparable 
pathogenesis and is characterised by an excessive inflammatory response with the release of pro-
inflammatory cytokines and eicosanoids. Moreover, the alveolar-capillary barrier is altered, 
resulting in vascular permeability and neutrophil leakage into the alveolar and  interstitial space 
(1). The main clinical features of ARDS include rapid onset of dyspnoea, severe defects in gas 
exchange and imaging studies demonstrating diffuse pulmonary infiltrates (157). The PaO2/FiO2 
ratio in mild ARDS is 200mmHg– ≤300mmHg, in moderate ARDS is 100mmHg–≤200mmHg and in 
severe ARDS is ≤100mmHg (158). The role of nutrition in the management of ARDS has 
traditionally been supportive. Recent research has demonstrated the potential of certain dietary 
lipids (e.g fish oil, borage oil) to modulate pulmonary inflammation, thereby improving lung 
compliance and oxygenation, and reducing time on mechanical ventilation (157). 
While LE appear to be safe in patients with normal lung function or chronic obstructive pulmonary 
disease, soybean-based emulsions have been shown to induce several modifications in gas 
exchange and pulmonary inflammation in patients with acute respiratory failure (159, 160). The 
deleterious effects appear to be predominantly due to their high proportion of LA and to excessive 
or rapid LCT infusion (161). This results in a reduction in PaO2/FiO2 ratio, pulmonary blood 
pressure and vascular resistances, through an imbalance in production of vasodilating and 
vasoconstricting eicosanoids (160, 162).  
Emulsions with mixtures of FA have been administered to reduce the deleterious effects of high 
doses of omega-6 FA, while replacing the carbohydrate energy source by lipids. In addition the 
omega-6:omega-3 ratio is significantly reduced in the latest generation LE (1). Morlion et al. 
suggested that in patients receiving PN, a n-6:n-3 PUFA ratio of approximately 2:1 may be optimal 
(134). 
The effects of a fish oil containing LE as part of PN was studied in 25 septic patients showing 
improved gas exchange. At day 6, the PaO2/FiO2 ratio was significantly higher in the fish-oil group 
and there were fewer patients with PaO2/FiO2 <200 and <300 in the fish-oil group; however, days 
on MV were not different between the two groups (144). Another study (163) using the same LEs 
in patients with ARDS showed significant short-term changes in anti-inflammatory eicosanoid 
values. However, in an earlier study by the same group in ARDS patients, they didn’t show 
significant changes in haemodynamic and gas exchange parameters (164). 
Similar results have been shown in studies using n-3 PUFAs as part of enteral nutrition (165-168); 
however this will not be discussed as this falls beyond the scope of this review.  
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2.3.4.2.3 Lipid emulsions and surgical patients 
There are numerous clinical studies (Table 2-17) on the efficacy and safety of LE in surgical patients. 
LCTs were the first LEs used in post-surgical patients and were found to increase pro-inflammatory 
cytokines and decrease T-cell proliferation in stressed patients, while having no effect in unstressed 
patients (169). 
There is data using fish oil containing LE in surgical patients showing a good safety profile, 
generation of n-3 fatty acid-derived lipid mediators and a reduced length of stay. The use of fish oils 
in this group of patients has shown improved plasma levels of α-tocopherol and better liver 
tolerance (170-177). Based on a review of the available evidence, Mayer concluded that inclusion of 
n-3 PUFAs in PN improves immunologic parameters and LOS in surgical patients (178). 
A meta-analysis conducted by Chen et al. (179) looked at the safety and efficacy of fish oil- 
enriched PN in postoperative patients undergoing major abdominal surgery. He showed that fish 
oil-enriched PN had a positive effect on length of hospital stay (-2.98 days), length of ICU stay (-1.8 
days) and reduction in postoperative infection rate by 44%. Levels of aspartate aminotransferase 
and alanine aminotransferase were also reduced and plasma α-tocopherol increased. These 
results were also confirmed in the meta-analysis by Wei et al. (180). Tian et al. showed similar 
results in terms of reduction in liver enzymes, triglycerides and CRP in the FO group; however, 
showed no difference in hospital LOS (181). 
Recently, a more extensive meta-analysis was performed to analyse the clinical efficacy and safety 
of n-3 PUFA-enriched parenteral LE in elective surgical and ICU patients. The results showed that 
n-3 PUFA-enriched emulsions were associated with a clinically significant reduction in infection 
rate and length of stay, both in ICU (-1.92 days) and in hospital overall (-3.29 days). Other 
beneficial effects shown included reduced markers of inflammation, improved lung gas exchange, 
liver function, antioxidant status and fatty acid composition of plasma phospholipids, and a trend 
towards less impairment of kidney function (152). See Table 2-18 for meta-analyses on FO 
containing PN. 
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Table 2-17: Clinical studies in post-surgery patients 
Study Patients Duration Lipid Emulsion Effects 
Antebi 
(170) 
20 pts 
undergoing 
major surgery 
≥5 days  LCT/MCT/OO/FO  vs  
LCT 
LCT grp: significant ↑ in TG, ALT, ALP & GGT and ↑ in CRP. 
FO grp:↑ in α-tocopherol & better liver function. 
Mertes 
(174) 
199 post-op 
Patients 
5 days LCT/MCT/OO/FO vs 
LCT 
FO grp: no effect on TG & AST, ALT & GGT & clinical outcome.  
LCT grp: AST, ALT & ALP levels were above normal range on D6. 
Piper 
(182) 
44 post-op 
patients  
5 days LCT/MCT/OO/FO vs 
OO/LCT  
LCT/MCT/OO/FO grp : improved liver function. 
Berger 
(183) 
20 patients 
with 
AAA surgery 
4 days  LCT/MCT/FO vs  
MCT/LCT 
LCT/MCT/FO grp: no significant difference in laboratory parameters & clinical 
outcome. Significant↑ EPA & DHA on Day 4. No difference in TG levels. Trend for 
shorter ICU and hospital stay. 
Han (172) 30 post-op 
major surgical 
Patients 
7 days MCT/LCT vs LCT/MCT 
+FO 
LCT/MCT grp: had significant ↑ in TG on D4, no difference on D7.  
Trend for ↑ in AST, ALT & bilirubin, not significant.  
LCT/MCT +FO grp: ↓ in IL-1. IL-8, IFN-γ, TNF-α, significant ↓ in IL-6. 
↓ in infection rate and liver dysfunction.  No difference in mortality. 
Wu (184) 40 GI surgery 
patients 
5 days LCT/MCT/OO/FO vs 
MCT/LCT 
MCT/LCT grp: significant ↑ in TG on D2 & D6.  
No difference in other laboratory parameters (LFTs).  
No difference in inflammatory markers.  
FO grp: non-significant trend for shorter hospital stay.  
Tsekos 
(185) 
249 ICU pts 
Major  
abdominal 
surgery 
2-year 
database 
MCT/LCT grp 1 
MCT/LCT + FO grp 2 
MCT/LCT + FO preop 
grp 3 
 
 
 
Significant ↓ in mortality in grp 3 vs grp 1. 
No. of pts requiring MV lower in grp 3. No difference in ICU LOS.  
Hospital LOS was significantly ↓ in grp 3. 
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Study Patients Duration Lipid Emulsion Effects 
Zhu (186) 76 
pancreatico-
duodenectomy 
patients 
5 days MCT/LCT vs MCT/LCT 
+ FO 
FO grp: less ↓ in total protein & prealbumin.  
Significant ↓ in ALT, AST & LDH on D6. 
Significant ↓ in infectious complications & post op hospital LOS.  
No difference in mortality. 
Badia-
Tahull 
(187) 
27 elective GI 
surgery 
patients 
5 days FO + OO/LCT vs 
OO/LCT 
FO grp: Significant ↓ in infections.  
CRP, prealbumin & leukocytes not significantly different.  
No difference in safety parameters. 
Wang 
(176) 
64 GI surgery 
patients 
5 days MCT/LCT vs  
MCT/LCT/FO 
No difference in infectious complications. 
FO grp: ↓ in total bilirubin vs ↑ in control grp.  
No difference in CRP, IL-1, IL-8, IL-10. 
Significant ↑in LTB5:LTB4 ratio & ↓ in IL-6, TNF-α & NFĸB.  
No difference in LFTs or TG. 
Jiang (173) 206 GI cancer 
surgical 
pateints 
7 days LCT vs LCT/FO  FO grp: Less infectious complications & significantly ↓ SIRS.  
Hospital LOS significantly ↓ 
Wei (188) 48 GI cancer 
surgery 
patients 
6 days LCT vs LCT + FO  No significant difference in LFTs & renal function.  
FO grp: Post op WBC, IL-6, IL-1β & TNF-α significantly ↓  
Rate of complications ↓. 
Llop-  
Talaveron 
(189) 
52 PN patients 14–31.8 
days 
MCT/LCT or 
OO/LCT for 1st wk 
FO LE added 2nd wk 
GGT, ALP & total bilirubin ↑ significantly in 1st wk.  
After FO added GGT, ALP & ALT ↓. 
 
Grimm 
(171) 
33 major 
abdominal 
surgical 
patients 
5 days LCT vs 
LCT/MCT/OO/FO 
TG, phospholipids & total cholesterol similar in both grps. 
FO grp: On D6 α-tocopherol significantly ↑. ↓ LOS . ↑LTB5:LTB4 ratio. ↑LTB5 
release and ↓ LTB4 
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Study Patients Duration Lipid Emulsion Effects 
Heller 
(190) 
44 major 
abdominal 
surgical 
patients 
5 days LCT vs LCT + FO  No differences were observed in terms of coagulation & platelet function at 0.2g/kg 
FO. 
 
Heller 
(191) 
661 post-op & 
septic pts 
≥ 3 days Different n-6:n-3 PUFA  
ratio 
n-6:n-3 ratio 2:1 ↓ ICU LOS. 
No difference in mortality. 
Genton 
(192) 
32 post-op 
patients 
7–14 days LCT vs 
LCT/MCT/OO/FO 
No difference in TG, total cholesterol and liver functions. 
Ma (193) 99 
gastrointestinal 
cancer surgery 
patients 
1 day 
before & 7 
days post-
op 
MCT/LCT/FO vs 
MCT/LCT 
FO grp: Improved lipid metabolism. 
No effect on metabolic parameters, pro-inflammatory cytokine levels, adverse 
events and clinical outcomes. 
Metry 
(194) 
83 
postoperative 
ICU patients 
7 days LCT/MCT/OO/FO vs 
LCT 
No significant differences with regard to vital signs and laboratory profiles of 
cholesterol, TG and liver enzymes. 
IL-6 levels were significantly different between 2 group on D4 & D7; IL-6 was 
significantly lower in FO group on D4 & D7. 
Senkal 
(195) 
40 colorectal 
surgery 
patients 
5 days MCT/LCT vs 
LCT/MCT/FO 
FO grp: significant ↑ in EPA and DHA levels. Increase in n-6:n-3 PUFA ratio.  
AA not significantly different in both groups 
Wichmann 
(177) 
256 major 
abdominal 
surgical 
patients 
5 days LCT vs LCT/MCT/FO FO grp: ↑in EPA, LTB5 and α-tocopherol levels. ↓n-6:n-3 ratio on d6. 
Shorter length of hospital stay (17.2 days versus 21.9 days). 
No difference in mortality. 
Abbreviations:  
AAA: abdominal aortic aneurysm; TG: triglycerides; LOS: length of stay; FO: fish oil; LCT: long-chain triglyceride; MCT: medium-chain triglyceride; OO: olive oil; MV: mechanical 
ventilation; WBC: white blood count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl transferase; IL-6: interleukin-6; IL-1β: interleukin-1β; 
IL-8: interleukin-8; TNF-α: tumour-necrosis factor-alpha; IFN-γ: interferon – gamma; LDH: lactate dehydrogenase; LFTs: liver function tests; ICU: intensive care unit; grp: group; 
CRP: C-reactive protein; NFĸB: nuclear factor kappa-light-chain-enhancer of activated B cells; SIRS: systemic inflammatory response syndrome; pts: patients; GI: gastrointestinal; 
post-op: post-operative; LTB5: leukotriene B5; LTB4: leukotriene B4; D: days; AA: arachidonic acid; EPA: eicosapentanoic acid; DHA: docosahexaenoic acid  
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Table 2-18: Meta-analysis on FO-containing PN 
Author Patients No. of  
Studies 
Lipid Emulsion Effects 
Pradelli (152) 1502 surgical 
& ICU 
patients 
 
23 FO-enriched PN vs 
LCT, MCT/LCT or 
OO/LCT 
FO grp: Significant ↓ in infection rate, LOS in ICU & hospital. Reduced markers of 
inflammation, especially significant reduction in IL-6, shift towards LTB5 series, improved 
lung gas exchange, significant ↓ in ALT & AST, ↑ in antioxidant status & FA composition 
of plasma phospholipids.  
No difference between coagulation times, platelet count, serum TG, CRP or bilirubin. No 
difference in mortality. 
Tian (181) 306 surgical 
pts 
6 LCT/MCT/OO/FO vs 
LCT, MCT/LCT or 
OO/LCT 
FO grp: Lower levels of liver enzymes, significant difference in AST between FO & LCT grp. 
↓ in TG & CRP vs LCT & OO/LCT grp. 
No difference in hospital LOS. No difference between MCT/LCT vs LCT/MCT/OO/FO. 
Chen (179) 892 major 
abdominal 
surgical pts  
13 FO PN vs PN + 
other LE 
FO grp: ↓ hospital & ICU LOS, post op infection rate, levels of AST & ALT,  
↑ α-tocopherol on POD6. Significant differences in EPA & DHA levels but not AA. 
LTB5:LTB4 ratio significantly enhanced in FO grp. 
No difference in mortality, cardiac complications or bilirubin & TG levels.  
Palmer (151) 391 critically 
ill pts  
8 FO-supplemented 
PN 
Significant reduction in hospital LOS.  
No difference in mortality, infectious complications & ICU LOS. 
Manzanares 
(150) 
733 critically 
ill pts  
10 FO LE vs EN, PN 
with SO-based LEs 
or a non-FO based 
LE, including saline 
solution 
FO significantly ↓ infections & hospital LOS. 
No effect on overall mortality. 
Wei (180) 611 surgical 
pts  
6 FO LE vs MCT/LCT 
or LCT or OO 
FO grp:  Significant ↓ in infectious complications.  Trend to shorter hospital LOS. 
Significant ↓ in ICU LOS. 
No mortality benefit. 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
50 
 
Author Patients No. of  
Studies 
Lipid Emulsion Effects 
Kreymann 
(196) 
380 critically 
ill pts 
1005 surgical 
pts with 
malignancies 
 FO LE + OO/SO 
FO LE + MCT/LCT 
LCT/MCT/OO/FO 
LCT/MCT/FO 
35% reduction in infection rates in critically ill pts and 59% reduction in surgical pts with 
malignancy. 
Significant reduction in IL-6 levels. 
Significant reduction in hospital LOS by 1.84 days in surgical pts.  
Abbreviations:  Pts: patients; LOS: length of stay; ICU: intensive care unit; FO: fish oil; LE: lipid emulsion; IL-6: interleukin-6; LTB5: leukotriene B5; ALT: alanine 
aminotransferase;  AST: aspartate aminotransferase; FA: fatty acid; EN: enteral nutrition; PN: parenteral nutrition; CRP: C-reactive protein; TG: triglycerides; LCT: 
long-chain triglyceride; MCT: medium-chain triglyceride; OO: olive oil; POD6: post-operative day 6; LTB4: leukotriene B4 
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2.3.4.2.4 Lipid emulsions and PNALD 
The administration of PN has been associated with liver changes such as steatosis, steatohepatitis, 
fibrosis, cirrhosis, and biliary changes such as cholestasis, cholelithiasis and cholecystitis. These 
changes may occur in 25 – 100% of adult patients who receive PN. In studies conducted in Spanish 
ICUs, the prevalence of such changes has been reported in 30% of critically ill patients on PN. If 
liver involvement progresses, it may lead to cirrhosis, and liver and bowel transplant may be 
required (83). 
Diagnosis is mainly based on bilirubin and liver enzyme levels and the cut-off values change 
depending on the hospital or in different studies. Moreover, the correlation between changes in 
laboratory tests and histopathological findings in liver biopsies is low. The etiology of changes is 
thought to be multifactorial (see Table 2-19) (197). 
Table 2-19:  Factors associated with liver changes associated with PN (10, 11, 83, 197) 
Changes associates with PN: 
 Duration on PN 
 Overfeeding, particularly with calories 
 CHO overload 
 Lipid overload and high phytosterol intake 
 Amino acid overload or deficiency 
 Carnitine, choline or taurine deficiency 
 Excess manganese and copper administration 
 Long-term continuous infusion  
Patient-associated factors: 
 Underlying disease 
 Sepsis 
 Intestinal bacterial overgrowth 
 The presence of short-bowel syndrome 
 Lack of enteral nutrition 
 Hyperinsulinism 
 
 
There are four factors with regard to lipids in PN that have been related to liver dysfunction.  
 
a.  Lipid dose 
Both a deficiency and an excess provision of essential FA may cause liver damage. A lipid dose of   
> 1g/kg/day is associated with a marked increase in liver changes and a 2 – 5 times greater risk of 
experiencing some severe change in the liver (198). At least 2–4% of total calories should be 
administered as linoleic acid to prevent deficiency. The ratio of calories provided by CHOs and 
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lipids also appears to be important and should not exceed 60:40 in home patients (199). The 
mechanism by which toxicity is related to the lipid dose is not clear, but it could be changes in liver 
macrophages, phospholipid elimination in bile, or a blockade of liver capacity to mobilise lipids 
(127, 197, 198). 
b.  Lipid composition 
LE based on SO, with high n-6 PUFA content, have been associated with greater liver toxicity, 
particularly when they are used over a long period of time (10,11). To decrease this toxicity, an 
alternative LE with lower n-6 FA content (e.g. MCTs) as well as n-3 PUFAs  have been proposed 
(170, 182).  
c.  Phytosterols 
LEs are mostly of plant origin and contain substantial amounts of phytosterols. See Table 2-12 for 
the phytosterol content of IVLE. These phytosterols have been related to liver toxicity in PN 
because they are considered to be able to alter cholesterol and bile acid production and to 
contribute to cholestasis (11, 136). 
d.  α-Tocopherol 
This may act as a potent antioxidant in cases of steatosis, protecting the liver from oxidative 
damage. Omega-3 PUFA LEs have greater amounts of α-tocopherol than those derived from SO 
(200). See Table 2-12 for α-tocopherol content in IVLE.  
The effects of FO-containing LEs compared with other LEs on liver dysfunction have been studied 
in surgical patients. FO LEs showed improvement in liver enzymes and plasma α-tocopherol levels 
(170, 171, 174, 176, 182, 186, 189). Some studies showed no difference in terms of liver function 
tests with FO LEs (184, 188, 192). 
Sungurtekin et al. demonstrated an increase in liver steatosis on day 7 and 10 in patients with 
sepsis and SIRS on PN without FO (145). Recently, a retrospective study was conducted in adult 
patients receiving FO supplementation in PN. GGT, ALP and ALT decreased with FO PN 
supplementation. The decrease was greater when the doses of FO were higher (0.71g FO/kg – 
5.28g FO/kg) (201). 
Two studies were conducted in patients undergoing liver transplantation, comparing PN with and 
without FO. A significant reduction in ALT and prothrombin time was seen in the FO group and a 
significant decrease in post-transplant hospital stay (202, 203).  
Reduction in liver enzymes and improved antioxidant status was also shown in four meta-analyses 
(152, 179, 181, 204) . The dosage of FO that showed benefit was 0.1 – 0.15g/kg/day (152) and 0.07 
– 0.225g/kg/day (179). 
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Klek et al. (205) performed a study to evaluate the safety and efficacy of a soybean/MCT/olive/fish 
oil containing LE vs a soybean oil emulsion in intestinal failure patients on long-term parenteral 
nutrition. After four weeks on PN, the patients receiving the fish oil containing LE had significantly 
lower liver enzymes, increased serum α-tocopherol and a positive change in their fatty acid profile.  
 
2.3.4.3  Complications associated with IV lipid emulsions 
The IVLE component in PN can cause several metabolic and physiological adverse effects (AEs). 
a.  Hypertriglyceridaemia 
Hypertriglyceridaemia is one of the most common AEs and can predispose patients to elevations 
in liver enzymes, haemolysis and respiratory distress (125). The tolerance of lipids is monitored by 
measuring plasma triglyceride levels. An increase in plasma triglyceride levels indicates that the 
rate of lipid infusion exceeds the rate of hydrolysis. Lipoprotein lipase (LPL) is the enzyme 
responsible for hydrolysing triglycerides into two free fatty acids. Sepsis and the administration of 
steroids are two examples of factors which decrease LPL activity (206).  
LCT and LCT/MCT LEs have been shown to increase plasma triglyceride levels, whereas FO 
containing LEs have been shown  to reduce plasma triglyceride levels significantly in both surgical 
and septic patients or maintain the levels within normal ranges (170, 172, 174, 182-184). (Tables 
2-15 & 2-16.) 
A meta-analysis conducted by Chen et al. on the safety and efficacy of FO-enriched PN in 
postoperative patients undergoing major surgery found no significant difference in plasma TG 
levels compared with PN without FO (179). However, the meta-analysis conducted by Tian et al. 
found significant differences between LCT/MCT/OO/FO vs LCT and vs OO/LCT, suggesting the 
beneficial effect of FO containing LE in surgical patients (181). 
In general, IVLE should not be infused in patients with plasma triglycerides (TGs) >3–4 mmol/l and 
should be closely monitored in those with high basal (>2–3mmol/l) TG concentrations to avoid 
complications (11). The SA National Parenteral Nutrition Practice Guidelines for Adults 
recommend that in the case of hypertriglyceridemia, the amount of lipid infused should be 
reduced and/or the type of fat should be changed (65). 
 
b.  Fat overload syndrome 
Fat overload syndrome is another complication of IVLE therapy. It is characterised by headaches, 
jaundice, hepatosplenomegaly, respiratory distress and spontaneous haemorrhage. It has been 
described in several case reports in the presence of rapid infusion and/or high doses of IVLE. Other 
symptoms of fat overload include anaemia, leukopaenia, thrombocytopaenia, low fibrinogen 
levels, and depressed levels of coagulation factor V. These symptoms can be reversed by stopping 
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the IVLE infusion or prevented by administering LE as part of an all-in-one PN solution, infused at a 
controlled rate over 24 hours (125). Guidelines from ESPEN recommend that IVLEs be 
administered at a rate of 0.7 – 1.5 g/kg over 12 – 24 hours (11). FO LEs seem to reduce the risk of 
lipid overload by accelerating TG clearance more than SO LEs. Despite being cleared more 
efficiently, FO LEs undergo less catabolism than SO LEs. The mechanism involved in the hydrolysis 
of FO LE and SO LE is very different. It appears that FO does not reduce the production of TGs but 
rather enhances the clearance of emulsion particles and may not predispose patients to the 
complications associated with rapid infusion of SO LE (125). 
c.  Hepatic abnormalities 
The hepatic abnormalities induced by PN administration manifest differently depending on 
whether they occur in adults or children. In adults, fat accumulation more often leads to benign, 
asymptomatic steatosis, with mild to moderate transaminitis (ALT > 42 IU/L & AST >40 IU/L) (83)  
and hyperbilirubinaemia (>34 µmol/L) (136). Risk factors for the development of parenteral 
nutrition-associated liver disease (PNALD) have been addressed previously. Refer to Table 2-19. 
d.  Essential fatty acid deficiency (EFAD) 
Linoleic acid and alpha linolenic acid are the two essential FAs that cannot be synthesised by the 
human body. The typical ICU patient requires 9–12g/day LA and 1–3g/day ALA. Their importance is 
emphasised by their further metabolism to AA, EPA and DHA (68). Low essential FA intake 
eventually leads to EFAD, which is associated with water losses from the skin owing to increased 
permeability, susceptibility to infections, lowered resistance to irradiation injury and impaired 
wound healing, haematologic disturbances, fat infiltration of the liver, impaired chylomicron 
synthesis, and heightened fat absorption. EFAD is a potential effect of FO LE therapy as sole FA 
source or a reduction of SO LE (11). At least 2–4% of total calories should be administered as 
linoleic acid to prevent EFA deficiency (200) or essential FA should be provided at  7–10g/day, 
equating to 14–20g LCT or 30–40g/day LCT from OO/LCT mix (65). 
e.  Pulmonary complications 
Parenteral SO LEs have been shown to induce inflammation of pulmonary vessels, leading to 
pulmonary hypertension, phagocyte activation, and the formation of granulomas (159, 160). The 
accumulation of lipid droplets in the microcirculation can compromise pulmonary gas exchange by 
actions of lipid-derived mediators such as eicosanoids and peroxides or by the diminished 
availability of the vascular relaxant NO (11, 162). 
The administration of FO LE has been shown to improve gas exchange and reduce pro-
inflammatory eicosanoids (144 152). 
f.  Oxidative stress 
Unsaturated FAs, such as LAs may lead to oxidative stress because they can undergo lipid 
peroxidation that involves incorporation of an oxygen molecule into the FA when breaking down 
Stellenbosch University  https://scholar.sun.ac.za
55 
 
the double bonds. This produces lipid peroxides, which are unstable molecules and are converted 
to volatile metabolites that can trigger chain reactions, resulting in inactivation of enzymes, 
proteins and other elements necessary for viability of cells (127). 
Vitamin E, a powerful antioxidant, can protect against peroxidation. Storage conditions, such as 
light exposure and temperature can also influence peroxidation. MCTs consist of saturated FA, and 
oleic acid in olive oil is a MUFA; both of these FA types are resistant to peroxidation (11). 
g.  Coagulation complications 
Thrombosis is a common and serious complication for many critically ill, surgical and trauma 
patients. The patients might experience changes in the availability of clotting factors and 
alterations in the fibrinolytic pathway, resulting in disseminated intravascular coagulation (207). 
The effect of LEs on coagulation have not been extensively assessed (124).  
Currently there is no evidence of adverse effects of FO LEs based on an increased bleeding risk due 
to their antiplatelet effects (152). Heller et al. (190), investigated the issue of potential coagulation 
disturbances associated with postoperative parenteral FO administration after major abdominal 
surgery. Their findings suggest that the infusion of fish oil in doses up to 0.2g/kg BW per day is safe 
regarding coagulation and platelet function. Even with administration for up to four weeks, FO 
containing PN did not alter the haematological parameters and the INR remained unchanged 
(205). 
h.  Immune function and infections 
LEs can influence the immune system, as addressed previously; there are concerns that pure SO 
LEs might impair clinical outcomes due to their potential to promote inflammation and inhibit 
immune responses, especially in situations with an overproduction of pro-inflammatory mediators 
such as trauma or sepsis (see Table 2-16, 2-17 and 2-18). Early clinical trials alluded to this effect; 
however the clinical evidence for this is not strong. Methodologically flawed studies using 
hypercaloric feeding regimens and extrapolations from highly experimental approaches play an 
important role in this debate (11). 
It has been recommended that new lipid emulsions should be composed of a reduced n-6 PUFAs, 
especially linoleic acid, counterbalanced by MCT, MUFA and long-chain n-3 PUFAs. Based on 
experimental and clinical studies, the most favourable n-6:n-3 PUFA ratio is proposed to range 
between 2:1 and 4:1 (11, 133-135). 
 
2.3.5  Micronutrients 
Micronutrients play a central role in metabolism and in the maintenance of tissue function. Trace 
elements are involved in the activity of virtually all enzymes, whether at the active site of the 
enzyme or as co-factors. Vitamins act as co-factors. These are clearly necessary for the 
Stellenbosch University  https://scholar.sun.ac.za
56 
 
maintenance of intermediary metabolism and adequate amounts are vital to the body’s ability to 
cope with the metabolic response to critical illness. Hypermetabolism gives rise to increased 
production of ROS, as a result of increased oxidative metabolism. This may lead to oxidative 
damage at various points within the cell, but particularly to PUFAs in the cell membrane, or to 
nucleic acids in the nucleus. The body has a well-developed antioxidant system to neutralise the 
most harmful effects of these oxidant species. Micronutrients have important functions in this, 
either directly in the immediate quenching of the oxidative particle, for example the antioxidant 
action of vitamin E or C, or more indirectly as part of metallo enzymes such as glutathione 
peroxidase (selenium) or superoxide dismutase (zinc, copper) which catalyse removal of the 
oxidant species. The micronutrients also have other key functions, such as modulating gene 
transcription where they may be involved in either activation of particular genes, or in the control 
of this activation (208).  
Recent findings suggest that Vitamin D is a marker for outcomes in critical illness. Vitamin D 
deficiency is defined as 25 (OH)-D concentrations < 50nmol/L and is common in hospitalised 
patients requiring long-term EN or PN (209, 210). The prevalence of vitamin D deficiency is 
considerably higher in patients with various disorders of the digestive system, including cystic 
fibrosis, acute and chronic pancreatitis, coeliac disease, short-bowel syndrome and inflammatory 
bowel disease (209). Restoration of optimal vitamin D status with high-dose supplemental vitamin 
D is required in most cases (210). A meta-analysis by De Haan et al. suggested that vitamin D 
deficiency increases susceptibility to severe infections and mortality of the critically ill (211); 
however no difference in 90-day mortality was reported by the FINNAKI cohort study (212). In 
severe vitamin D deficiency (<30nmol/L), lower mortality was observed with supplementation 
(58).  
Adequate micronutrient (electrolytes, trace elements and vitamins) intake is essential to avoid 
depletion especially if refeeding syndrome is suspected (50). Guidelines on Parenteral Nutrition in 
ICU recommend that all PN prescriptions should include a daily dose of multivitamins and of trace 
elements (65, 68). ASPEN suggests that a combination of antioxidant vitamins and trace minerals 
in doses reported to be safe in critically ill patients be provided to those patients who require 
specialised NT (66). However, most issues of administration, such as dosage, frequency, duration 
and route of therapy, have not been well standardised as there is not good evidence to inform 
this. See Table 2-20: Parenteral recommendations of micronutrient intake in critical illness.  
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Table 2-20: Parenteral recommendations of micronutrient intake in critical illness (65, 213-216) 
Micronutrient Recommended intake Amount provided in PN per day 
Thiamine 1.1–300mg 2.5mg 
Riboflavin 1.1–3.6mg  3.6mg 
Niacin 35–40mg 40mg 
Folic acid 400–1000µg 400µg 
Pantothenic acid 5–15mg 15mg 
Vitamin B6 1.3–6mg 4mg 
Vitamin B12 2.4–5µg 5µg 
Biotin 30–60µg 60µg 
Ascorbic acid 100mg–2000mg 100mg 
Vitamin A 700–3000µg 1980µg or 3300IU 
Vitamin D 5–50µg 5µg or 200IU 
Vitamin E 10–1000mg 9mg or 10IU 
Vitamin K 90–1000µg 150µg 
Adapted from ASPEN 2002, Sriram 2009, Berger & Shenkin 2006, Visser 2014, & SA National DoH 
Guidelines on PN 2016. 
 
2.4  Monitoring 
Close monitoring on all patients receiving PN daily should include assessment of clinical, 
laboratory and nutritional indices (see Table 2-21 and 2-22). This guarantees that the nutrition 
prescription is appropriate and adequate and that the risks of complications are minimised (63, 
70).  
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Table 2-21: Clinical evaluation on PN patients (63, 65, 70, 213). 
Parameter Evaluation Frequency 
Vital signs Temperature, blood pressure, 
respiratory & heart rate 
Hourly in unstable patients, 6-hourly in 
stable patients 
Physical 
examination 
Abdomen:  
 distention or discomfort 
 Stool/ostomy/fistula 
output & consistency 
Fluid balance 
Daily 
 
 
 
Hourly in unstable patients otherwise daily 
PN bag Leaking, cracking or separation 
of content 
Ongoing 
Infusion 
rate & 
pump 
Correct rate & pump is running Ongoing 
Line site Infection, inflammation, 
oedema, rash & tenderness 
Daily 
General 
response to 
therapy 
Wound healing, functional 
status, muscle & protein stores 
& micronutrient status 
Ongoing 
Nutritional 
intake 
Adequacy of delivery, readiness 
to introduce enteral or oral 
nutrition 
Daily 
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Table 2-22: Biochemical monitoring during PN administration (63, 65, 70) 
Parameter Frequency Rationale 
Na, K, urea, 
creatinine 
 Baseline 
 Daily until stable 
 1–2 times/week 
Assessment of renal function, Na & K status and 
fluid status. 
Magnesium, 
phosphate, 
calcium 
 Baseline 
 Daily if refeeding risk 
 3 times/week until 
stable 
 Weekly once stable 
Depletion is common and under recognised. 
Albumin, 
CRP 
 Baseline 
 2–3 times/week 
 Weekly once stable 
Hypoalbuminaemia.  
Provide information on level of inflammation and 
severity of disease. 
Total 
bilirubin, 
ALT, AST & 
ALP, 
including 
INR 
 Baseline 
 2 times/week 
 Weekly once stable 
Complex, may be due to sepsis, drug toxicity, 
overfeeding, glucose intake, IVLE. 
Triglycerides 
& 
cholesterol 
 Baseline 
 2 times/week 
 Weekly once stable 
↑ could be due to non-nutritional fat intake, IVLE, 
sepsis. 
Glucose  Baseline 
 4–6 hourly while on 
PN 
↑: suspect overfeeding or infections 
↓: improving condition 
Full blood 
count 
 Baseline 
 1–2 times/week 
 Weekly once stable 
Sepsis and immunosuppression, anaemia. 
Zn, Se, Mn, 
Cu, Cr 
 As clinically indicated In at-risk patients (CRRT, intestinal fistulae, 
prolonged feeding). 
Folate & vit 
B12 
 As clinically indicated Interpret with full blood count. 
Na: sodium; K: potassium; CRP: C-reactive protein; CRRT: continuous renal replacement therapy; Zn: zinc; 
Se: selenium; Mn: manganese; Cu: copper; Cr: chromium; IVLE: intravenous lipid emulsion; ALT: alanine 
aminotransferase;  AST: aspartate aminotransferase  AST: ALP: alkaline phosphatase; INR: international 
normalised ratio; Vit: vitamin 
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Serum phosphate, magnesium, potassium, and glucose should be tested if the patient is at risk of 
refeeding syndrome and replaced if depleted, before starting NT. Further close monitoring of 
these electrolytes is imperative (51, 213). 
Monitoring patients on PN is necessary to determine efficacy of specialised nutrition therapy, 
detect and prevent complications, evaluate changes in clinical condition, and document clinical 
outcomes. (63, 70). 
 
2.5  Conclusion 
Sepsis remains the leading cause of death in critically ill patients. These patients have life-
threatening organ dysfunction caused by a dysregulated host response to infection(16). The 
metabolic response to stress is complex and many patients experience ongoing immune 
dysregulation and develop persistent inflammation, immunosuppression and catabolism 
syndrome (3).  
Critically ill patients depend on artificial nutrition for the maintenance of their metabolic functions 
and lean body mass (63). Parenteral nutrition is a well-tolerated and important mode of nutrition 
for ICU patients, if correctly prescribed. Recent evidence points to the importance of early and 
adequate feeding in critically ill patients. However, special attention is needed to avoid 
overfeeding during the first 2–3 days in the ICU (79). Many of the deleterious effects attributed to 
PN result from wrong indications, composition of the formulation and/or from overfeeding (63).  
Lipids are undoubtedly an indispensable element of PN regimens, as they are not only an 
important energy source, they provide essential FA and can also modulate metabolic processes 
(10). The composition of LE has evolved over the years and the development of improved 
formulations are characterised by four distinct generations (125).  
The addition of FO to nutritional regimens in critically ill patients offers the possibility to 
counterbalance the unfavourable effects of SO LEs and n-6 PUFAs on immune system function and 
regulation of vascular tone. There is data on the use of n-3 lipids in surgical and ARDS patients; 
however the results are variable. In addition, there is some initial promising data on their use in 
septic patients (124, 125, 178). The results of the various studies are variable owing to study 
heterogeneity, varying quality and study design, small sample sizes, and differences in the timing 
and dose of FO administration as well as the different LEs studied (155). 
To date there is no study comparing the use of a combination 4-oil lipid emulsion containing fish 
oil (SMOFlipid®) in septic patients. In South Africa this LE is readily used in ICUs in critically ill 
patients and it would thus be beneficial to have data showing efficacy and safety, as well as 
improved oxygenation, reduced inflammation, improved total phospholipid plasma FA 
composition, and improved clinical outcome in this group of patients. 
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It was hypothesised that including FO as part of a 4-oil LE in patients with SIRS, with or without 
sepsis, or ARDS, requiring PN may be associated with less inflammation, improved gas exchange, 
increased plasma EPA, modified plasma total phospholipid fatty acid profile and improved clinical 
outcomes.  
The research questions are: 
What is the effect of a 4-oil LE-containing FO as part of PN in terms of effect on triglyceride levels 
and liver enzymes? 
Does the inclusion of a 4-oil LE-containing FO in PN result in less inflammation, by reducing the 
pro-inflammatory cytokines TNF-α, IL-1β and IL-6, and maintaining the levels of anti-inflammatory 
cytokine, IL-10? 
Does the inclusion of a 4-oil LE containing FO in PN result in improved gas exchange? 
Does the inclusion of a 4-oil LE containing FO in PN increase plasma EPA and modify other plasma 
total fatty acids? 
Will the inclusion of a 4-oil LE containing FO in PN improve clinical outcomes?  
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3.1  Aim 
To compare the difference between a 4-oil lipid emulsion containing fish oil (SMOFlipid®) and a 
100% soybean-based lipid emulsion in patients with the Systemic Inflammatory Response 
Syndrome (SIRS) with or without sepsis, or the acute respiratory distress syndrome (ARDS) in the 
intensive care unit (ICU), requiring parenteral nutrition (PN) for more than 5 days. 
 
3.2  Objectives 
To compare a 4-oil lipid emulsion (SMOFlipid®) containing omega-3 fatty acids from fish oils to a 
soybean-based lipid emulsion rich in omega-6 fatty acids, in terms of it’s impact on 
1. the inflammatory response; c-reative protein, tumour necrosis factor alpha (TNF-α), 
Interleukin-1β (IL-1β), IL-6 and IL-10,  
2. gas exchange, measuring PaO2/FiO2 ratio in patients with SIRS, or sepsis or ARDS, 
3. plasma EPA levels, and 
4. clinical outcome in terms of Sequential organ failure assessment (SOFA) score, length of 
ICU stay and mortality.   
 
3.3  Implementation objectives 
The results from this study will assist prescribers of PN to optimised nutrition therapy for critically 
ill patients with sepsis, in particular with regards to the type of lipid emulsions used in the PN 
prescriptions. 
 
3.4  Study design 
Double-blind, randomised, multi-centre, controlled trial. 
 
3.5  Study population and sampling 
3.5.1  Study population 
The study population consisted of adult (i.e ≥ 18 years) patients with SIRS with or without sepsis or 
ARDS in ICU, which were recruited from the multi-disciplinary ICU and surgical ICU at Universitas, 
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ICU at Pelonomi Hospital in Bloemfontein, and ICU and high care at Wits Donald Gordon Medical 
Centre (WDGMC).  
At Universitas Hospital the multi-disciplinary ICU had 7 beds and the surgical ICU had 4 beds. 
Pelonomi Hospital had 10 ICU beds. The ICU at WDGMC had 15 beds and High Care had 16 beds. 
(Appendix A: Data collection Protocol) 
The study was initially planned to be a multicentre study, however the recruitment at Universitas 
and Pelonomi hospital was very slow owing to challenges in the healthcare administration in the 
province and subsequently only 9 patients were recruited in 10 months. It was decided to open 
another centre at Wits Donald Gordon Medical Centre (WDGMC), Johannesburg, to continue with 
the study and to close the centres in Bloemfontein. Only the patients recruited from WDGMC 
were included in the two manuscripts. It was decided to exclude the patient recruited in 
Bloemfontein as there were insufficient biochemical results (namely cytokine and plasma fatty 
acid analysis).  
 
3.5.2  Sample size 
The total number of study participants needed was determined, with the help of a statistician, to 
be at least 72 individuals (36 in each subgroup). This number was calculated using a power analysis 
for ANOVA with two groups, significance level of 0.05 and an effect size of 0.55. Sample size n=36 
in each group was expected to yield 90% power to detect this effect size (Appendix C). 
A total number of 84 patients were included into the study, however 16 patients were excluded 
due to insufficient biochemical results (10 patients), protocol violations (4 patients) and 2 patients 
withdrew consent, leaving a total of 68 patients. Thirty five patients were randomised to the study 
group (SG) and 33 patients to the control group (CG). 
 
3.5.3   Sampling 
All patients admitted to the ICU or high care units were screened for eligibility. A screening form 
was completed with columns representing the eligibility criteria of each patient to be included.  
Consecutive patients meeting the inclusion criteria were enrolled in the study until the required 
sample size was reached. Data collection commenced in the last week of June 2014 in 
Bloemfontein at Universitas and Pelonomi Hospital and in April 2015 at WDGMC. Data collection 
was completed on 9th June 2016. (Appendix A: Data collection Protocol) 
Adult patients (>18 yrs) male or female with SIRS with or without sepsis or ARDS admitted to the 
ICU, who were predicted to need PN for more than 5 days were entered into the study.  
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3.5.4  Inclusion and exclusion criteria 
 
3.5.4.1  Inclusion criteria 
The inclusion criteria for this study was as follows; 
 all adult patients (>18 yrs) male or female admitted to ICU 
 with SIRS with or without sepsis, 
 or ARDS, and  
 predicted to need PN for more than 5 days. 
 
3.5.4.2  Exclusion criteria 
The exclusion criteria for this study included patients  
 Younger than 18 years,  
 on full enteral feeding,  
 pregnancy,  
 treatment with immunosuppressive drugs,  
 treatment with hydrocortisone >300mg/day at admission,  
 plasma triglycerides >400mg/dl (4,52mmol/l) 
 chronic liver disease and/or acute hepatitis,  
 chronic renal failure and/or end stage renal disease (According to the Rifle criteria, 
Appendix AI Table 3),  
 recent stroke,  
 known allergic reaction to fish or egg proteins confirmed by previous medical history. 
 
3.6   Methods of data collection 
Once the screening form (Appendix AII) was completed and the eligibility of the patient assessed, 
the patient was requested to complete the consent form (see Appendix B). If the patient was 
unable to give consent, the closest relative was asked. If the closest relatives are unable to give 
consent, the Clinical Manager at the site decided if the patient could be included into the study. 
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The patient was re-consented when it was possible. Once consent was obtained, the patient was 
allocated a research number and the research assistant started the data collection.  
 
3.6.1  General data collection procedure 
The clinician in charge of the study participant decided when the PN should commence, the 
dietitian was consulted to do a nutritional assessment on the patient and recommended a PN 
prescription to the clinician. The clinician ordered blood tests according to the laboratory 
measurements protocol before PN was started. The PN prescription form, was completed by the 
dietitian and signed by the clinician. The hospital pharmacy was contacted to inform them of the 
PN prescription and the patient’s inclusion into the study. The hospital pharmacy then contacted 
Fresenius Kabi Bloemfontein or Johannesburg (the supplier of PN), and placed the order for PN 
and explained that the patient was participating in the study.  
On receiving the PN prescription, the dispensing pharmacists in Bloemfontein or Johannesburg 
were responsible for the randomisation of  all the patients according to a randomisation sheet. 
This sheet allocated the type of PN according to the ITN code to the patient’s research number, 
name, file number, ICU and hospital. 
The patients was randomised to either receive PN containing a 4-oil lipid emulsion (SMOFlipid®: 
30% LCT, 30% MCT, 25% Olive Oil, 15% Fish oil, provided in a complete All-in-One PN bag by 
Fresenius Kabi: study group) or a Soybean-based lipid emulsion (Intralipid® 100% LCT, provided in 
a complete All-in-One PN bag by Fresenius Kabi: control group).  
The all-in-one PN, was compounded using isolator technology according to a validated procedure 
at Fresenius Kabi in Midrand, Johannesburg. The compounded PN bags all looked identical and 
were only differentiated by a barcode. The PN bags were stored at 20C - 80C in Johannesburg and 
then flown to Bloemfontein in a controlled temperature environment. On arrival in Bloemfontein 
the PN bags were refrigerated until they were dispensed to the various hospitals participating in 
the study. 
Before the PN was dispensed, a special sticker was placed on the outer pouch as well as the PN 
bag to identify it as a study bag and to avoid confusion when all the PN was delivered to the 
hospitals participating in the study. The outer pouch and PN bags look exactly the same, a label 
with the patient’s name, hospital, ward information and the nutritional composition of the bag 
was placed on the outer pouch and on the PN bag. This guaranteed that the correct PN was 
administered to the correct patient. 
The dispensing pharmacist checked that the correct bag was dispensed to the correct patient 
according to the randomisation sheet.  
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The PN bags were delivered to the hospital pharmacy before 14h00 daily. On receiving the PN, the 
hospital pharmacy dispensed it to the ICU where the appropriate patient was. The PN bags were 
refrigerated until the nursing sister was ready to administer the PN. The PN was administered 
continuously over a 24 hour period. The PN was started on the day after admission to the study 
(day 2). 
Fresenius Kabi Bloemfontein and Johannesburg employ a dispensing pharmacist and as well as a 
locum pharmacist. These two people are the only ones who had access to the randomisation sheet 
and were involved in the dispensing of the PN. The randomisation sheets were kept locked away in 
a cabinet for safe keeping. Only the pharmacist and locum pharmacist had access to the keys of 
the cabinet and the randomisation sheets. Once the study was completed, the randomisation 
sheets were obtained from the pharmacist and the study was un-blinded. 
The research assistant entered all the patient information required on the case report form daily 
until the patient was discharged (see Appendix AIII). 
By following the above procedure there was no deviation from usual standardised PN prescription 
techniques. The only difference being the fat composition of the PN bags. All the patient 
information was recorded daily until discharge from the ICU. 
 
3.6.2   Sociodemographic and general medical data 
The patient’s admission date, gender, age, primary diagnosis, SOFA score, APACHE II score was 
documented on entry into the study. The RIFLE classification to determine renal failure and the 
SOFA score was documented throughout the study. 
 
3.6.3   Baseline anthropometrical data 
 
3.6.3.1  Height 
The dietitian or research assistant measured the study participant’s height with the patient lying 
flat in bed, or used the height charted on the ICU chart 
 
3.6.3.2  Body Weight (BW) 
Weight charted on the study participant’s ICU chart was used. If there was no admission weight 
recorded, the dietitian estimated the patient’s weight. The patient’s Body Mass Index (BMI) was 
calculated on admission using estimated weight (kg)/height in m2 and recorded. The patient was 
then classified as undernourished, normal, overweight or obese according to the table in the case 
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report form (Appendix AIII). The dietitian documented which weight was used for calculations and 
any adjustments made to the weight, e.g. for underweight or overweight. All the above baseline 
measurements were recorded by the research assistant (see Appendix AIII and AIV).  
 
3.6.4  Nutritional prescription 
The study participant’s energy and protein requirements were calculated individually using the 
American Society of Parenteral and Enteral Nutrition (ASPEN) and European Society of Clinical 
Nutrition and Metabolism (ESPEN) guidelines (25 – 30kcal/kg/day total energy (TE) and protein 
1.2g – 2g/kg/day) (see Appendix AIV; SOP for calculating nutritional requirements). Both groups of 
study participants received glutamine, vitamins, minerals, trace elements and electrolytes as part 
of the complete PN. The PN prescription form (see Appendix AV) was completed by the dietitian 
and signed by the clinician. The PN order was then placed at the hospital pharmacy. The hospital 
pharmacy then contacted Fresenius Kabi Bloemfontein or Johannesburg with the PN orders for the 
day. 
The PN bag, in SG or CG, were prescribed according to the study participant’s requirements and 
the administration rate was adjusted accordingly. (see Table 3-1 for the composition of the PN 
bags). The dietitian clearly marked the PN administration rate on the study participant’s ICU Chart.  
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Table 3-1: The composition of the Parenteral Nutrition Bag is as follows: 
Contents of PN ITN 8807 ITN 8007 
Fluid 2390ml 2390ml 
Total Energy  2220 2220 
Energy (NPE) 1800kcal 1800kcal 
Carbohydrates 200g (45% of NPE) 200g (45% of NPE) 
Fat 
Soybean oil 
MCT 
Olive oil 
Fish oil: 
EPA + DHA 
n-6:n-3 fatty acid ratio 
100g (55% of NPE) 
30g 
30g 
25g 
15g 
4.6g 
2.5:1 
100g (55% of NPE) 
100g 
0 
0 
0 
0 
7:1 
Nitrogen 16.8g 16.8g 
Glutamine 15g 15g 
Vitamins, minerals and trace 
elements 
RDA  RDA 
Osmolarity 981mOsm/l 978mOsm/l 
Abbreviations : NPE: Non-Protein Energy ; RDA: Recommended Daily Allowance ; MCT : 
Medium Chain Trigylcerides ; EPA : Eicosapentaenoic acid ; DHA : Docosahexaenoic acid 
 
The nursing staff looking after the patient removed the PN bag from the fridge 1 hour before it 
was administered to the study participant. Aseptic techniques were used according to the hospital 
protocol to administer the PN bag. The nursing staff checked that the PN bag was correct for the 
study participant and as well as the rate at which the PN bag needed to be administered. Once the 
PN bag was connected to the study participant, the nursing staff documented the time at which 
the PN bag was started and the rate. The study participant was monitored according to the ICU 
protocol. All information was recorded on the study participant’s chart. The research assistant 
recorded all the relevant nutritional prescription and administration on the case report form. 
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3.6.5  Daily fluid and nutritional data 
Fluid input and output data was collected daily, according to the case report form as well as 
nutritional prescription versus nutrition delivered. (see Appendix AIII). Other intravenous fluids 
administered were documented and their composition was assessed to determine the effect on 
the study participant’s energy intake. Medication was also documented, particularly medication 
that could contribute to the study participant’s fat and energy intake, e.g. Propofol®and glucose-
containing IV fluids. The SOFA score (Appendix AI table 2) was assessed on a daily basis. The 
patient’s renal function was also assessed daily using the RIFLE classification (Appendix AI table 3). 
 
3.6.6   Biochemical data 
a.   Routine blood samples: 
All blood samples were collected on admission, immediately prior to starting the PN (day 1), 24hr 
after initiating PN (day2), 48hr after initiating PN (day 3) and five days after initiating PN (day 6). 
These include full blood count (FBC), urea, creatinine & electrolytes, c-reactive protein (CRP), 
calcium, magnesium & phosphate, liver function tests (AST, ALT, GGT and total bilirubin), 
triglycerides, glucose & blood gases. Blood samples were collected at the same time each day via 
an arterial line and analysed on site.  
Routine laboratory measurements were taken as part of the monitoring protocol for patients on 
PN. Electrolytes were corrected as per patients’ individual requirements. Glycaemic control was 
managed according to ICU protocol. Based on the laboratory measurements the SOFA score and 
PaO2/FiO2 ratio were calculated daily.Once the blood samples were taken, the tubes were labelled 
with the study participant’s name and the participant’s hospital sticker was placed on the form.  
 
b. Special blood samples for study 
The additional special laboratory measurements were ordered by ticking a request form which 
indicated which special tests were requested on that day and the tubes needed, e.g. day 1: TNF-α 
and IL-1β, 1 yellow top tube 10ml (see Appendix AVII). The form, was a different colour to the 
routine laboratory request form, and was pre-packed in a specimen bag with all the tubes inside 
needed for the tests for that day. The specimen bags were labelled on the outside according to the 
day, e.g. day 1. This enabled the doctor and/or phlebotomist to know which bloods needed to be 
drawn on that particular day.  
These samples were then centrifuged for 5 minutes at 4000rpm and stored at -800C. 
Once the study was completed half of the stored, frozen blood samples were couriered to the 
Centre for TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicien 
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and Health Sciences, Stellenbosch University for analysis and the other half of frozen samples 
were couriered to the University of Potchefstroom, Nutrition Department for analysis of total 
plasma phospholipid fatty acids. 
A total of 55ml of blood was needed for all the laboratory measurements on day 1, day 3 and day 
6, i.e. 5ml whole blood for FBC and 2, 10ml yellow top tubes for the routine blood tests, 3, 10ml 
yellow top tubes for the cytokines and fatty acids test. On the other days 25ml of blood was 
needed for the tests. 
 
Table 3-2: Additional laboratory measurements: 
Test Colour top 
tube  
Day 1    
(pre-PN) 
Day 3          
(48hr on PN) 
Day 6           
(120 hr on PN) 
Handling procedure 
TNF-α, IL-1 β, 
IL-6, IL-10, 
Fatty acids 
2 yellow top 
tubes 10ml 
   Centrifuge sample ,freeze at -200C 
and store at  -800C 
 
3.6.7   Logistics 
All the study participants’ data was collected by the research assistant at all sites. The whole 
process of the study was controlled by the primary study investigator. Weekly contact was made 
with the research assistant, and ICU dietitian, and daily contact with the pharmacist at Fresenius 
Kabi if a patient was on the study. WDGMC was visited three to five times per week to assist with 
data collection and patient recruitment, especially over weekends if special laboratory 
measurements were needed. The study investigator visited Bloemfontein quarterly.  
The study investigator was responsible for the training of the research assistant, the pharmacist 
and locum at Fresenius Kabi Bloemfontein and Johannesburg as well as the ICU dietitian at all the 
sites. The hospital pharmacy was also informed about the study and their role was defined in the 
process. The study investigator actively communicated regularly with the NHLS laboratory at 
Universitas and Pelonomi, Prof Meiring at the department of Haematology, and Beverly Grose at 
BARC SA. 
The study investigator was responsible for the quality control checks. The quality control form (see 
Appendix AVI), was be completed by the research assistant as well as the pharmacists at Fresenius 
Kabi Bloemfontein and Johannesburg, and kept separately. The case report forms were sent to the 
study investigator by the research assistant. These completed forms were placed in a sealed 
envelope and couriered to the study investigator at the end of each week, or collected from the 
site. The study investigator captured all the data once the forms were received. 
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3.7  Data management and statistics 
The data was captured by the study investigator using Excel on a weekly basis. The data was 
backed up using a hard drive as well as a storage device. Only the research assistant and study 
investigator had access to the raw data. The participant’s study number was used at all times to 
guarantee confidentiality. Any outlier values were checked by the study investigator. The final 
study data collected was kept in a locked cabinet in Midrand and only made available once the 
study had been closed. 
 
3.7.1  Statistical Analysis of Data: 
All data was analysed in consultation with Professor Nel, the allocated statistician at the University 
of Stellenbosch.  
MS Excel was used to capture the data and STATISTICA version 13.2 (StatSoft Inc. (2016 
STATISTICA (data analysis software system, www.statsoft.com.)) was used to analyse the data.  
 
Summary statistics were used to describe the variables. Distributions of variables were presented 
with histograms and/or frequency tables. Medians or means were used as the measures of central 
location for ordinal and continuous responses and standard deviations and quartiles as indicators 
of spread. 
 
The relationship between two continuous variables were analysed with regression analysis and the 
strength of the relationship measured with Pearson’s correlation; or Spearman’s correlation if the 
continuous variables were not normally distributed. If one continuous response variable was 
related to several other continuous input variables, multiple regression analysis was used and the 
strength of the relationship measured with multiple correlation. 
 
The relationships between continuous response variables and nominal input variables (like 
different diets) were analysed using appropriate analysis of variance (ANOVA) and appropriate 
repeated measures analysis of variance (RMANOVA) when responses were measured at specific 
time intervals.  
 
When ordinal response variables were compared versus a nominal input variable, non-parametric 
ANOVA methods was used. For completely randomised designs the Mann–Whitney test or the 
Kruskal–Wallis test was used and for repeated measures designs the Wilcoxon- or Friedman tests 
was used.   
 
The relation between nominal variables was investigated with contingency tables and appropriate 
chi-square tests, namely the likelihood ratio chi-square test or the McNemar’s test. 
 
A p-value of p < 0.05 represented statistical significance in hypothesis testing and 95% confidence 
intervals was used to describe the estimation of unknown parameters. 
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3.7.2  Analysis of other data 
Fluid input and output was analysed, as well as the contribution of energy and fat from Propofol 
and the energy contribution from other I.V fluids. 
 
3.7.3  Biochemical data 
The biochemical data that was recorded on a daily basis was entered into a database by the study 
investigator. Normal values for the different measurements was obtained from the laboratory and 
entered into the database. Standard cut off values were determined by the laboratory. 
 
3.7.4  Nutrition status assessment 
All the nutritional assessment criteria as defined by Appendix A was entered into the database.  
 
3.7.5  Any other relevant data  
The SOFA score, RIFLE criteria for renal failure, the patient’s blood pressure, temperature as well 
as blood gases, particularly PaO2/FiO2 defined by Appendix A was entered into the database. 
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3.8  Ethical and legal aspects 
The study protocol was approved by the Health Research Ethics Committee of Stellenbosch 
University on the 26th of March 2013, by the Ethics Committee of the University of the Free State 
on 4th March 2014 and by the Human Research Ethics Committee (Medical) of the University of 
Witwatersrand on 6th February 2015. 
Permission was granted by Dr Galaejwe, head of clinical services Universitas Academic Hospital as 
well as Professor R S du Toit, head of department of surgery at Universitas Academic Hospital. 
Permission was also been granted from the director of clinical services at Pelonomi Hospital, Dr 
Benganga. Permission was granted by Dr Sue Tager (hospital hanager) and Dr Günter Schleicher 
(director of ICU) from WDGMC. 
Consent was obtained from the study participant or his/her closest relatives. When the closest 
relatives were unable to give consent, the Clinical Manager at the site decided if the patient could 
be included into the study. This was in accordance to the standard practices of Universitas Hospital 
and WDGMC in the case of the patient being unable to consent. The Clinical Manager was 
independent from the daily patient management and assessed the research based on the study 
merits and the inclusion criteria. The patient was re-consented once possible and if the patient did 
not agree to continue participating in the study or did not want to give permission for his/her data 
to be used, the data was destroyed immediately. The study was conducted in accordance to Good 
Clinical Practice (GCP) guidelines as well as the declaration of Helsinki.  
The study was registered on the South African National Clinical Trials Register database, 
registration number: DOH-27-0616-4323. 
Only the research assistant and study investigator had access to the raw data. The participant’s 
study number was used at all times to guarantee confidentiality. 
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CHAPTER 4 
RESULTS 
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4. Introduction 
The results chapter is discussed in the form of two manuscripts prepared for publication in two of 
the following journals: Critical Care Medicine or Clinical Nutrition or American Journal of Clinical 
Nutrition or Nutrition in Clinical Practice. 
The first manuscript focuses on the effects of a fish oil (FO) containing intravenous lipid emulsion 
(IVLE) on inflammatory markers, gas exchange and clinical outcomes in patients with the systemic 
inflammatory response syndrome (SIRS) or sepsis. In this manuscript the results of the nutritional 
intake, laboratory parameters, cytokines analysis, gas exchange and clinical outcomes are 
addressed. 
The second manuscript focuses on the effects of a FO containing IVLE on the plasma phospholipid 
fatty acid composition in septic patients, namely, oleic, linoleic, alpha-linolenic, myristic, and 
arachidonic acid, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In this manuscript 
the results of nutritional intake, plasma total phospholipid fatty acid composition, dose of fish oil 
intake, omega-6:omega-3 polyunsaturated fatty acid ratio, and clinical outcomes are addressed. 
Some additional results not included in either of the manuscripts are discussed in Section 4.3. 
The study was initially planned to be a multicentre study including two centres in Bloemfontein, 
namely, the multi-disciplinary ICU and surgical ICU at Universitas Hospital and the ICU at Pelonomi 
Hospital. Recruitment at these centres started in June 2014; however it was very slow owing to 
challenges in the healthcare administration in the province and subsequently only 9 patients were 
recruited in 10 months. It was decided to open another centre at Wits Donald Gordon Medical 
Centre (WDGMC), Johannesburg, to continue with the study and to close the centres in 
Bloemfontein. Only the patients recruited from WDGMC were included in the two manuscripts. 
A total of 400 adult ICU patients admitted to WDGMC were screened for eligibility between April 
2015 and June 2016. Only 75 patients met the inclusion criteria and were randomised after 
obtaining consent. In the study group, four patients were excluded due to protocol violation (n=2), 
consent withdrawal (n=1) and insufficient biochemical results (n=1). In the control group three 
patients were excluded due to protocol violation (n=2) and withdrawn consent (n=1) (See Figure 1: 
Flow diagram of patient inclusion). 
The commencement of enteral nutrition, as well as the calculation of nutrients, was not defined in 
the protocol. Enteral nutrition was started as soon as possible according to the hospital protocol 
and guidelines. The composition as well as the contribution of enteral nutrition was similar in both 
groups. The commencement of early enteral nutrition in nearly half the patients resulted in a 
reduced intake of parenteral FO in the Study group (SG) and a reduction in IV lipids in both groups.  
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4.1 MANUSCRIPT ONE 
 
EFFECT OF A FISH OIL CONTAINING INTRAVENOUS LIPID 
EMULSION ON INFLAMMATORY MARKERS, GAS EXCHANGE 
AND CLINICAL OUTCOMES IN SEPTIC PATIENTS  
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EFFECT OF A FISH OIL CONTAINING INTRAVENOUS LIPID EMULSION ON INFLAMMATORY 
MARKERS, GAS EXCHANGE AND CLINICAL OUTCOMES IN SEPTIC PATIENTS 
Donoghue Va,d, Spruyt MGLb, Nel DGc & Blaauw Rd 
a Fresenius Kabi, Midrand, South Africa 
b Head, Clinical Department: Critical Care, Faculty of Health Sciences, University of the Free State, 
Bloemfontein, South Africa 
c Centre for Statistical Consultation, Stellenbosch University, South Africa 
d Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch University, 
South Africa 
 
Abstract: 
Introduction 
The effect of parenteral nutrition (PN) lipid emulsions containing omega-3 polyunsaturated fatty 
acid in critically ill patients has not been studied widely and shows conflicting results. This study 
compared the effects of a 4-oil lipid emulsion containing fish oil (SMOFlipid®) with a 100% 
soybean-based lipid emulsion in terms of biochemical parameters, inflammatory mediators, 
sequential organ failure assessment (SOFA) score, gas exchange, and clinical outcomes in ICU 
patients with the systemic inflammatory response syndrome (SIRS), with or without sepsis, or the 
acute respiratory distress syndrome (ARDS).   
Design 
Double-blind, randomised, single-centre study. 
Method 
Seventy-five patients predicted to need PN for five days or more were randomised to receive 
either a 4-oil lipid emulsion (Study Group (SG)) or a 100% soybean lipid emulsion (Control Group 
(CG)). Isocaloric, isonitrogenous PN was administered continuously over a period of 5 days. 
Routine haematological and biochemical measurements were performed and SOFA score 
assessment was calculated daily. Plasma cytokines were analysed on days 1, 3 and 6. 
Results 
The triglyceride levels increased significantly from day 1 to day 6, in both the SG and CG (p<0.001 
for both groups); however the range was wider in the CG. 
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin improved in both 
treatment groups. The ALT levels decreased, whereas the gamma-glutamyl transferase (GGT) 
levels increased in both groups. There was a trend for a bigger decrease in ALT, AST and bilirubin 
levels from day 1 to day 6 in the SG. The biggest decrease in bilirubin occurred between day 1 and 
day 3 and continued to decrease in the SG, whereas levels increased significantly in the CG after 
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day 3 (p=0.039). Concentrations of TNF-α decreased from day 1 to day 6 in the SG, whereas they 
increased in the CG, but the change was not statistically significant (p=0.112). Concentrations of 
Interleukin-1β (IL-1β) and IL-6 decreased in the SG during the intervention and had a tendency to 
increase in the CG after day 3 (p=0.175 for IL-1β and p=0.056 for IL-6) but the difference was not 
significant. IL-10 concentrations decreased in both groups between day 1 and day 3, but then 
increased from day 3 to day 6 in the SG. This difference was not significant (p=0.972). 
In the SG, a weak correlation was found between day 3 eicosapentaenoic acid (EPA) intake and 
bilirubin levels (r=-0.125, p=0.527), fewer days on mechanical ventilation (r=-0.201, p=0.224) and a 
reduction in C-reactive protein (CRP) levels (r=-0.027, p=0.097) and a significant correlation was 
found for improvement in the Sequential Organ Failure Assessment Score (SOFA) (r=0.4047, 
p=0.018). A weak correlation was also seen between day 6 fish oil (FO) intake and ICU length of 
stay (LOS) (r=-0.167, p=0.437). 
Days on mechanical ventilation (1.24 ± 0.83 days in SG versus 0.88 ± 1.63 days in CG, p=0.385) and 
ICU LOS (9.5 ± 7.09 days in SG versus 10.7 ± 7.6 days in CG, p=0.49) were not different between 
the two groups. Even though the baseline APACHE score was higher in the SG, there was no 
difference in mortality between the groups.  
Conclusion 
This study results suggest that PN containing a 4-oil LE with FO at a dose of 0.09 – 0.22g/kg in ICU 
participants with SIRS, with or without sepsis, or ARDS, is safe and well tolerated in this patient 
population. The 4-oil LE showed a tendency to reduce plasma TNF-α, liver enzymes (ALT and 
bilirubin), SOFA score and ICU length of stay but no difference in mortality. Additional studies need 
to be done in this patient population paying particular attention to the dose, duration and timing 
of FO, EPA and n-6:n-3 PUFA ratio per day and their effect on clinical outcomes. 
. 
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Introduction 
Sepsis remains a common problem in critically ill patients. The reported prevalence of the systemic 
inflammatory response syndrome (SIRS) is estimated to range from 20% to 60%. Approximately 
40% of patients with sepsis may develop septic shock (1). Severe sepsis and septic shock have high 
mortality rates and are the leading causes of death in intensive care units (2). There is an 
increasing awareness that patients who survive sepsis often have long-term physical, psychological 
and cognitive disabilities with significant health care and social implications (3). 
In most patients, critical illness starts with varying degrees of physiological deterioration, 
developing into a catabolic state and intense metabolic changes, resulting in malnutrition and 
impaired immune functions (4). Intravenous lipid emulsions (IVLEs) constitute the main source of 
energy and fatty acids (FAs) in parenteral nutrition (PN) formulations and are associated with the 
development of adverse effects. Different types of lipid emulsions (LEs) have different effects on 
blood function tests and metabolic functions. Clinical data in surgical and critical care patients 
suggest that the addition of fish oil lipid emulsions (FO LEs) at 0.1 – 0.2g/kg/day (with omega-3 
polyunsaturated FA (PUFAs) to PN attenuates the inflammatory process by reducing pro-
inflammatory cytokines and maintaining concentrations of anti-inflammatory cytokines, improves 
oxygenation by increasing PaO2/FiO2 ratio, and reduces the incidence of parenteral nutrition-
associated liver disease (PNALD) by having less derangement of liver enzymes. These changes have 
been shown to improve clinical outcomes such as reduction in time on mechanical ventilation and 
in ICU, and hospital length of stay (LOS) (5-8). 
The aim of this study was to compare a 4-oil lipid emulsion containing fish oil (SMOFlipid®) with a 
100% soybean-based lipid emulsion in terms of specified clinical and biochemical parameters, 
inflammatory mediators in plasma, SOFA score, gas exchange, and clinical outcome, in ICU 
patients with SIRS, with or without sepsis, or ARDS, requiring PN for five days or more. Our 
hypothesis is that inclusion of fish oil will decrease circulating inflammatory cytokine 
concentrations, improve gas exchange, and improve clinical outcomes.   
 
Materials and Methods 
Study design 
This study was a double-blind, single-centre, randomised controlled trial in adult patients admitted 
to Wits Donald Gordon Medical Centre (WDGMC) ICU with diagnosed SIRS or sepsis and ARDS.  
Sample size 
The total number of study participants needed was determined to be at least 72 individuals (36 in 
each subgroup). This number was calculated using a power analysis for ANOVA with two groups, 
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significance level of 0.05 and an effect size of 0.55. Sample size n=36 in each group was expected 
to yield 90% power to detect this effect size. 
A total of 75 patients were included in the study, and seven patients were excluded due to 
insufficient biochemical results, protocol violations and withdrawn consent, leaving a total of 68 
patients. Thirty-five patients were randomised to the study group versus 33 patients to the control 
group (Figure 1).
Stellenbosch University  https://scholar.sun.ac.za
94 
 
 
n=400 ICU patients screened for eligibility  
       
    n= 325 PN not indicated or did not meet inclusion criteria 
 
n=75 PN indicated and patients randomised after obtaining consent 
 
 
 
n=39 study group        n=36 control group 
 
Patients excluded:       Patients excluded:  
Insufficient biochemical results (n=1)   Consent withdrawn (n=1) 
Consent withdrawn (n=1)     Protocol violation (n=2) 
Protocol violation (n=2)    
 
n=35 completed study        n=33 completed study 
 
Figure 1: Flow diagram of patient inclusion
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Patient selection 
Seventy-five adult (18 years or older) patients with diagnosed SIRS, with or without sepsis, or 
ARDS, who were predicted to need PN for 5 days or more were recruited consecutively at the time 
of admission to the ICU between April 2015 and June 2016. Seven patients were excluded leaving 
a total of 68 patients. Sepsis was defined as suspected or proven infection plus SIRS (that is, 
presence of pyrexia, tachycardia, tachypnoea and/or leukocytosis). Severe sepsis was defined as 
sepsis with organ dysfunction (hypotension, hypoxaemia, oliguria, metabolic acidosis and/or 
thrombocytopaenia). Septic shock was defined as severe sepsis with hypotension despite 
adequate fluid resuscitation (9, 10).  
The exclusion criteria were as follows: younger than 18 years, on full enteral feeding, pregnancy, 
treatment with immunosuppressive drugs, treatment with hydrocortisone >300mg/day at 
admission, plasma triglycerides >4,52mmol/l (>400mg/dl), chronic liver disease and/or acute 
hepatitis, chronic renal failure and/or end-stage renal disease according to the RIFLE criteria, 
recent stroke and known allergic reaction to fish or egg proteins confirmed by previous medical 
history. 
Once the patient was identified as eligible and consent was obtained, the dietitian calculated the 
APACHE II and SOFA scores and nutritional assessment was performed. A PN prescription was then 
recommended to the clinician, taking laboratory results into account. The PN was ordered from 
Fresenius Kabi, Johannesburg (the supplier of the PN). On receiving the PN prescription, the 
dispensing pharmacist was responsible for randomising all the patients to either receive PN 
containing a 4-oil lipid emulsion including fish oil (SMOFlipid®: 30% LCT, 30% MCT, 25% olive oil, 
15% fish oil, provided in a complete all-in-one PN bag by Fresenius Kabi: study group) or a 
soybean-based lipid emulsion (Intralipid® 100% LCT, provided in a complete all-in-one PN bag by 
Fresenius Kabi: control group), according to a randomisation sheet. 
The dispensed PN bags looked identical. The PN was started on the day after admission to the 
study. By following the above procedure there was no deviation from usual standardised PN 
prescription techniques, the only difference being in the fat composition of the bags. (Refer to 
Table 1.) All the patient information was recorded daily until discharge from ICU.  
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Table 1: Composition of the parenteral nutrition bags 
Contents of PN 
Per 1000ml 
Study group 
PN Code : ITN 8807 
Control group 
PN Code : ITN 8007 
Total energy  929 kcal 929 kcal 
Energy (NPE) 753 kcal 753 kcal 
Carbohydrates 84g (45% of NPE) 84g (45% of NPE) 
Fat 
Soybean oil 
MCT 
Olive oil 
Fish oil 
EPA + DHA 
n-6:n-3 fatty acid ratio 
42g (55% of NPE) 
12.6g 
12.6g 
10.5g 
6.3g 
1.9g 
2.5:1 
42g (55% of NPE) 
42g 
0 
0 
0 
0 
7:1 
Nitrogen 7g 7g 
Glutamine 6.3g 6.3g 
Vitamins, minerals and trace 
elements 
RDA  RDA 
Osmolarity 981mOsm/l 978mOsm/l 
Abbreviations: NPE: Non-Protein Energy; RDA: Recommended Daily Allowance; MCT: 
Medium-Chain Triglycerides; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid 
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Anthropometric assessment 
Weight and height were determined or estimated on admission according to acknowledged 
procedures and used to calculate body mass index (BMI) (weight (kg)/height m2). 
Dietary intervention 
Energy and protein requirements were calculated individually using the American Society of 
Parenteral and Enteral Nutrition (ASPEN) and European Society of Clinical Nutrition and 
Metabolism (ESPEN) guidelines (25 – 30kcal/kg/day total energy (TE) and protein 1.2g – 
2g/kg/day)(11, 12). All study participants received glutamine, vitamins, minerals, trace elements 
and electrolytes as part of the complete PN. The PN bags, in SG or CG, were prescribed according 
to study participant requirements and the administration rate was adjusted accordingly.  
The commencement of enteral nutrition (EN) was not defined in the protocol and was started as 
soon as possible according to hospital protocol and guidelines. The nutritional requirements were 
recalculated to ensure that the nutritional intake did not exceed the requirements and to avoid 
overfeeding. 
Laboratory measurements 
All blood samples were collected on admission, immediately prior to starting the PN (day 1), 24 h 
after initiating PN (day 2), 48 h after initiating PN (day 3) and five days after initiating PN (day 6), 
included full blood count (FBC), urea, creatinine & electrolytes, c-reactive protein (CRP), calcium, 
magnesium & phosphate, liver function tests (AST, ALT, GGT and total bilirubin), triglycerides, 
glucose & blood gases. Blood samples were collected at the same time each day via an arterial line 
and analysed on site. The 6ml blood required for cytokine levels was taken on day 1, 3 and 6 at the 
same time as the routine bloods. These samples were centrifuged and stored at -80 0C until 
analysed. 
Routine laboratory measurements were taken as part of the monitoring protocol for patients on 
PN. Electrolytes were corrected as per patients’ individual requirements. Based on the laboratory 
measurements, the SOFA score and PaO2/FiO2 ratio were calculated daily. 
 
Cytokine analysis  
Cytokine levels (TNF-α, IL-1α, IL-6 & IL-10) were measured using MILLIPLEX® kits (Merck Millipore, 
Billerica, MA, USA) on the MAGPIX® instrument according to the Milliplex instructions. All samples 
were evaluated in duplicate by a single technician who was blinded to participant groups. All 
analyte levels in the quality-control reagents included in the kits were within the expected ranges. 
All median fluorescent intensity data were acquired using the Bio Plex MP™ software (Bio-Rad, 
Hercules, CA, USA) and analysed on the Bio Plex manager version 6.1 software (Bio-Rad) (13). The 
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cytokine levels were measured at the Centre for TB Research, Division of Molecular Biology and 
Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University. 
Statistical analysis 
STATISTICA version 13.2 (StatSoft Inc. (2016) STATISTICA (data analysis software system, 
www.statsoft.com) was used to analyse the data.  
 
Summary statistics were used to describe the variables. Distributions of variables were analysed 
with histograms and/or frequency tables. Medians or means were used as the measures of central 
location for ordinal and continuous responses and standard deviations or quartiles as indicators of 
spread. 
 
Descriptive statistical analysis was performed to evaluate the result of the laboratory parameters, 
cytokines, PaO2/FiO2 ratio and clinical data for each variable at day 1, day 3 and day 6.  
 
The relationships between nutritional intake, TG, liver enzymes, PaO2/FiO2 ratio, cytokines, SOFA 
score, ICU mortality and nutritional efficacy and type of PN were analysed using appropriate 
analysis of variance (ANOVA) and appropriate repeated measures analysis of variance 
(RMANOVA), when responses were measured at day 1, day 3 and day 6.  
 
Results were compared using the Mann–Whitney test or the Kruskal–Wallis test for ordered 
categorical counts in case of non-paired data. In case of paired data, the Wilcoxon or Friedman 
tests were used. 
 
The relationship between two continuous variables was analysed with regression analysis and the 
strength of the relationship measured with Pearson’s correlation coefficient or Spearman’s 
correlation coefficient if the continuous variables were not normally distributed or if the input was 
ordinal. The relation between nominal variables was investigated with contingency tables and 
appropriate chi-square tests, namely the likelihood ratio chi-square test or McNemar’s test. 
 
A p-value of p < 0.05 represented statistical significance in hypothesis testing and 95% confidence 
intervals were used to describe the estimation of unknown parameters. 
 
Ethics and legal aspects 
The study was approved by the Health Research Ethics Committee of Stellenbosch University and 
the Human Research Ethics Committee (Medical) of the University of the Witwatersrand. 
Permission was granted by the hospital manager and the director of the ICU at WDGMC. Consent 
was obtained from the study participant or his/her closest relatives. The study was conducted in 
accordance with the Helsinki Declaration and was registered on the South African National Clinical 
Trials Register database, registration number: DOH-27-0616-4323. 
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Results 
Of the 68 participants, 66% were male and 34% female in the SG versus 56% male and 45% female 
in the CG (p=0.333). The majority of the participants were surgical admissions (85% in SG versus 
91% in CG) and the remainder were medical admissions. The average age was 60.8 ± 13.9 years in 
SG versus 55.7 ± 14.8 years in CG.  
On admission to the study, the baseline characteristics of the participants in the two groups did 
not differ (Table 2). 
Nutrient intakes 
Total energy, protein, fat, carbohydrate and glutamine intakes did not differ between the groups 
throughout the study period (Table 3), except on day 3, the energy provided per kilogram body 
weight was significantly more in the CG (p=0.041). The SG fish oil (FO) intake was between 0.09 ± 
0.03g/kg/day (day 1) and 0.22 ± 0.11g/kg/day (day 3), providing between 1.15 ± 0.44 to 2.37 ± 
0.79g EPA and 1.72 ± 0.42 to 2.18 ± 0.44g DHA per day. The EPA and DHA intake was the highest 
on day 3. The phytosterol intake was significantly more in the CG (p=0.008) and α-tocopherol 
intake was significantly more in the SG (p<0.001). 
EN was started on days 4.03 ± 2.1 in the SG versus 3.64 ± 1.90 in CG (p=0.42). The nutritional 
intake from EN was documented, but the nutritional value not calculated accurately owing to 
missing data. Thus, the nutrient intake tabulated on day 6 was less than that of day 3, as it only 
included intake from PN. Table 3 includes only nutritional intake from PN.  
Only 63% of participants in the SG and 54% in CG received PN for 6 days, and the cumulative FO 
intake was significantly more in the SG participants that received PN for 6 days compared with 
those who received PN for fewer days (p=0.032). 
 
Laboratory measurements 
There were no statistically significant differences between the groups with regard to white cell 
count (WCC), blood glucose, triglycerides, liver enzymes and total bilirubin (Table 4) throughout 
the study period. Assessing the groups individually, the triglyceride levels increased from day 1 to 
day 6, in both groups (p<0.001 for SG and CG); however the range was wider in the CG (Fig. 2). 
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Figure 2: Differences in triglycerides on day 1 and day 6 in both treatment groups 
AST, ALT and bilirubin improved in both groups (Table 4). The ALT levels decreased whereas the 
GGT levels increased in both groups. There was a trend for a bigger decrease in ALT, AST and 
bilirubin levels from day 1 to day 6 in the SG. The biggest decrease in bilirubin occurred between 
day 1 and day 3 and remained fairly stable after day 3 in the SG, whereas levels increased in the 
CG after day 3 (Figure 3). The difference between the levels in both groups on day 6 was 
significant (p=0.039). A weak, negative correlation was found between day 3 EPA intake and levels 
(r=-0.125, p=0.527). 
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Figure 3: Overall change in bilirubin levels between the two groups (p=0.228) 
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Table 2: Baseline characteristics of participants in the two treatment groups 
 Study Group (n=35) Control Group (n=33) Comparison 
between SG & CG  
Characteristic Mean ± SD -95%LCL +95% UCL Mean ± SD -95%LCL +95% UCL p value 
Age 60.77 ± 13.93 56.19 65.35 55.71 ± 14.78 50.46 60.95 p=0.142 
BMI kg/m2 29.2 ± 11.01 25.47 32.93 27.57 ± 5.91 25.48 29.67 p=0.452 
APACHE II score 13.65 ± 7.47 11.08 16.21 11.15 ± 8.08 8.27 14.02 p=0.190 
SOFA score 5.66 ± 4.01 4.28 7.036 5.06 ± 4.17 3.558 6.57 p=0.554 
Temperature (0C) 36.97 ± 1.18 36.58 37.36 36.79 ± 0.81 36.50 37.07 p=0.453 
Heart rate 95.53 ± 22.91 88.00 103.06 97.88 ±  14.68 92.67 103.09 p=0.614 
WCC (109 cells/L) 13.60 ± 8.68 10.75 16.46 17.36 ±  12.89 12.79 21.93 p=0.150 
CRP (mg/L) 205.17 ± 127.3 161.44 248.9 220.52 ± 129.14 172.30 268.74 p=0.632 
Albumin (g/L) 25.85 ± 5.65 23.85 27.85 25.84 ±  5.48 23.83 27.85 p=0.994 
PaO2/FiO2 ratio 279.41 ± 139.33 231.55 327.27 314.8 ±  107.63 275.99 353.6 p=0.252 
BMI: body mass index; SOFA: Sequential Organ Failure Assessment; WCC: white cell count; PaO2/FiO2: partial pressure arterial oxygen to fractional inspired 
oxygen; LCL: lower confidence limit; UCL: upper confidence limit 
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Table 3: Nutritional intake from parenteral nutrition 
 Study Group (n=35) Control Group (n=33)  
 Day 1 Day 3 Day 6 Day 1 Day 3 Day 6 Comparison between SG & CG  
Nutritional intake Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD p value 
Energy (kcal) 1130.82 ± 
429.26 
2249.87 ± 386.1 1132.45 ± 1034.46 1034 ± 430.18 2222.6 ± 352.41 1176.13 ± 984.67 p=0.357* 
p=0.758** 
p=0.858*** 
Energy (kcal/kg) 14.3 ± 5.64  25.69 ± 8.61  14.46 ± 13.44  13.85 ± 5.69  29.39 ± 5.85 15.463 ± 13.28  p=0.712* 
p=0.041** 
p=0.754*** 
Protein (g/kg) 0.67 ±  0.26 1.33 ± 0.16  0.68 ± 0.64  0.65 ± 0.25  1.39 ± 0.2  0.7 ±  0.61 p=0.74* 
p=0.157** 
p=0.914*** 
Glutamine (g/kg) 0.09 ± 0.03  0.18 ±  0.03 0.09 ± 0.1  0.09 ± 0.03  0.2 ± 0.07  0.09 ± 0.09  p=0.873* 
p=0.230** 
p=0.862*** 
Fat (g/kg) 0.63 ± 0.24  1.26 ± 0.16  0.65 ± 0.59  0.624 ± 0.24  1.32 ± 0.19  0.66 ± 0.57  p=0.892* 
p=0.188** 
p=0.877*** 
Carbohydrate (g/kg) 1.36 ± 0.61  2.58 ± 0.34  1.34 ± 1.27  1.3 ± 0.62  2.8 ± 0.59  1.47 ± 1.27  p=0.675* 
p=0.05** 
p=0.651*** 
Fish oil (g/kg) 0.09 ± 0.03  0.22 ± 0.11  0.14 ± 0.06      
EPA (g) 1.15 ± 0.44  2.37 ± 0.47  1.75 ± 0.79      
DHA  (g) 1.72 ± 0.42  2.18 ± 0.44  1.61 ± 0.72      
Phytosterol (mg) 48.76 ± 18.26  102.35 ± 20.16  52.23 ± 45.41  96.15 ± 33.39  205.98 ± 34.19  99.83 ± 92.78  p<0.001* 
p<0.001** 
p=0.009*** 
a-tocopherol (mg) 48 ± 17.67  100.04 ± 17.88  50.95 ± 45.56  9.85 ± 8.69  18.49 ± 3.1 8.93 ± 8.29  p<0.001* 
p<0.001** 
p<0.001*** 
* Difference between groups on day 1 ** Difference between groups on day 3 *** Difference between groups on day 6 EPA; Eicosapentaenoic acid, DHA; Docosahexaenoic acid 
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Table 4: Laboratory measurements on day 1, day 3 and day 6 
 Study Group (n=35) Control Group (n=33) Comparison 
between SG & 
CG  Day 1 Day 3 Day 6 Day 1 Day 3 Day 6 
Measurement Mean ± SE Mean ± SE Mean ± SE Mean ± SD Mean ± SE Mean ± SE P value 
TG (mmol/L) 1.47 ± 0.11 1.1.78 ± 0.17 1.99 ±0.19 1.44 ± 0.11 2.27 ± 0.17 2.17 ± 0.18 p=0.035 
AST (IU/L) 73.36 ± 15.73 35.3 ± 4.35 35.9 ± 5.01 53.9 ± 16.23 33.13 ± 4.49 38.84 ± 5.17 P=0.377 
ALT (IU/L) 45.84 ± 9.23 32.90 ± 8.18 20.13 ± 2.53 28.9 ± 9.38 26.83 ± 8.31 17.7 ± 2.58 p=0.377 
GGT (IU/L) 76.79 ± 18.01 68.89 ± 12.38 126.96 ± 23.39 75.86 ± 17.7 67.35 ± 12.17 150.41 ± 22.98 p=0.571 
Bilirubin 
(mmol/L) 
12.5 ± 3.39 8.64 ± 1.83 9.22 ± 2.05 19.58 ± 3.25 11.54 ± 1.75 16.08 ± 1.97 p=0.228 
PaO2/FiO2 ratio 285.79 ± 25.39 228.51 ± 22.51 254.02 ± 25.01 319.3 ± 29.5 293.25 ± 26.15 305 ± 29.07 p=0.769 
WCC (10̂9 cells/L) 14.16 ± 1.97 12.1 ± 1.39 14.84 ± 1.67 17.85 ± 2.03 14.24 ± 1.44 14.99 ± 1.73 p=0.37 
Glucose 
(mmol/L) 
7.44 ± 0.33 8.44 ± 0.35 7.75 ± 0.48 6.79 ± 0.35 8.54 ± 0.36 7.92 ± 0.5 p=0.483 
TG: triglyceride; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl transferase; PaO2/FiO2: partial pressure arterial oxygen to fractional inspired oxygen; WCC: 
white cell count 
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Table 5: Changes in cytokines from day 1, day 3 and day 6 
 Study Group (n=35) Control Group (n=33)  
 Day 1 Day 3 Day 6 Day 1 Day 3 Day 6 Comparison between 
SG & CG  
Measurement Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD p value 
CRP (mg/L) 205.17 ± 127.3 169 ± 101.36 
 
109.6 ± 69.7 
 
220.52 ± 129.1 
 
145.84 ± 73.57 
 
119.05 ± 82.41 
 
p=0.632* 
p=0.292** 
p=0.631*** 
TNF – α 
(pg/ml) 
8.84 ± 15.11 
 
3.62 ± 5.76 
 
5.09 ± 10.81 
 
5.27 ± 11.55 
 
8.92 ±   21.97 
 
8.59 ± 21.03 
 
p=0.301* 
p=0.205** 
p=0.428*** 
IL-1β (pg/ml) 2.79 ±  10.01 
 
2.38 ± 8.78 
 
0.98 ± 3.21 
 
0.167 ± 0.45 0.146 ± 0.41 
 
0.18 ±   0.50 
 
p=0.151* 
p=0.156** 
p=0.175*** 
IL-6 (pg/ml) 101.24 ± 238.47 
 
26.93 ±   42.82 
 
11.53 ±28.42 
 
125.76 ± 343.3 
 
32.16 ± 76.1 
 
41.8 ± 78.8 
 
p=0.749* 
p=0.742** 
p=0.056*** 
IL-10 (pg/ml) 98.36 ± 353.03 
 
23.66 ± 34.95 
 
35.98 ±102.5 
 
103.95± 444.8 
 
37.54 ± 88.51 
 
35.12 ± 86.23 
 
p=0.957* 
p=0.426** 
p=0.972*** 
* Difference between groups on day 1   ** Difference between groups on day 3  *** Difference between groups on day 6 
CRP: c-reactive protein; TNF-α: tumour necrosis factor – alpha; IL-1β: interleukin-1β; IL-6: interleukin-6; IL-10: interleukin-10 
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Table 6: Clinical outcome measurements day 1 and day 6 
 Study Group Control Group  
 Day 1 Day 6 Day 1 Day 6 Comparison 
between SG 
& CG  
 Mean ± SE  -95% 
LCL 
+95% 
UCL  
Mean ± SE   -95% 
LCL 
 +95%  
UCL 
Mean ± 
SE 
-95% 
LCL 
 +95% 
UCL  
Mean ± 
SE  
-95% 
LCL  
+95% 
UCL 
p value 
SOFA  5.77 ± 0.75 4.26 7.28 4.27 ± 0.77 2.72 5.82 5.91 ± 
0.86 
4.191 7.635 3.83 ± 
0.88 
2.06 5.6 p=0.578 
CRP (mg/L) 199.82 ± 23 153.74 245.9 103.6 ± 
13.9 
75.71 131.46 215.47 ± 
23.4 
168.56 262.37 116.99 ± 
14.16 
88.62 145.36 p=0.951 
TNF-α 
(pg/ml) 
9.45 ± 2.53 4.38 14.52 5.09 ± 3.12 -1.16 11.34 4.95 ± 
2.49 
-0.03 9.93 8.59 ± 
3.06 
2.44 14.73 p=0.122 
SOFA: Sequential Organ Failure Assessment; CRP: c-reactive protein; TNF-α: tumour necrosis factor – alpha; LCL: lower confidence limit; UCL: upper confidence 
limit 
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Gas exchange 
There was no statistical difference in the PaO2/FiO2 ratio between the two groups (Table 4). A non 
significant positive correlation was found between the intake of EPA on day 3 and the 
improvement in PaO2/FiO2 ratio (r=0.237, p=0.192).  
Plasma cytokine concentrations 
Plasma cytokine concentrations did not differ statistically between the two groups prior to 
initiation of PN and throughout the study period. Concentrations of TNF-α decreased from day 1 
to day 6 in the SG, whereas they increased in the CG, but the change was not statistically 
significant (Fig. 4). Concentrations of IL-1β and IL-6 decreased in the SG during the intervention 
and had a tendency to increase in the CG on day 6; however the difference was not statistically 
significant. IL-10 concentrations decreased in both groups; however in the SG on day 6 the 
concentration increased but not significantly (Table 5). A positive, non-significant correlation was 
found between the FO intake and the concentrations of IL-10 (r=0.232, p=0.082).  
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Figure 4: Plasma tumour necrosis factor-α concentration 
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Clinical outcomes 
As expected the CRP levels decreased in both groups during the intervention. A weak negative 
correlation was shown between the intake of EPA on day 3 and the reduction in CRP levels (r= -
0.029, p=0.097). Days on mechanical ventilation (1.24 ± 0.83 days in SG vs 0.88 ± 1.63 days in CG, 
p=0.385) and ICU LOS (9.5 ± 7.09 days in SG vs 10.7 ± 7.6 days in CG, p=0.49) were not different 
between the two groups; however the SG has a shorter ICU LOS.  
Even though the baseline mean APACHE score was higher in the SG (p=0.19), there was no 
difference in mortality between the two groups (p= 0.071). Two participants died within the 
course of the intervention from neutropenic sepsis, both in the SG. A further nine participants died 
after the completion of the intervention period but before day 28 (five from the SG and four from 
the CG. The SOFA score improved in both treatment groups during the intervention as expected 
(Table 6). A strong negative correlation was found between day 3 EPA intake and day 3 SOFA score 
(r=-0.4047, p=0.018) (see Fig. 5). A non-significant negative correlation was also shown for day 3 
EPA intake and days on mechanical ventilation (r=-0.201, p=0.224) as well as between day 6 FO 
intake and ICU LOS (r=-0.167, p=0.437). 
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Figure 5: Correlations between day 3 eicosapentaenoic acid intake and day 3 sequential organ 
      failure assessment score 
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Discussion 
This study set out to compare a 4-oil LE containing FO (SMOFlipid®) with a 100% soybean-based 
LE in terms of routine biochemical and physiological markers, gas exchange, inflammatory 
mediators, SOFA score and clinical outcomes in ICU participants with SIRS, with or without sepsis, 
or ARDS. It found a significant increase in α-tocopherol and a decrease in phytosterol intake but no 
statistical difference in inflammatory cytokines, liver enzymes, SOFA score, and length of ICU stay. 
Even though the mean baseline APACHE score was higher in the SG, there was no difference in 
mortality between the two groups.  
EN was started on day 4 in the SG versus day 3.6 in the CG and only 63.2% of participants in the SG 
and 54.5% in CG received PN for the full six days. The cumulative FO intake was significantly more 
in the SG between the participants that received PN for 6 days versus those that received it over 
fewer days (p=0.032). The maximum intake of FO, EPA and DHA was on day 3. Day 3 EPA intake 
was associated with improved bilirubin levels, fewer days on mechanical ventilation, a reduction in 
CRP levels, and a significant improvement in SOFA score.  
To our knowledge this is the first randomised controlled study using SMOFlipid® in septic ICU 
participants, although it has been studied previously in post-surgery participants (14-21). In these 
studies SMOFlipid® was found to decrease production or concentration of inflammatory cytokines 
and eicosanoids (15, 21), decrease liver enzymes (14, 16, 18), increase plasma α-tocopherol (14, 
15) and reduce length of hospital stay (15).  
Other FO containing LEs have also been studied in post-surgical participants where they decreased 
production or concentration of inflammatory eicosanoids and cytokines (22-24), improved 
immune function, reduced liver enzymes (23, 25) and improved clinical outcomes (24-29). 
These other FO containing LEs have also been studied in critically ill and septic participants (30-34). 
In some of these studies the use of FO containing LE was associated with decreased inflammatory 
markers and improved respiratory function (30) and significant reduction in nosocomial infections 
and prolonged predicted time free of infection (31). Heller et al. (32) used an FO supplement in a 
heterogeneous group of participants including trauma, post-surgical and septic participants and 
identified a dose-dependent (0.1–0.2g/kg) reduction in mortality, infection rate and length of stay. 
A recent study by Grau-Carmona et al. showed a shorter length of mechanical ventilation and 
hospital stay in the FO group but it was not statistically significant (31). However, other studies 
reported no effect on mortality and length of stay (2, 33). 
The dose of fish oil administered in this study ranged between 0.09 – 0.22g/kg and is consistent 
with the dose that other studies have found to be clinically favourable (31, 32, 34). The highest 
dose of FO was on day 3 as EN was started afterwards and resulted in a reduction in PN intake and 
FO intake.  
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This study did not demonstrate a statistical difference between the PaO2/FiO2 ratio on day 1 and 
day 6 between the two groups, which has been demonstrated previously (23, 30). This could be 
due to the fact that the optimal dose of FO was only received for 2 days. 
Plasma cytokines did not differ statistically in this study between the two groups; however plasma 
levels of TNF-α decreased in the SG and increased in the CG. Similar results were shown in surgical 
participants with an FO supplement and SO vs SO alone (24, 35), and FO supplement plus MCT/LCT 
vs MCT/LCT alone (22). Kreymann et al. found no clear-cut effect on TNF-α levels in both FO 
admixtures and FO-supplemented LE (36). 
A recent meta-analysis confirmed a significant reduction in infection rates by 35% in critically ill 
participants with no overall effect on ICU LOS. They concluded that FO admixtures and FO 
supplement LEs are advantageous for the majority of participants compared with LCT or MCT/LCT 
LE owing to their balancing omega-3 content (36). 
Adverse reactions did not differ between groups and no serious or unexpected adverse events 
were reported, confirming the findings of a variety of clinical trials that PN containing FO is safe in 
critically ill participants (30, 31, 32, 33, 34, 37).  
Nutritional efficacy was similar between the two groups. However, the intake of α-tocopherol was 
significantly higher and phytosterol significantly lower in the SG. There is evidence that large 
intakes of phytosterols can cause cholestasis and PN-associated liver disease (7). This study 
showed a non significant reduction in liver enzymes, particularly ALT and bilirubin in the SG. 
The limitations of this study are that only half the participants received PN for the full six days; this 
affected the duration as well as the dose of FO over the study period. There was a definite signal 
that the intake of EPA and FO on day 3 showed a beneficial effect. It was not possible to determine 
the full nutritional intake throughout the study period owing to the incomplete recording of EN 
intake. Infection rate as well as days on antibiotics was also not documented and would have 
provided valuable information about clinical outcomes. The study population may have been 
somewhat heterogenous as to the causes and severity of SIRS and ARDS. Finally, we were unable 
to test plasma α-tocopherol levels, which would have been an interesting additional result as the 
intake was significantly different between the two groups. 
Conclusion 
This study results suggest that PN containing a 4-oil LE with FO at a dose of 0.09 – 0.22g/kg in ICU 
participants with SIRS, with or without sepsis, or ARDS, is safe and well tolerated in this patient 
population. The 4-oil LE showed a tendency to reduce plasma TNF-α, liver enzymes (ALT and 
bilirubin), SOFA score and ICU length of stay but no difference in mortality. Additional studies need 
to be done in this patient population paying particular attention to the dose, duration and timing 
of FO, EPA and n-6:n-3 PUFA ratio per day and their effect on clinical outcomes. 
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Abstract: 
Introduction 
The effect of intravenous lipid emulsions, containing omega-3 polyunsaturated fatty acid in 
Parenteral Nutrition (PN) has not been studied widely in critically ill patients and shows conflicting 
results. This study compared the effects of a 4-oil lipid emulsion (30% soybean oil, 30% medium- 
chain triglycerides, 25% olive oil and 15% fish oil) (SMOFlipid®) with a 100% soybean-based lipid 
emulsion in terms of routine biochemical parameters, plasma total phospholipid fatty acid (FA) 
composition; organ dysfunction, and clinical outcomes in patients with the systemic inflammatory 
response syndrome (SIRS), with or without sepsis, or the acute respiratory distress syndrome 
(ARDS) in intensive care units (ICUs).   
Design 
This was a double-blind, randomised, single-centre study. 
Method 
Seventy-five patients predicted to need PN for more than 5 days were randomised to receive 
either a 4-oil lipid emulsion (Study Group (SG)) or a 100% soybean lipid emulsion (Control Group 
(CG)). Isocaloric, isonitrogenous PN was administered continuously for 5 days. Routine biochemical 
measurements were assessed. Sequential organ failure assessment (SOFA) score was calculated 
and the plasma total phospholipid FA composition was analysed. 
Results 
The nutritional intakes did not differ, except the SG received fish oil (FO), eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA), as well as increased amounts of α-tocopherol and reduced 
amounts of phytosterols. The highest intake of FO, EPA and DHA was on day 3, as EN was started 
on approximately day 4 in both groups. Multiple changes in plasma total phospholipid FA 
percentages were demonstrated. Oleic acid (p=0.022) and alpha-linolenic acid (p<0.0005) 
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increased in both groups. Plasma EPA showed a significant increase in the SG (p<0.000), whereas 
DHA increased after day 3. DHA levels decreased in the CG resulting in a difference between the 
two groups on day 6 (p<0.001). Arachidonic acid decreased in both groups. The omega-6:omega-3 
polyunsaturated fatty acid (n-6:n-3 PUFA) ratio decreased in the SG and remained fairly constant 
in the CG. 
A weak correlation was found between EPA intake on day 3 and fewer days on mechanical 
ventilation (r=-0.201, p=0.224) and a reduction in C-reactive protein (CRP) levels (r=-0.027, 
p=0.097) and a significant improvement in SOFA score (r=0.4047, p=0.018). Days on mechanical 
ventilation (1.24 ± 0.83 days in SG versus 0.88 ± 1.63 days in CG, p=0.385) and ICU LOS (9.5 ± 7.09 
days in SG versus 10.7 ± 7.6 days in CG, p=0.49) were not different between the two groups. Even 
though the mean baseline APACHE II score was higher in the SG, there was no difference in 
mortality between the groups (p=0071).  
 
Conclusion 
The results of this study suggest that PN containing a 4-oil LE with FO at a dose of 0.09 – 0.22g/kg 
in adult ICU patients with SIRS, with or without sepsis, or ARDS, showed multiple changes in the 
plasma total phospholipid FA profile. Both plasma EPA and DHA increased significantly in the SG. 
The n-6:n-3 PUFA ratio decreased in the SG and remained fairly constant in the CG. The 4-oil LE 
appears to be safe and well tolerated. There was no significant difference in terms of CRP, SOFA, 
length of ICU stay and mortality. Additional studies need to be done in this patient population, 
paying particular attention to the dose, duration and timing of FO, EPA and n-6:n-3 PUFA ratio per 
day and their effect on clinical outcomes. 
 
Introduction 
Critical illness is a multisystem process that can result in significant morbidity and mortality. In 
most patients, critical illness is preceded by a physiological deterioration, characterised by a 
catabolic state and intense metabolic changes, resulting in malnutrition and impaired immune 
functions (1). 
Sepsis remains a common problem in critically ill patients. According to a worldwide survey, 29.5% 
of patients had sepsis on admission or during the Intensive care unit (ICU) stay. ICU mortality rates 
were 25.8% in patients with sepsis (2). There is an increasing awareness that patients who survive 
sepsis often have long-term physical, psychological and cognitive disabilities with significant health 
care and social implications (3). 
Nutrition therapy is important in all critically ill patients and the goals focus on attenuating the 
metabolic response to stress, preventing oxidative cellular injury, and favourably modulating the 
immune response (4). The enteral route is preferable and should be commenced once the patient 
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is haemodynamically stable (5). Where enteral nutrition (EN) is impossible or not tolerated, 
parenteral nutrition (PN) (either as total or supplementary) may safely be administered (6). 
Intravenous lipid emulsions (IVLEs) constitute the main source of energy and FAs in parenteral 
nutrition formulations. However, they are also associated with the development of adverse effects 
(7). 
FAs are classified according to their structure, carbon chain length (short, medium or long), degree 
of saturation (number of double bonds), and the location of double bonds (counted from the 
methyl carbon of the hydrocarbon chain) (7, 8). They play key roles in determining the structural 
integrity and fluidity of cell membranes and can give rise to several important bioactive mediators. 
They can also regulate the expression of a variety of genes and modulate cell-signalling pathways, 
such as those involved in apoptosis, inflammation and cell-mediated immune responses (7, 9). 
Changing the FA composition of cells involved in the inflammatory response influences their 
functions. The anti-inflammatory effects of n-3 PUFAs suggest that they may be useful as 
therapeutic agents in disorders with an inflammatory component (10). 
The metabolites of n-3 PUFAs, primarily from EPA and DHA, compete with arachidonic acid (AA) 
(from n-6 PUFA) for use of the same enzymes, cyclooxygenase and lipoxygenase (11, 12). Fish oil 
(FO) has high concentrations of EPA and DHA, and is thought to have anti-inflammatory potential 
by interfering with the AA pathway and producing the anti-inflammatory eicosanoids 
prostaglandins E3 (PGE3), thromboxanes A3 (TXA3) and leukotrienes B5 (LTB5) as well as resolvins, 
protectins and maresins. FO is also rich in the antioxidant α-tocopheral, which is added to prevent 
the oxidation of its fatty acids (12, 13). Based on experimental and clinical studies, the most 
favourable n-6:n-3 PUFA ratio is proposed to range between 2:1 and 4:1 (14-17).  
There is clinical data suggesting that n-3 PUFAs, particularly fish oil (0.1 – 0.2g/kg/day), has 
beneficial effects on the immune system, organ function and improves clinical outcomes in 
surgical and ARDS patients. In addition, there is some promising data on their use in septic 
patients (8, 9, 17, 18).  
The aim of this study was to compare a 4-oil lipid emulsion (30% soybean oil (SO), 30% medium- 
chain triglycerides (MCTs), 25% olive oil (OO) and 15% fish oil (FO)) (SMOFlipid®) with a 100% 
soybean-based lipid emulsion in terms of certain outcomes (routine biochemical parameters, total 
phospholipid plasma fatty acid composition and clinical outcome) in patients with SIRS, with or 
without sepsis, or ARDS in ICU, requiring parenteral nutrition (PN) for more than 5 days. It was 
hypothesised that inclusion of FO would increase plasma EPA, modify plasma total phospholipid 
fatty acid profile and improve clinical outcomes. This specific article addresses the impact of 
intravenous FO on changes in plasma EPA and fatty acid composition. The rest of the results from 
this study are available in Donoghue et al. (19). 
 
 
Stellenbosch University  https://scholar.sun.ac.za
118 
 
Materials and Methods 
Study design 
This study was a single-centre, double-blind, randomised controlled trial in ICU patients admitted 
to Wits Donald Gordon Medical Centre (WDGMC) ICU with diagnosed SIRS or sepsis and ARDS.  
 
Sample size 
The total number of study participants needed was determined to be at least 72 individuals (36 in 
each subgroup). This number was calculated using a power analysis for ANOVA with two groups, 
significance level of 0.05 and an effect size of 0.55. Sample size n=36 in each group was expected 
to yield 90% power to detect this effect size. 
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n=400 ICU patients screened for eligibility  
       
n= 325 PN not indicated or did not meet inclusion criteria 
 
n=75 PN indicated and patients randomized after obtaining consent 
 
 
n=39 in Study group        n=36 Control group 
 
Patients excluded:       Patients excluded:  
Insufficient biochemical results (n=1)   Consent withdrawn (n=1)  
Consent withdrawn (n=1)     Protocol violation (n=2)  
Protocol violation (n=2)  
 
n=35 completed study        n=33 completed study 
 
Figure 1: Flow diagram of patient inclusion
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Patient selection 
A total number of 75 adult patients were included in the study; seven patients were excluded due 
to insufficient biochemical results, protocol violation and withdrawn consent, leaving a total of 68 
patients. Thirty-five patients were in the study group (SG) versus 33 patients in the control group 
(CG) (Fig. 1). 
Adult patients diagnosed with SIRS or sepsis and ARDS who were predicted to need PN for more 
than 5 days were included consecutively at the time of admission to the ICU. Patients were 
recruited between April 2015 and June 2016. Sepsis was defined as suspected or proven infection 
plus SIRS (that is, presence of pyrexia, tachycardia, tachypnoea and/or leukocytosis). Severe sepsis 
was defined as sepsis with organ dysfunction (hypotension, hypoxaemia, oliguria, metabolic 
acidosis and/or thrombocytopaenia). Septic shock was defined as severe sepsis with hypotension 
despite adequate fluid resuscitation (20, 21).  
The exclusion criteria were as follows: <18 yr old, on full enteral feeding, pregnancy, treatment 
with immunosuppressive drugs or treatment with hydrocortisone >300mg/day at admission, 
plasma triglycerides >4,52mmol/l (>400mg/dl), chronic liver disease or acute hepatitis, RIFLE stage 
III and IV renal failure, recent stroke and known allergic reaction to fish or egg proteins confirmed 
by previous medical history.  
The full methodology of this study is discussed in another unpublished article (223). In short, after 
consent was obtained, patients were randomised according to a randomisation sheet to received 
either PN containing a 4-oil lipid emulsion (SMOFlipid®: 30% LCT, 30% MCT, 25% olive oil, 15% fish 
oil, provided in a complete all-in-one PN bag by Fresenius Kabi: Study Group) or a soybean-based 
lipid emulsion (Intralipid® 100% LCT, provided in a complete all-in-one PN bag by Fresenius Kabi: 
Control Group). Only the fat composition was different (refer to Table 1), otherwise the bags were 
identical. 
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Table 1: The composition of the parenteral nutrition bag  
Contents of PN 
Per 1000ml 
Study group 
PN Code : ITN 8807 
Control group 
PN Code : ITN 8007 
Total Energy  929 kcal 929 kcal 
Energy (NPE) 753 kcal 753 kcal 
Carbohydrates 84g (45% of NPE) 84g (45% of NPE) 
Fat 
Soybean oil 
MCT 
Olive oil 
Fish oil 
EPA + DHA 
n-6:n-3 fatty acid ratio 
42g (55% of NPE) 
12.6g 
12.6g 
10.5g 
6.3g 
1.9g 
1 
42g (55% of NPE) 
42g 
0 
0 
0 
0 
7:1 
Nitrogen 7g 7g 
Glutamine 6.3g 6.3g 
Vitamins, minerals and trace 
elements 
RDA  RDA 
Osmolarity 981mOsm/l 978mOsm/l 
Abbreviations : NPE: Non-Protein Energy; RDA: Recommended Daily Allowance; MCT: 
Medium-Chain Triglycerides; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid 
 
Stellenbosch University  https://scholar.sun.ac.za
122 
 
Anthropometric assessment 
Weight and height were determined or estimated according to acknowledged procedures. Body 
Mass Index (BMI) was calculated on admission using estimated weight (kg)/height in m2 and used 
to classify patients as undernourished, normal, overweight or obese (5, 22). 
Dietary intervention 
The American Society of Parenteral and Enteral Nutrition (ASPEN) and European Society of Clinical 
Nutrition and Metabolism (ESPEN) guidelines (25 – 30kcal/kg/day total energy (TE) and protein 
1.2g – 2g/kg/day) were used to calculate energy and protein requirements (5,22). Both groups of 
study participants received micronutrients, glutamine and electrolytes as part of the complete PN. 
The PN bags in the SG or CG were prescribed according to the study participants’ nutritional and 
fluid requirements and the administration rate was adjusted accordingly.  
The commencement of enteral nutrition (EN) was not defined in the protocol and was started as 
soon as possible according to guidelines and hospital protocol. The nutritional requirements were 
recalculated when EN was started to ensure that the nutritional intake did not exceed the 
requirements and to avoid overfeeding.  
Laboratory measurements 
All blood samples were collected on admission, immediately prior to starting the PN (day 1), 24h 
after initiating PN (day 2), 48h after initiating PN (day 3) and five days after initiating PN (day 6). 
These included full blood count (FBC), urea, creatinine & electrolytes, c-reactive protein (CRP), 
calcium, magnesium & phosphate, liver function tests (AST, ALT, GGT and total bilirubin), 
triglycerides, glucose & blood gases. Blood samples were collected at the same time each day via 
an arterial line and analysed on site. The 6ml blood required for plasma total phospholipid fatty 
acids were taken on day 1, 3 and 6 at the same time as the routine bloods. These samples were 
centrifuged and stored at -80 0C until analysed. 
Routine biochemical measurements were taken as part of the monitoring protocol for patients on 
PN. Electrolytes were corrected as per patients’ individual requirement. Glycaemic control was 
managed according to ICU protocol. Based on the laboratory measurements, the SOFA score was 
calculated daily. 
Plasma total phospholipid fatty acid composition analysis  
Total phospholipid fatty acid composition analysis in plasma was performed within 18 months 
after collection. The detailed method was described in a previous publication (24). Fatty acids 
were analysed by using quadrupole gas chromatography-electron impact-mass spectrometry on 
an Agilent Technologies 7890A Gas Chromatograph system equipped with an Agilent Technologies 
5975C VL mass selective detector (Agilent Technologies). The gas chromatography separation of 
fatty acid methyl esters (FAMEs) was carried out on a BPX 70 capillary column (60 m 3 0.25 mm; 
SGE Analytical Science) by using helium as the carrier gas at a flow rate of 1.3 mL/min. 
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Quantitation of FAME was performed by using the selected ion-extraction method on the basis of 
the response of two diagnostic ions. FAME peaks were identified and calibrated against a standard 
reference mixture of 33 FAMEs (Nu-Chek Prep) and two single FAME standards (Larodan Fine 
Chemicals AB). Relative percentages of fatty acids were calculated by taking the concentration of a 
given fatty acid derivative as a percentage of the total concentration of all fatty acids identified in 
the sample. This analysis was conducted at the Department of Nutrition, North-West University, 
Potchefstroom campus. 
 
Statistical analysis 
Statistical analyses were performed using STATISTICA version 13.2 (StatSoft Inc. (2016) STATISTICA 
(data analysis software system, www.statsoft.com). 
 
Summary statistics were used to describe the variables. Distributions of variables were analysed 
with histograms and/or frequency tables. Medians or means were used as the measures of central 
location for ordinal and continuous responses and standard deviations or quartiles as indicators of 
spread. 
 
Evaluations of the results of the nutritional intake, laboratory parameters, total plasma 
phospholipid FA and clinical data were performed by descriptive statistical analysis for each 
variable and at day 1, day 3 and day 6. Baseline was defined as the data obtained before the 
intervention. Endpoints were defined as net change of post intervention from baseline. 
 
The relationship between total plasma phospholipid FA and the treatment groups was analysed 
with regression analysis and the strength of the relationship measured with Pearson’s correlation 
coefficient or Spearman’s correlation coefficient if the continuous variables were not normally 
distributed. 
 
The fatty acid composition of the SG and the CG were compared using appropriate analysis of 
variance (ANOVA) and appropriate repeated measures analysis of variance (RMANOVA) when 
responses were measured at day 1, day 3 and day 6. For completely randomised designs the 
Mann–Whitney test or the Kruskal–Wallis test was used and for repeated measures designs the 
Wilcoxon or Friedman tests were used.   
 
The relation between nominal variables was investigated with contingency tables and appropriate 
chi-square tests, namely the likelihood ratio chi-square test or the McNemar test. 
 
A p-value of p < 0.05 represented statistical significance in hypothesis testing and 95% confidence 
intervals were used to describe the estimation of unknown parameters. 
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Ethics and legal aspects 
The study was approved by the Health Research Ethics Committee of Stellenbosch University and 
the Human Research Ethics Committee (Medical) of the University of Witwatersrand. Permission 
was granted by the director of the ICU and the hospital manager at WDGMC. Consent was 
obtained from the study participant or his/her closest relatives. The study was conducted in 
accordance with the Helsinki Declaration and was registered on the South African National Clinical 
Trials Register database, registration number: DOH-27-0616-4323. 
Results 
A total number of seventy-five patients were included in the study; however after the exclusion of 
seven patients, a total of 68 patients remained. Thirty-five patients were in the study group (SG) 
versus 33 patients in the control group (CG) (Fig. 1). Patients were followed up for 5 days after PN 
was commenced. On admission to the study the baseline characteristics of the patients in the two 
treatment groups did not differ (Table 2). 
The gender distribution was 66% male and 34% female in the SG vs 56% male and 45% female in 
the CG (p=0.334). The average age was 60.8 ± 13.9 years in SG vs 55.7 ± 14.8 in CG. The majority of 
the participants were surgical admissions (85% in SG vs 91% in CG) and the remainder were 
medical admissions.  
Nutritional intakes 
Total energy, protein, fat, carbohydrates and glutamine intakes did not differ between the groups 
throughout the study period (Table 3), except on day 3 the energy provided per kilogram body 
weight was significantly more in the CG (p=0.041). The SG received FO ranging between 0.09 ± 
0.03g/kg/day (minimum) and 0.22 ± 0.11g/kg/day (maximum), providing between 1.15 ± 0.44g to 
2.37 ± 0.79g EPA and 1.72 ± 0.42g to 2.18 ± 0.44g DHA per day. The total FO intake ranged from 
7.2g ± 2.7 to 15 ± 2.7g. The phytosterol and α-tocopherol intake were significantly different 
between the groups over the entire study period (p=0.008 and p<0.001 respectively). 
EN was started on day 4.03 ± 2.1 in the SG versus day 3.64 ± 1.9 in CG (p=0.42). Unfortunately the 
nutritional intake from EN was not documented, especially oral intake. Thus, the nutrient intake 
tabulated on day 6 was less than that of day 3, as it only included intake from PN. Please note that 
Table 3 only includes nutritional intake from PN. 
Only 63% of patients in the SG and 54% in the CG received PN for the full 6 days, and the 
cumulative FO intake was significantly more in the SG patients that received PN for 6 days 
compared  with those who received PN for fewer days (p=0.032). 
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Laboratory measurements 
There were no differences between the treatment groups with regard to white cell count (WCC), 
blood glucose, triglycerides, liver enzymes and total bilirubin (results in unpublished article (19)). 
The increase from baseline in triglycerides from day 1 to day 6 was significant in both groups 
(p<0.001 for SG and CG); however there was a trend for lower triglyceride levels in the SG.  
Plasma total phospholipid fatty acids composition 
The five-day infusion of a 4-oil LE in the SG providing 0.09 – 0.22g FO/kg/day resulted in multiple 
changes in the plasma total phospholipid FA composition (Table 4). Baseline plasma FA 
compositions were similar between the two treatment groups except for lower linoleic acid (LA, 
p=0.008) and higher arachidonic acid (AA, p=0.005) levels in the SG. 
Oleic acid (OA) percentages increased from day 1 to day 3 in both groups, and then remained fairly 
constant until day 6. OA was higher in the SG than in the CG on day 6 (p=0.022) (Table 4). The 
percentages of LA increased from day 1 to day 3 in the CG and then remained fairly constant. LA 
decreased in the SG (17.34 ± 3.37 on day 1 to 15.05 ± 2.14 on day 6). The differences in LA levels 
between the two groups were significant throughout the study period (Fig. 2A & B). 
Alpha linolenic acid (ALA) increased significantly in both groups (p=0.004); however the increase 
was greater in the CG. AA decreased in both treatment groups: the decrease in the SG occurred 
throughout the study period, whereas the decrease in the CG occurred between day 1 and day 3 
and then remained fairly constant until day 6. The difference between the two groups was 
significant (p=0.005) (Fig. 2C & D). 
Myristic acid (MA) levels were similar in both groups at baseline. The levels increased in the SG 
from day 1 to day 6 and only increased in the CG from day 3 to day 6. On day 3 the MA levels were 
significantly different (p=0.003) in both groups; however on day 6 (p=0.054) the difference was no 
longer significant (Fig. 2E). 
EPA increased significantly in the SG: the biggest increase was from day 1 to day 3 and it continued 
to increase up to day 6 (Fig. 2F). DHA remained fairly constant in the SG and increased slightly 
after day 3 but decreased in the CG. The difference between the two groups was significant 
(p<0.000)(Fig. 2G).   
The plasma n-6 PUFA:n-3 PUFA ratio at baseline was similar between the two groups. This ratio 
decreased in the SG (5.61 ± 1.8 day 1 to 2.84 ± 0.73 day 6) and remained fairly constant in the CG 
(6.38 ± 2.1 day 1 to 6.52 ± 1.81 day 6). In comparing the two groups, the ratio was different on day 
3 and day 6 (Table 4) (p=<0.000).  
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Clinical outcomes 
CRP levels decreased in both groups during the intervention as expected. A correlation was shown 
between the intake of EPA on day 3 and the reduction in CRP levels (r=-0.029, p=0.097). Days on 
mechanical ventilation (1.24 ± 0.83 days in SG versus 0.88 ± 1.63 days in CG) and length of stay 
(LOS) in the ICU (9.5 ± 7.09 days in SG versus 10.7 ± 7.6 days in CG) were not different between the 
two groups (p=0.49); (Fig. 3). The SOFA score improved in both treatment groups during the 
intervention (Table 5). The positive significant correlation between day 3 EPA intake and day 3 
SOFA score (r=-0.4047, p=0.018) (Fig. 4) was noted. A correlation was also shown for EPA intake on 
day 3 and fewer days on mechanical ventilation (r=-0.201, p=0.224). 
Even though the mean baseline APACHE II score was higher in the SG (p=0.19), there was no 
difference in mortality (p=0.024).  
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Table 2: Baseline characteristics of patients in two treatment groups 
 Study Group (n=35) Control Group (n=33) Comparison 
between SG & 
CG group 
Characteristic Mean ± SD -95% LCL +95% UCL Mean ± SD -95% LCL +95% UCL p value 
Age 60.77 ± 13.93 56.19 65.35 55.71 ± 14.78 50.46 60.95 p=0.143 
BMI kg/m2 29.2 ± 11.01 25.47 32.93 27.57 ± 5.91 25.48 29.67 p=0.452 
APACHE II Score 13.65 ± 7.47 11.08 16.21 11.15 ± 8.08 8.27 14.02 p=0.190 
SOFA Score 5.66 ± 4.014 4.28 7.04 5.06 ± 4.17 3.56 6.57 p=0.554 
Temperature 36.97 ± 1.18 36.58 37.36 36.79 ± 0.81 36.50 37.07 p=0.454 
Heart Rate 95.53 ± 22.91 88.00 103.06 97.88 ± 14.68 92.67 103.09 p=0.614 
WCC (109 cells/L) 13.6 ± 8.68 10.75 16.46 17.36 ± 12.89 12.79 21.93 p=0.150 
C-reactive Protein 205.17 ± 127.3 161.44 248.9 220.52 ± 129.14 172.30 268.74 p=0.632 
Albumin (g/L) 25.85 ± 5.65 23.85 27.85 25.84 ± 5.48 23.83 27.85 p=0.994 
BMI: body mass index; SOFA: Sequential Organ Failure Assessment; WCC: white cell count; LCL: lower confidence limit; UCL: upper confidence limit
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Table 3: Nutritional intake from parenteral nutrition 
 Study Group (n=35) Control Group (n=33)  
 Day 1 Day 3 Day 6 Day 1 Day 3 Day 6 Comparison between SG & CG  
Nutritional intake Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD p value 
Energy (kcal) 1130.82 ± 
429.26 
2249.87 ± 386.1 1132.45 ± 
1034.46 
1034 ± 430.18 2222.6 ± 352.41 1176.13 ± 984.67 p=0.357* 
p=0.758** 
p=0.858*** 
Energy (kcal/kg) 14.3 ± 5.64  25.69 ± 8.61  14.464 ± 13.44  13.854 ± 5.69  29.39 ± 5.85 15.46 ± 13.28  p=0.712* 
p=0.041** 
p=0.754*** 
Protein (g/kg) 0.67 ±  0.26 1.33 ± 0.16  0.68 ± 0.64  0.65 ± 0.25  1.39 ± 0.2  0.70 ±  0.61 p=0.74* 
p=0.157** 
p=0.914*** 
Glutamine (g/kg) 0.09 ± 0.03  0.18 ±  0.03 0.09 ± 0.1  0.09 ± 0.03  0.2 ± 0.07  0.09 ± 0.09  p=0.873* 
p=0.230** 
p=0.862*** 
Fat (g/kg) 0.63 ± 0.24  1.26 ± 0.16  0.65 ± 0.59  0.62 ± 0.24  1.32 ± 0.19  0.66 ± 0.57  p=0.892* 
p=0.188** 
p=0.877*** 
Carbohydrate 
(g/kg) 
1.36 ± 0.61  2.58 ± 0.34  1.34 ± 1.27  1.3 ± 0.62 2.80 ± 0.59  1.47 ± 1.27  p=0.675* 
p=0.05** 
p=0.651*** 
Fish oil (g) 7.2 ± 2.65 15 ± 2.68 11.2 ± 4.84     
Fish oil (g/kg) 0.09 ± 0.03  0.19 ± 0.03  0.14 ± 0.06      
EPA (g) 1.15 ± 0.44  2.372 ± 0.47  1.75 ± 0.79      
DHA (g) 1.72 ± 0.42  2.18 ± 0.44  1.61 ± 0.72      
Phytosterol (mg) 48.76 ± 18.3  102.35 ± 20.2  52.23 ± 45.41  96.15 ± 33.4  205.98 ± 34.2  99.83 ± 92.8  p<0.001* 
p<0.001** 
p=0.009*** 
a-tocopherol (mg) 48 ± 17.7  100.04 ± 17.9  50.95 ± 45.6  9.85 ± 8.7  18.49 ± 3.1 8.93 ± 8.29  p<0.001* 
p<0.001** 
p<0.001*** 
* Difference between groups on day 1 ** Difference between groups on day 3 *** Difference between groups on day 6   
EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid 
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Table 4: Plasma total phospholipid fatty acids composition on day 1, day 3 and day 6 
 Study Group (n=29) Control Group (n=30)  
Measurement Day 1 Day 3 Day 6 Day 1 Day 3 Day 6 Comparison between SG & CG  
 Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD p value 
Oleic acid 9.71 ± 2.25 11.95 ± 2.33  11.89 ± 2.51 9.7 ± 1.83 10.94 ± 2.08  10.44 ± 2.03 p=0.98 
p=0.086** 
p=0.022*** 
Linoleic acid 17.34 ± 3.37 16.28 ± 2.63  15.05 ± 2.14  19.7 ± 3.22 21.47 ± 3.87 20.66 ± 3.15 p=0.008* 
p<0.001** 
p<0.001*** 
Alpha linolenic acid 0.09 ± 0.06 0.15 ± 0.07 0.18 ± 0.09  0.12 ± 0.13  0.29 ± 0.15  0.34 ± 0.21  p=0.243* 
p<0.001** 
p<0.001*** 
Arachidonic acid 14.78 ± 3.16  12.55 ± 2.09 11.28 ± 1.59  13.25 ± 2.61  11.47 ± 2.9 11.64 ±  2.57 p=0.048* 
p=0.108** 
p=0.053*** 
Myristic acid 0.24 ± 0.08 0.29 ± 0.08 0.36 ± 0.13 0.23 ± 0.07 0.23 ± 0.05 0.30 ± 0.11 p=0.45* 
p=0.003** 
p=0.054*** 
Eicosapentaenoic acid 0.66 ± 0.56  2.07 ± 0.77 3.42 ± 0.95  0.55 ± 0.35  0.54 ± 0.42 0.94 ± 0.8  p=0.36* 
p<0.001** 
p<0.001*** 
Docosahexaenoic  acid 5.11 ± 1.58  5.09 ± 1.16  5.86 ± 1.19  4.4 ± 1.38  4.07 ± 1.19  3.74 ± 1.31  p=0.071* 
p=0.017** 
p<0.001*** 
n-6:n-3 fatty acid ratio 5.61 ± 1.8 4.03 ± 0.97 2.84 ± 0.73 6.38 ± 2.1 6.67 ± 1.79 6.52 ± 1.81 p=0.137 
p<0.001** 
p<0.001*** 
* Difference between groups on day 1 ** Difference between groups on day 3 *** Difference between groups on day 6 
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Figure 2A: Change in oleic acid per group over the study period 
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Figure 2B: Change in linoleic acid per group over the study period 
 
Stellenbosch University  https://scholar.sun.ac.za
131 
 
 Study Group
 Control Group
Day 1 Day 6
DAYS
0.0
0.1
0.2
0.3
0.4
0.5
A
lp
h
a
 L
in
o
le
n
ic
 A
c
id
p=0.004
 
Figure 2C: Change in alpha linolenic acid per group over the study period 
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Figure 2D: Change in arachidonic acid per group over the study period 
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Figure 2E: Change in myristic acid per group over the study period 
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Figure 2F: Change in eicosapentaenoic acid per group over the study period 
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Figure 2G: Change in docosahexaenoic acid per group over the study period 
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Table 5: Clinical outcome measurements day 1 and day 6 
 Study Group Control Group  
 Day 1 Day 6 Day 1 Day 6 Comparison 
between SG 
and CG 
 Mean ± 
SE  
-95% 
LCL 
+95%  
UCL 
Mean ± 
SE  
 -95% 
LCL  
 +95%  
UCL 
Mean ± 
SE 
-95% 
LCL 
 +95% 
UCL   
Mean ± SE  -95% 
LCL  
+95% 
UCL 
p value 
SOFA score 5.77 ± 
0.75 
4.26 7.28 4.27 ± 
0.77 
2.72 5.82 5.91 ± 
0.86 
4.191 7.635 3.83 ± 0.88 2.06 5.6 p=0.578 
CRP (mg/L) 199.82 ± 
23 
153.74 245.9 103.6 ± 
13.9 
75.71 131.46 215.47 ± 
23.4 
168.56 262.37 116.99 ± 
14.16 
88.62 145.36 p=0.951 
SOFA: Sequential Organ Failure Assessment; CRP: C-reactive protein; LCL: lower confidence limit; UCL: upper confidence limit 
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Figure 3: Length of stay in ICU 
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Figure 4: Correlations between day 3 eicosapentaenoic acid intake and day 3 Sequential 
Organ Failure Assessment Score 
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Discussion 
This study set out to compare a 4-oil LE containing FO (SMOFlipid®) with a 100% soybean-based 
LE in terms of routine biochemical and physiological markers, plasma total phospholipid FA profile, 
organ dysfunction, and clinical outcomes in ICU patients with SIRS, with or without sepsis, or 
ARDS. To our knowledge this is the first randomised controlled study using SMOFlipid® in septic 
ICU patients, although it has been used previously in post-surgery patients (25).  
In this study the baseline characteristics of the patients did not differ between the two groups. 
The nutritional intakes also did not differ, except on day 3 the CG received more energy per 
kilogram body weight and the SG received FO, providing EPA and DHA over the study period, as 
well as α-tocopherol. The highest intake of FO, EPA and DHA was on day 3, as EN was started on 
approximately day 4 in both groups. This study demonstrated a significant increase in OA and ALA 
in both groups. Plasma EPA showed a significant increase in the SG, whereas DHA increased after 
day 3. DHA levels decreased significantly in the CG. AA decreased in both groups. Similar results 
were seen using the same LE in surgical patients. Grimm et al. demonstrated an increase in n-3 
PUFAs, EPA and DHA, and a decrease in LA, AA and total n-6 PUFAs after 6 days (25).  
Similar results were seen with other FO containing LEs studied in critically ill and septic patients. In 
the study by Barbosa et al., the use of FO containing LE was associated with increases in plasma 
EPA, but showed no differences in DHA and AA concentrations (26). Mayer et al. demonstrated a 
marked increase in EPA and DHA concentrations in patients receiving FO-based infusions. The 
levels plateaued after 7 days; the sum of EPA and DHA surpassed the AA level nearly twofold (27).  
Other FO containing LEs have also been used in post-surgical patients, demonstrating a significant 
increase in EPA and DHA levels and n-6:n-3 PUFAs ratio, but showing no difference in AA levels in 
both groups (28) and improved clinical outcomes (29-34). 
The optimal ratio of n-6:n-3 PUFAs has been questioned and whether the provision of an LE with 
an optimum ratio would be associated with metabolic and clinical benefits. Based on previous 
studies, a ratio between 2:1 and 4:1 can be considered as beneficial to severely ill patients (14-17). 
SMOFlipid® was developed to have an optimal n-6:n-3 PUFAs ratio of 2.5:1. In this study, the 
plasma n-6:n-3 PUFAs ratio decreased significantly in the SG, whereas it remained fairly constant 
in the CG. The plasma ratio on day 6 in the SG was similar to the values recommended for lipid 
emulsions (34). Similar results were also seen in surgical patients where the ratio n-6:n-3 PUFAs 
was profoundly elevated and leukotriene B5 release from n-3 PUFAs was also enhanced on day 6, 
whereas the release of leukotriene B4 from n-6 PUFAs was lowered with SMOFlipid® (25). 
In terms of clinical outcomes, this study showed an improvement in CRP levels in both groups and 
a positive correlation was shown between day 3 EPA intake and reduction in CRP levels. Days on 
mechanical ventilation, LOS in the ICU and mortality were not different between the two 
treatment groups; however the SG was associated with a shorter ICU LOS. SOFA score also 
improved in both groups: a significant correlation was found between day 3 EPA intake and day 3 
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improvement in the SOFA score. Grimm et al. demonstrated a significant reduced length of 
hospital stay (13.4 ± 2.0 vs 20.4 ± 10 days) (25). Heller et al. demonstrated a reduction in ICU LOS 
when the n-6:n-3 PUFAs ratio was 2:1 (34).  
A secondary analysis of data comparing the effects of different IV fat emulsions from a prospective 
multicentre study showed that patients receiving soybean oil, compared with patients receiving 
either olive or fish oil, had a shorter time to termination of mechanical ventilation and ICU 
discharge alive (35). Heller et al. (36) used an FO supplement in a heterogeneous group of patients 
including trauma, post-surgical and septic patients, and identified a dose-dependent (0.1–0.2g/kg) 
reduction in mortality, infection rate and length of stay. Grecu et al. showed significant reduction 
in reoperation rates, ICU and hospital LOS, but no difference in mortality (37). Another study using 
the same FO supplement showed a significant decrease in new organ dysfunction, but no 
significant decrease in LOS (38). Other FO-containing LE studies reported no effect on length of 
stay (26, 39-41), days on mechanical ventilator (26, 27, 39, 41) and mortality (26, 27, 39-41). 
A recent meta-analysis confirmed a significant reduction in infection rates by 35% in critically ill 
patients with no overall effect on ICU LOS. They concluded that FO admixtures and FO supplement 
LE are advantageous for the majority of patients compared with LCT or MCT/LCT LE because of 
their balancing omega-3 content (42). However, a review published recently found insufficient 
high-quality data investigating the true effect of PN with FO containing LEs compared with other 
IVLEs on clinical outcomes (43). 
It is difficult to compare the results of this study with other FO studies owing to the different dose 
of FO and duration of treatment. 
The limitations of this study are that only half the patients received PN for 6 days; this affected the 
duration as well as the dose of FO over the study period. There was a definite signal that the 
intake of EPA and FO on day 3 showed a beneficial effect. It was not possible to determine the full 
nutritional intake throughout the study period owing to the incomplete recording of EN intake. 
Infection rate, as well as days on antibiotics, was also not documented and would have provided 
valuable information about clinical outcomes. The study population may have been somewhat 
heterogenous as to the causes and severity of SIRS and ARDS. Finally, we were unable to test 
plasma α-tocopherol levels, which would have been an interesting additional result as the intake 
was significantly different between the two groups. 
 
Conclusion 
This study results suggest that PN containing a 4-oil LE with FO at a dose of 0.09 – 0.22/kg in adult 
ICU patients with SIRS, with or without sepsis, or ARDS, showed multiple positive changes in the 
plasma total phospholipid fatty acid profile. Both plasma EPA and DHA increased significantly in 
the SG. The n-6:n-3 PUFA ratio decreased in the SG and remained fairly constant in the CG. The 4-
oil LE appears to be safe and well tolerated. There was no significant difference in terms of CRP, 
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SOFA, length of ICU stay and mortality. Additional studies need to be done in this patient 
population, paying particular attention to the dose and timing of FO, EPA and n-6:n-3 PUFA ratio 
per day, and their effect on clinical outcomes. 
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4.3 ADDITIONAL RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
143 
 
Dietary data 
Both groups were well matched for baseline characteristics. Nutritional intake of total energy, 
protein, fat and glutamine did not differ significantly between the groups throughout the study 
period, except on day 3 the energy provided per kilogram body weight was significantly more in 
the CG (p=0.041). The study group (SG) fish oil (FO) intake was significantly higher throughout the 
study providing between 0.09 ± 0.03g (day 1) and 0.22 ± 0.11g/kg/day (day 3) (Figure 1). The time 
of commencement of enteral nutrition as well as the calculation of all nutrients (including oral, 
enteral and parenteral) was unfortunately neither defined nor controlled in the protocol. In line 
with hospital protocol and guidelines, early enteral nutrition was initiated in nearly half the 
patients, which resulted in a reduced fish oil intake through IVLE.   
The phytosterol intake was significantly more in the control group (CG) (p<0.001) (Fig. 2) 
throughout the study. Similarly, the alpha-tocopherol intake was significantly more in the SG 
(p<0.001) (Fig. 3). 
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Figure 1: Fish oil intake in the study group 
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Figure 2: Phytosterol intake throughout study period 
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Figure 3: Alpha-tocopherol intake throughout study period 
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Ventilatory function 
Days on mechanical ventilation did not differ between the two groups (Table 1). Both groups 
received steroids: the mean days on steroids were slighter longer in the SG but were not 
significant (p=0.775). A correlation was found between days on steroids and days on mechanical 
ventilation (r=0.298, p=0.012) (Fig. 4). A non-significant negative correlation was also shown for 
day 3 EPA intake and days on mechanical ventilation (r=-0.201, p=0.224). 
Table 1: Days on mechanical ventilation 
 Study Group (n=38) Control Group (n=33) p value 
Days on mechanical 
ventilation 
1.658 ± 2.317 1.515 ± 1.805 p=0.775 
 
Correlation: r = 0.29800
-1 0 1 2 3 4 5 6 7
Days on Steroids
-1
0
1
2
3
4
5
6
7
D
a
y
s
 o
n
 M
e
c
h
a
n
ic
a
l 
V
e
n
ti
la
ti
o
n
p=0.012  
 
Figure 4: Correlation between days on steroids and days on mechanical ventilation 
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CHAPTER 5 
DISCUSSION 
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This study set out to compare a 4-oil lipid emulsion (LE) (30% soybean oil (SO), 30% medium-chain 
triglycerides (MCTs), 25% olive oil (OO) and 15% fish oil (FO)) (SMOFlipid®) with a 100% soybean- 
based LE in terms of its effect on (i) routine biochemical and physiological parameters, (ii) gas 
exchange, (iii) inflammatory mediators, (iv) plasma total phospholipid fatty acid (FA) composition, 
and various clinical outcomes in adult intensive care unit (ICU) patients with SIRS, with or without 
sepsis, and acute respiratory distress syndrome (ARDS). 
It was postulated that the LE containing FO would result in improved biochemical markers, i.e. less 
effect on plasma triglycerides and liver enzymes, improved oxygenation, reduced concentrations 
of pro-inflammatory cytokines, i.e. tumour necrosis alpha (TNF-α), interleukin (IL)-1 and IL-6, and 
increased concentrations of anti-inflammatory cytokine IL-10, improved plasma eicosapentaenoic 
acid (EPA) and reduced omega-6 (n-6):omega-3 (n-3) polyunsaturated FA (PUFA) ratio, and 
improved clinical outcomes, i.e. reduction in sequential organ failure assessment (SOFA) score, 
fewer days on mechanical ventilation, reduced ICU length of stay (LOS) and reduced mortality. 
To our knowledge, this is the first randomised controlled study using SMOFlipid® in adult septic 
ICU patients, although it has been studied previously in post-surgery patients (1-8). 
5.1 Patient description and baseline parameters 
A total number of 75 adult patients were included in the study and randomised to receive either 
parenteral nutrition (PN) with a 4-oil LE (Study Group (SG)) or PN with a 100% soybean oil LE 
(Control Group (CG)). Seven patients were excluded, a total of 68 patients remained, and 35 
patients were randomised in the SG and 33 in the CG.  
A number of studies have been conducted in critically ill patients comparing the effects of 
intravenous (IV) FO LE with other LE. Table 5-1 compares the current study with previous studies 
in terms of number of study participants, duration of intervention, and baseline descriptors, 
namely, SOFA score, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, 
Simplified Acute Physiology Score (SAPS II), age, and body mass index (BMI). The APACHE II or 
SAPS II scores are used in the various studies to predict the severity of the disease and risk of 
short-term mortality (9). The number of study participants of this study was relatively high 
compared with the other studies. 
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Table 5-1: Comparison of study participants and baseline descriptors of the current study versus 
previous studies in critically ill patients 
Author Patient number Duration of 
intervention 
Baseline descriptors 
 Study Group Control 
Group 
Our study 68 SIRS and septic 
patients 
5 days  APACHE II 
SOFA 
Age 
BMI 
13.7 ± 7.5 
5.7 ± 4 
60.8 ± 13.9 
29.2 ± 11 
11.2 ± 8.1 
5.1 ± 4.2 
55.7 ± 14.8 
27.6 ± 5.9 
Barbosa (10) 25 sepsis patients 5 days SOFA  
SAPS II 
Age 
BMI  
9.5 ± 0.9 
47.5 ± 5 
70 ± 2 
28.9 ± 1.7 
8.9± 1.2 
41.6 ± 6.5 
57 ± 5 
28.5 ± 2.6 
Sungurtekin (11) 20 sepsis and 20 
SIRS patients 
7 days APACHE II 
Age 
BMI 
19.8 – 21.9 
44.4 – 54.0 
25.4 – 26.3 
20.5 – 28.0 
61.4 – 69.6 
26.4 - 28 
Friesecke (12) 116 critically ill 
medical patients 
≥ 7 days SAPS II 
Age 
49 ± 18 
63 ± 13 
54 ± 17 
66 ± 11 
Hall (13) 60 sepsis patients 14 days or 
until discharge 
APACHE II 
SOFA 
Age 
19.1 ± 6.7 
7.2 ± 3.0 
63.8 ± 11.7 
17.9 ± 6.2 
7.6 ± 3.2 
64.5 ± 13.4 
Edmunds (14) 451 critically ill 
patients 
19 pts in FO 
group 
12 day or 
death  
APACHE II 
Age 
BMI 
24.3 ± 6.8 6 
66.2 ± 18.3 
27.4 ± 18.3 
22.4 ± 7.9 
63.5 ± 15.9 
28.4 ± 8 
Khor (15) 28 patients with 
severe sepsis 
5 days  APACHE II 
Age 
BMI 
19.3 ± 7.8 
64.8 ± 17.4 
21.5 ± 5.2 
16.3 ± 7.2 
73.8 ± 14.2 
21.4 ± 5.6 
Mayer (16) 21 septic patients 5 days N/A N/A N/A 
Mayer (17) 10 septic patients 10 days APACHE II 14 - 34 9 - 23 
Heller (18) 661 ICU patients ≥ 3 days FO at 
different 
doses 
SAPS II 
Age 
BMI  
32.2 ± 13.6 
62.8 ± 16.5 
25.1 ± 4.2 
 
Grecu (19) 54 patients with 
abdominal sepsis 
5 days N/A N/A N/A 
Grau-Carmona 
(20) 
159 critically ill 
patients 
5 days APACHE II 
SOFA 
Age 
BMI 
21 ± 5 
6.8 ± 3.6 
60.7 ± 17.3  
26.6 ± 4 
21 ± 6 
7 ± 3.3 
60.6 ± 16.4 
27.1 ± 4 
Wang (21) 40 patients with 
acute pancreatitis 
5 days APACHE II 
SOFA 
Age 
BMI 
12 ± 3 
6 ± 0.8 
40 ± 10 
22.3 ± 1.2 
13 ± 4 
7 ± 1.1 
37 ± 9 
21.8 ± 2.1 
Abbreviations: SOFA: Sequential Organ Failure Assessment; SAPS II: Simplified Acute Physiology Score; 
APACHE II: Acute Physiology and Chronic Health Evaluation II; BMI: body mass index measured as kg/m2; 
Age: measured in years; N/A: not available in article. 
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The majority of the participants were surgical admissions with an average age of 61 years in the SG 
and 56 years in the CG. The ages were similar to those of the study participants in Grau-Carmona 
et al. (Table 5-1), Ma et al. and Allingstrup et al., where the average ages ranged from 61.55 to 
62.9 years and 58.8 to 60.3 years respectively (20, 22, 23).  
The average body mass index (BMI) in this study was 29 kg/m2 in the SG and 28 kg/m2 in the CG. 
The study conducted by Veldsman et al. in another South African ICU showed similar results, with 
a mean BMI of 28.5 ± 8.1 kg/m2 (24). The mean APACHE II score was 14 (SG) and 11 (CG), which 
was similar to Wang et al., but lower than other studies on critically ill patients (21). These values 
are reported in Table 5-1 (11, 13-16, 20, 21) and the average SOFA score on admission was 5.7 in 
the SG and 5 in the CG, which was also lower than the other studies performed in critically ill 
patients (see Table 5-1 for SOFA scores from other studies) (10, 13, 20, 21). 
The baseline characteristics of the patients did not differ between the two treatment groups with 
regard to age, BMI, APACHE II and SOFA scores, temperature, heart rate, biochemical parameters, 
including triglycerides and liver functions, PaO2/FiO2 ratio, and cytokine levels. 
The nutritional intake in terms of total energy, carbohydrates, protein, lipids, glutamine and 
micronutrients also did not differ, except the CG had a higher energy per kilogram body weight 
intake on day 3 and the SG received FO (0.09g/kg minimum to 0.22g/kg maximum), providing EPA, 
DHA and higher levels of α-tocopherol over the study period. The highest intake of FO, EPA and 
DHA was on day 3, as enteral nutrition (EN) was started on approximately day 4 in both groups. 
The cumulative FO intake was statistically significant in the SG between the patients that received 
PN for 6 days compared with those who did not (p=0.032). The intake of phytosterol was 
significantly less in the SG. There is evidence that large intakes of phytosterols can cause 
cholestasis and PN-associated liver disease (PNALD) (25). A study conducted in adult patients on 
home PN showed a correlation between total plasma phytosterol levels, liver function tests and 
platelet counts. A strong correlation was shown between total plasma phytosterol levels, total 
bilirubin levels and AST levels and a weaker correlation for platelet counts (26). A study conducted 
by Ellegård et al. concluded that adult patients with short-bowel syndrome (SBS) receiving PN had 
higher serum levels of phytosterols compared with other SBS patients not receiving PN, possibly 
owing to the phytosterol content in LE (27). PNALD has also been studied in the paediatric 
population. Savini et al. measured plasma phytosterol concentrations in preterm infants receiving 
five different LEs. The participants receiving the 100% soybean oil LE had significantly higher 
plasma phytosterol concentrations (28). Clayton et al. reported a link between plasma phytosterol 
concentrations and cholestatic liver disease in 29 children (29). Although these two studies were 
conducted in children, the concept of PN and the LE content contributing to the phytosterol levels 
remains the same. 
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5.2 Biochemical and physiological markers 
Biochemical and physiological markers were measured at baseline (day 1), day 3 and day 6. 
Throughout the study comparisons were made between the two treatment groups, as well as 
within each group to detect differences between baseline and day 6 measurements. 
There were no statistically significant differences between the groups with regard to WCC, blood 
glucose, triglycerides (TGs), liver enzymes and total bilirubin throughout the study period. Looking 
at within-group changes over time, however, showed a significant increase for triglyceride levels 
from day 1 to day 6, in both groups; however the range was wider in the CG. LEs containing only 
long-chain triglycerides (LCTs) and those containing 50% long-chain triglycerides and 50% medium- 
chain triglycerides (LCTs/MCTs) have been shown to increase plasma TG levels (1, 6, 11, 30), 
whereas FOs containing LEs have shown a significant reduction in plasma TG levels in surgical 
patients or maintaining the levels within normal ranges (1, 4-6, 23, 30, 31). A meta-analysis 
conducted by Chen et al. on the safety and efficacy of FO-enriched PN in postoperative patients 
undergoing major surgery found no significant difference in plasma TG levels compared with PN 
without FO (32). However, the meta-analysis conducted by Tian et al. found significant differences 
between a 4-oil LE containing SO/MCT/OO/FO vs LCT and vs OO/LCT, suggesting the beneficial 
effect of FO containing LE in surgical patients (33). 
There are various factors associated with liver changes associated with PN, namely, duration on 
PN, overfeeding, especially with calories, lipid load, high phytosterol intake and low α-tocopherol 
intake. In this study, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and 
bilirubin levels decreased in both treatment groups. AST levels decreased from day 1 to day 3 but 
then increased again after day 3, whereas ALT levels decreased throughout the study period in the 
CG. The ALT levels decreased and the gamma-glutamyl transferase (GGT) levels increased in both 
groups. Bilirubin levels decreased in both groups between day 1 and day 3 and then continued to 
decrease in the SG, but levels increased significantly in the CG after day 3 (p=0.039). A weak, 
negative correlation was found between day 3 EPA intake and bilirubin levels. These results are 
similar to findings from other studies in surgical patients, comparing FO containing LE to other LE, 
showing a decrease in ALT (1, 3, 5, 30,34), AST (5, 30, 34) and bilirubin (3, 30, 35), and an increase 
in GGT (1, 3). Some studies showed no difference in liver function test with FO LE (4, 6-8, 36). 
Sungurtekin et al. demonstrated an increase in liver steatosis on day 7 and 10 in patients with 
sepsis and SIRS on PN without FO (11). A retrospective study conducted in adult patients receiving 
FO supplementation in PN, showed GGT, alkaline phosphatase (ALP) and ALT decrease with FO PN 
supplementation. The decrease was greater when the doses of FO were higher (0.71g FO/kg – 
5.28g FO/kg) (37). Two studies conducted in patients undergoing liver transplantation, compared 
PN with and without FO. A significant reduction in ALT and prothrombin time was seen in the FO 
group with a significant decrease in post-transplant hospital stay (34, 38). Reduction in liver 
enzymes and improved antioxidant status with FO containing LE was also shown in four meta-
analyses (32, 33, 39, 40).  
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Klek et al. (41) performed a study to evaluate the safety and efficacy of a 4-oil (SO/MCT/OO/FO) LE 
vs an LCT LE in intestinal failure patients on long-term parenteral nutrition. After four weeks on 
PN, the patients receiving the fish oil containing LE had significantly lower liver enzymes.  
5.3 Gas exchange 
This study did not demonstrate a statistical difference between the PaO2/FiO2 ratio between the 
two treatment groups on day 1 or day 6. This could be because the optimal dose of FO was only 
received for 2 days. Barbosa et al. showed a significantly higher PaO2/FiO2 ratio in the FO group 
compared with the MCT/LCT group, and the proportion of patients with PaO2/FiO2 ratio > 300 was 
significantly higher on Day 6 (10). Wang et al. showed a significantly better oxygenation index with 
n-3 PUFA supplemented PN at doses of 0.15 – 0.2g/kg/day (21). A positive non-significant 
correlation was found between the intake of EPA on day 3 and the improvement in PaO2/FiO2 ratio 
in the SG.  
 
5.4 Inflammatory markers 
Pro-inflammatory cytokines, namely, TNF-α, IL-1β and IL-6 and the anti-inflammatory cytokine IL-
10 were measured as well as C-reactive protein (CRP). Plasma cytokine concentrations did not 
differ statistically between the two groups prior to initiation of PN and throughout the study 
period. Concentrations of TNF-α decreased from day 1 to day 6 in the SG, whereas they increased 
in the CG, but the changes were not significant. Concentrations of IL-1β and IL-6 decreased in the 
SG during the intervention and increased in the CG after day 3; however the difference was not 
significant. IL-10 concentrations decreased in both groups between day 1 and day 3, but then 
increased from day 3 to day 6 in the SG. A positive correlation was shown between the FO intake 
and the concentrations of IL-10.  
Metry et al. demonstrated a significant reduction in IL-6 in postoperative ICU patients when 
comparing SMOFlipid® with LCT (8). Another study in surgical patients comparing an FO 
supplement and LCT versus LCT showed a significant decrease in IL-6, TNF-α and IL-1 in the FO 
group (36), while comparing the same LE in patients with acute pancreatitis showed a reduction of 
IL-6 in the FO-supplemented group at a dose of 0.15 – 0.2g/kg/day FO (226). Other studies in 
surgical patients comparing FO supplement plus MCT/LCT versus MCT/LCT showed a significant 
reduction in IL-6, TNF-α and IL-1 (30) and IL-6 and TNF-α, but no difference in IL-1 and IL-10 (35). 
Ma et al. compared MCT/LCT/FO LE with MCT/LCT and showed no significant difference in IL-6 and 
TNF-α levels (23). Wu et al. compared SO/MCT/OO/FO with MCT/LCT and reported no difference 
in IL-6, TNF-α and IL-10 levels (6). 
Other FO containing LEs have also been studied in critically ill and septic patients. Mayer et al. 
demonstrated an increase in TNF-α, IL-1 and IL-6 in the LCT group (high in omega-6 
polyunsaturated fatty acid (PUFA)) (16). Sungurtekin et al. demonstrated an increase in IL-6 and 
TNF-α on day 7 and an increase in IL-1 on day 3, 7 and 10 in septic patients receiving MCT/LCT LE. 
Stellenbosch University  https://scholar.sun.ac.za
152 
 
They also showed an increase in IL-10 in the group receiving FO LE at the dose of 0.6g/kg/day (11). 
Barbosa et al. showed a reduction in IL-6 and a lesser decrease in IL-10 in the MCT/LCT/FO group 
compared with MCT/LCT (10). However, other studies showed no effect on IL-6 levels (12) and 
TNF-α levels (15). 
This study showed an improvement in CRP levels in both groups as expected and a positive 
correlation was shown between day 3 EPA intake and reduction in CRP levels. Antebi et al. 
compared the same two LEs used in this study in surgical patients and demonstrated a reduction 
in CRP levels in the FO group (1). A reduction in CRP was also demonstrated in patients with acute 
pancreatitis receiving an FO supplement and LCT compared with LCT (21). However, other studies 
in surgical patients reported no difference in CRP levels (35, 42). Two studies in critically ill patients 
also reported a reduction in CRP levels in the patients receiving FO containing LE (13, 19). 
 
5.5 Total phospholipid fatty acid profile 
This study compared a 4-oil LE (30% SO, 30% MCT, 25% OO and 15% FO) (SMOFlipid®) with a 100% 
soybean-based LE. SO LEs are LCTs that are high in n-6 PUFA and contain high amounts of linoleic 
acid (LA) and moderate amounts of α-linolenic acid (ALA). MCTs are short-chain FAs and include 
caprylic, caproic and myristic acids. OO is rich in omega-9 FA and contains oleic acid (OA) and small 
amounts of LA, and FO LEs are high in n-3 PUFA and contain EPA and DHA (43). 
This study demonstrated a significant increase in OA and ALA in both groups. Plasma myristic acid 
increased in the SG throughout the study period and only increased between day 3 and day 6 in 
the CG. Plasma concentrations of myristic acid were significantly different on day 3 between the 
SG and the CG. Plasma EPA showed a significant increase in the SG, whereas DHA increased 
slightly only on day 6. DHA levels decreased significantly in the CG throughout. Arachidonic acid 
(AA) decreased in both groups. Similar results have also been shown in critically ill patients, in the 
study by Barbosa et al. who compared an LE containing MCT/LCT/FO with an LE with MCT/LCT. 
The FO containing LE was associated with a significant increase in plasma EPA, but showed no 
differences in DHA and AA concentrations between the two groups (10). Mayer et al. 
demonstrated a marked increase in EPA and DHA concentrations and a decrease in AA levels in 
septic patients receiving FO-based infusions and LCT compared with LCT. The FA profile remained 
unchanged in the LCT group (16, 17).  
In surgical patients, Grimm et al. compared an LCT/MCT/OO/FO LE with LCT and demonstrated an 
increase in n-3 PUFA, EPA and DHA, and a decrease in LA, AA and total n-6 PUFA after 6 days (2). 
Klek et al. (41) also showed a positive change in the fatty acid profile in intestinal failure patients 
on long-term parenteral nutrition receiving the same LE. 
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Other FO containing LEs have also been used in post-surgical patients, demonstrating a significant 
increase in EPA and DHA levels (31, 44) or just EPA levels (21,45), and showing a decrease in AA 
levels in both groups and no difference between the groups (44, 45).  
The optimal ratio of n-6:n-3 PUFA has been questioned and whether the provision of an LE with an 
optimum ratio would be associated with metabolic and clinical benefits. Based on previous 
studies, an n-6:n-3 PUFA ratio between 2:1 and 4:1 can be considered as beneficial to severely ill 
patients (25,46-48). SMOFlipid® was developed to have an optimal n-6:n-3 PUFA ratio of 2.5:1. In 
this study, the plasma n-6:n-3 PUFA ratio decreased significantly in the SG (from 5.61:1 to 2.84:1), 
whereas it remained fairly constant in the CG. Similar results were shown by Mayer et al. in septic 
patients where the ratio n-6:n-3 PUFA decreased to 2.5:1 after 3 days on an FO LE (17). A decrease 
in n-6:n-3 PUFA in surgical patients has also been demonstrated by Grimm et al., comparing the 
same two LEs used in this study (2). Various other studies in surgical patients using other FO 
containing LEs have also demonstrated a reduction in n-6:n-3 PUFA ratio (35, 44, 45, 49). 
Leukotriene B5 (LTB5) is generated from n-3 PUFAs and leukotriene B4 (LTB4) is generated from n-6 
PUFAs. These have also been studied in surgical patients by Grimm et al., showing an increased 
release of LTB5  and a decreased release of LTB4 on day 6 with LCT/MCT/OO/FO LE (2). Similar 
results have also been demonstrated with other FO containing LEs in critically ill (17) and surgical 
patients (35, 45). 
 
5.6 Clinical outcomes 
In terms of clinical outcomes, days on mechanical ventilation (MV), ICU LOS and mortality were 
not different between the two treatment groups; however the SG had a shorter ICU LOS. The 
SOFA score also improved in both groups, a medium and significant correlation was found 
between day 3 EPA intake and day 3 improvement in the SOFA score. Grimm demonstrated a 
significant reduced length of hospital stay (13.4 ± 2.0 days in FO group versus 20.4 ± 10 days in LCT 
group) comparing the same two LEs (2). Heller demonstrated a reduction in ICU LOS when the n-
6:n-3 PUFA was 2:1 (18).  
Other FO containing LEs studied in critically ill patients showed a significant reduction in 
nosocomial infections and prolonged predicted time free of infection; however the shorter length 
of mechanical ventilation and hospital stay in the FO group was not significant (20). Other studies 
demonstrated significant reduction in re-operation rates, ICU and hospital LOS (19), less new 
organ dysfunction (13), and reduced infection rate and antibiotic usage (18).  
Studies conducted in surgical patients receiving FO LEs have shown a reduction in infections (30, 
42, 50, 51), fewer days on mechanical ventilation (52) and reduction in hospital length of stay (45, 
50, 51). Berger et al. and Han et al. showed a non-significant trend to reduction in ICU and hospital 
length of stay (30, 31). A secondary analysis of data comparing the effects of different IV fat 
emulsions from a prospective multicentre study showed that patients receiving either olive or fish 
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oil compared to those receiving soybean oil had a shorter time to termination of mechanical 
ventilation and ICU discharge alive (14). 
Heller et al. (53) used an FO supplement in a heterogeneous group of patients, including trauma, 
post-surgical and septic patients, and identified a dose-dependent (0.1–0.2g/kg) reduction in 
mortality, infection rate and length of stay.  
A recent meta-analysis confirmed a significant reduction in infection rates by 35% in critically ill 
patients with no overall effect on ICU LOS, but found no clear-cut effect on TNF-α levels (54). 
There are a few studies in critically ill patients using FO containing LEs showing no effect on clinical 
outcomes, namely, effect on length of stay (10, 12, 15,16), days on mechanical ventilation (10, 12, 
17) and mortality (10, 12, 15-17, 19). In surgical patients, a few studies also showed no effect on 
mortality using FO containing LEs (30, 45, 49,50). 
The dose of fish oil administered in this study was 0.09 – 0.22g/kg and is consistent with the dose 
that other studies have found to be clinically favourable 13, 20, 37, 53). The highest dose of FO 
was on day 3 as EN was started afterwards and resulted in a reduction in PN intake and FO intake. 
The dosage of FO that showed benefit was 0.1 – 0.15g/kg/day (39) and 0.07 – 0.225g/kg/day (32). 
 
5.7 Safety 
Adverse reactions did not differ between the treatment groups and no serious or unexpected 
adverse events were reported, confirming the findings of a variety of clinical trials that PN 
containing FO is safe in critically ill patients (10, 13, 20, 49, 53, 55).  
 
5.8 Hypothesis statements 
This study supports the hypothesis that a FO containing IV LE compared with a soybean oil IV LE 
results in less inflammation (reduction in TNF-α levels) and increased plasma EPA levels. However, 
we could not prove a difference in gas exchange and clinical outcomes. Additional studies need to 
be conducted in the area of gas exchange and improved clinical outcomes, paying particular 
attention to the dose and duration of FO LE intake to prove this hypothesis. 
The hypothesis that FO containing IV LE results in less inflammation and increased plasma EPA 
levels is accepted. However, the hypothesis that FO containing IV LEs improves gas exchange 
(PaO2/FiO2 ratio) and clinical outcomes (days on mechanical ventilation, length of ICU stay and 
mortality) is rejected. 
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CHAPTER 6 
CONCLUSION AND RECOMMENDATIONS 
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6.1 Conclusion 
This study set out to determine the effects of a 4-oil lipid emulsion (LE) (30% soybean oil (SO), 30% 
medium-chain triglycerides (MCTs), 25% olive oil (OO) and 15% fish oil (FO)) (SMOFlipid®) 
compared with a 100% soybean-based LE on routine biochemical and physiological parameters, 
gas exchange, inflammatory mediators, plasma total phospholipid fatty acid (FA) composition, and 
clinical outcomes in adult Intensive care unit (ICU) patients with the systemic inflammatory 
response syndrome (SIRS), with or without sepsis, or the acute respiratory distress syndrome 
(ARDS).  
It was hypothesised that the 4-oil LE would improve biochemical markers, improve oxygenation, 
reduce pro-inflammatory cytokines and increase anti-inflammatory cytokine IL-10, improve 
plasma eicosapentaenoic acid (EPA) and reduced the omega-6 (n-6):omega-3 (n-3) 
polyunsaturated FA (PUFA) ratio, and improve clinical outcomes. 
The results suggest that PN containing a 4-oil LE with FO (Study Group (SG)) at a dose of 0.09 – 
0.22g FO/kg, compared with a 100% soybean oil LE (Control Group (CG)), had a tendency to 
reduce liver enzymes, particularly alanine aminotransferase (ALT) and bilirubin. ALT levels 
decreased in both groups. Bilirubin levels decreased in both groups between day 1 and day 3 and 
continued to decrease in the SG until day 6, but increased significantly in the CG after day 3. 
Triglyceride levels were similar between the two groups. 
In the SG, concentrations of TNF-α, IL-1β and IL-6 decreased from day 1 to day 6, whereas TNF-α 
increased in the CG, IL-1β and IL-6 also increased in the CG after day 3; however the difference 
was not significant. IL-10 concentrations decreased in both groups between day 1 and day 3, but 
then increased from day 3 to day 6 in the SG.  
The SG also showed multiple positive changes in the plasma total phospholipid fatty acid profile, 
namely an increase in oleic acid, linoleic acid, alpha-linolenic acid, myristic acid and a decrease in 
arachidonic acid. Plasma EPA levels increased significantly in the SG, whereas docosahexaenoic 
acid (DHA) increased slightly only after day 3. The n-6:n-3 PUFA ratio decreased in the SG and 
remained fairly constant in the control group (CG).  
No difference in PaO2/FiO2 ratio was shown between the two groups throughout the study period 
and the number of days on mechanical ventilation was no different.  
Even though the mean APACHE II score was higher in the SG, there was no difference in mortality. 
As expected there was a reduction in C-reactive protein (CRP) and Sequential Organ Failure 
Assessment (SOFA) score. The ICU length of stay (LOS) was also reduced; even though it wasn’t 
statistically significant, it could be clinically relevant.  
A weak correlation was found between day 3 EPA intake and bilirubin levels, fewer days on 
mechanical ventilation and a reduction in CRP levels, and a significant correlation was found for 
improvement in SOFA score. A weak correlation was also seen between day 6 FO intake and LOS. 
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Additional studies need to be done in this patient population, paying particular attention to the 
dose and timing of FO, EPA and n-6:n-3 PUFA ratio per day and their effect on clinical outcomes. 
In summary, this study showed that the administration of a 4-oil IVLE containing FO resulted in a 
significant increase in plasma EPA levels and n-6:n-3 PUFA ratio and a non-significant reduction in 
plasma TNF-α, liver enzymes (ALT and bilirubin), SOFA score and ICU LOS. 
 
6.2 Strengths and limitations 
As far as can be reasonable ascertained, this is the first randomised controlled study using 
SMOFlipid® in adult patients with SIRS, with or without sepsis, although it has been studied 
previously in post-surgery patients. The number of patients included in this study was relatively 
large compared with other trials in critically ill patients. The protocol of this study did not interfere 
with the standard of practice and ICU protocol. Although this transpired to be one of the 
limitations of the study in terms of the dose of FO administered over the entire study period, it is  
still believed to be a strength.  
The limitations of this study are as follows: 
Only half the patients received full parenteral nutrition (PN) for 6 days; this affected the duration 
as well as the dose of fish oil (FO) over the study period. There was a definite signal that the intake 
of EPA and FO on day 3 showed a beneficial effect.  
It was not possible to determine the full nutritional intake throughout the study period owing to 
the incomplete recording of enteral nutrition intake.  
Infection rate as well as days on antibiotics was also not documented and would have provided 
valuable information about clinical outcomes.  
The study population may have been somewhat heterogenous as to the causes and severity of 
SIRS and ARDS. 
Finally we were unable to test plasma α-tocopherol levels, which would have been an interesting 
additional result as the intake was significantly different between the two groups. 
 
6.3 Recommendations 
A similar study needs to be conducted where all nutritional intake (oral, enteral and parenteral) is 
documented and calculated to ensure that the patients are optimally fed throughout the study 
period.  
Commencing enteral nutrition as soon as possible in the intensive care unit is recommended by all 
the guidelines and thus a recommendation would be to include enteral nutrition in the study with 
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high doses of FO, similar to those in the parenteral nutrition, or adding an intravenous FO 
supplement, thereby guaranteeing the FO intake at an optimal dose throughout the study.  
Additional documentation or reporting on new infections and number of days on antibiotics would 
also be a useful measurement in terms of determining clinical outcomes as well as following up 
the patients for 28 days or until hospital discharge instead of just examining ICU length of stay. 
Lastly, adequately powered, randomised controlled clinical trials assessing the impact of nutrition 
therapy containing intravenous FO at the dose of ≥0.2g/kg FO for a minimum of 5 days in patients 
with SIRS with or without sepsis are recommended.  
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Appendix A 
Data collection protocol
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MULTI- & SURGICAL ICUs AT UNIVERSITAS, PELONOMI AND WDGMC  
 
CLINICAL NUTRITION RESEARCH 
 
STANDARDIZED DATA COLLECTION PROTOCOL 
 
1. General information: 
 
Research project title: To investigate the effect of a fish oil containing parenteral lipid 
emulsion on inflammatory markers, gas exchange and clinical 
outcomes in septic patients. 
 
Researcher: Veronique Donoghue 
 
Study leaders: Dr Maryke Spruyt 
Prof R Blaauw 
Dr Gunter Schleicher 
Contact details Veronique Donoghue 
c: +27833864001 
w: (011) 5450040  
Veronique.donoghue@fresenius-kabi.com 
 
Research Assistant & 
Contact details: 
 
 
2. Scoring Systems  
 
1. You will use the various scoring systems when assessing the patient.  
2. The APACHE II score needs to be documented when the patient is entered into the study. (Table 1, 
Appendix 1). This is a point based score assessing 12 routine physiological measurements. 
3. You will assess the SOFA score(Table 2, Appendix 1) on admission into the study . 
4. You will also record the SOFA score daily on the case report form. 
5. Renal function will be assessed using the RIFLE classification (Table 3, Appendix 1) on admission to 
the study and throughout the study period.  
6. The RIFLE classification will be recorded on the case report form as follows: 
R: for renal risk according to the definition 
I: for renal injury 
F: for renal failure 
L: for renal loss, and 
E: for End stage kidney disease 
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3. Screening 
 
1. You will consecutively enrol patients in the study. Beginning on the first day of data collection, 
record all patients discharged from ICU or who demised on or after that day in the screening log 
(Appendix II).  
2. Screening log columns represent eligibility criteria for purposes of data collection. Place a  in each 
column where a patient meets the eligibility criteria, or an  if the patient does not meet that 
criteria.  A research number should be allocated to each eligible patient and recorded on the 
screening log. Research numbers should be allocated consecutively from R1 to R72 as patients are 
entered into the study. Collect data on all patients who meet all eligibility criteria. If charts are 
missing and you are unable to collect all relevant data for a patient, please exclude this patient and 
include the next eligible patient. Screening should be continued until 72 consecutive eligible 
patients have been reached. 
 
Note: Consecutive means the very next patient that meets the criteria, instead of picking and choosing 
patients.  
3. Use additional pages of the screening log as necessary. 
4. Record each patient’s hospital number on the screening log. 
5. Each eligible patient’s research number (e.g. R1) will be recorded on the screening log. 
6. Please keep the screening log to help track down which patient corresponds to which research 
number in case there are data queries at a later date. 
Enrol all patients meeting the following eligibility criteria: 
Inclusion Exclusion 
 Adults (≥ 18 years of age) 
 Was admitted to the ICU of Universitas, 
Pelonomi, WDGMC and CHBAH 
 Was diagnosed with Sepsis (defined as 
suspected or proven infection plus SIRS, the 
presence of two or more of the following: 
 
 Temperature >38oC or <36oC, 
 Heart rate >90 bpm,  
 Respiratory rate > 20 bpm or PaCO2 <32 mmHg, 
and/or  
 White Blood count >12 000/mm3, <4000/mm3) 
 ARDS according to Berlin Definition (See 
Scoring Systems Table 4)Predicted to need 
Parenteral Nutrition for more than 5 days. 
 Patients < 18 years of age 
 On full Enteral Nutrition. 
 Pregnancy 
 Treatment with immunosuppressive drugs 
 Treatments with hydrocortisone > 300mg/day 
at admission. 
 Plasma Triglycerides >400mg/dl 
 Cirrhotic liver and/or acute hepatitis 
 Chronic renal failure and/or end stage renal 
disease (according to the RIFLE classification). 
 Recent stroke 
 Known allergic reaction to fish or egg proteins 
confirmed by previous medical history. 
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4. Case Report Forms 
 
 A case report form (CRF) (Appendix III) must be completed for each study participant. 
 All data requested in the CRF is to be taken retrospectively from the original source documents, i.e. 
the patient’s ICU chart/s or hospital file. 
 Collect data retrospectively from the day of ICU admission until day 6 of ICU stay, discontinuation of 
specialized nutritional support or death, whichever occurred first.  
 Please ensure that the CRFs of each patient are complete. 
 All data fields should be completed. 
o Please indicate if any given data is not charted on the patient’s records. 
o Asterisk (*) denote required fields. If required data is not charted on the patient’s records, 
exclude this patient and include the next eligible patient. 
 All dates must be recorded in the format YYYY-MM-DD. 
 All times must be recorded using the 24 hour (military) clock (HH:MM). Midnight will be 00:00 hr. 
 Anywhere in the CRF that “Other, specify” is indicated and/or has been selected, there must be an 
entry on the line provided further describing what “other” means. 
 Day 1 is the date of admission to the study, before Parenteral Nutrition is given. 
 Study days are defined according to ICU chart days (i.e. 07:00-06:59 hrs). Study days therefore 
begin and end at 07:00am. This will ease data collection.  
o Day 1 might not be a full 24 hour period. 
o The last day in the ICU might not be a full 24 hour period.  
 
a. Patient Information 
 
 
Sex* Place a  in the appropriate box (male or female) 
 
 
Age* Record patient’s age (year and months) 
 
ICU 
Admission 
Date/Time* 
Enter the date and time the patient was admitted to the ICU and tick which ICU and site  
Hospital Place a  in the appropriate box to specify which ICU the patient is admitted to. 
Type of 
admission* 
Place a  in only one of the following categories: 
 
Medical: defined as a patient admitted to the ICU for treatment without any surgical 
intervention (includes patients admitted from a cardiology/ radiology unit)  
Surgical: defined as (1) a patient admitted to the ICU from the operating room directly or a 
recovery unit following a planned surgical procedure or (2) a patient admitted to the ICU 
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from the operating room or a recovery unit following an unplanned surgical procedure.  
 
Note: If a surgical patient develops a medical complication and is transferred to the ICU 
from the ward, this would be a “medical” admission type. 
 
Primary ICU 
diagnosis 
Identify and write down the most pertinent diagnosis that resulted in the patient’s 
admission to ICU. Only one diagnosis can be chosen. Remember, symptoms are not an 
admission diagnosis (e.g. respiratory distress, hypotension, etc.) 
 
Example: A patient was admitted to hospital for gut shot abdomen. Post-operatively the 
patient developed sepsis and was subsequently admitted to the ICU. The patient would be 
classified as surgical admission type, and sepsis as the primary ICU diagnosis. 
 
APACHE II 
score* 
The APACHE II score must be calculated using Table 1 Appendix 1.  
 
Note: For each APACHE variable, use the single worst value out of all values from the first 
24 hours after ICU admission. If variables are not available from the first 24 hours, go 
outside the 24 hour window and use data closest to ICU admission.  
SOFA score The SOFA score must be calculated daily using Table 2 Appendix I 
RIFLE 
classification  
The RIFLE classification must be assessed daily using Table 3 Appendix 1  
 
b. Medical follow-up: 
 
Review study participants’ ICU charts and chart the following:   
 Medication/s 
 Other I.V Fluids 
 Tests/procedures 
 Monitoring parameters 
 Laboratory blood values 
 Arterial blood gas values 
 SOFA score 
 RIFLE classification 
 Fluid balance 
 Gastric aspirates 
 Vomiting 
 Stools 
 Clinical presentation 
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c. Baseline nutritional assessment 
  
Height* Record the patient’s height charted on his/her ICU chart. If there is no record, measure the 
patient’s height while lying flat in bed. 
Weight* Record the patient’s weight charted on his/her ICU chart. When applicable also record the 
adjustment of body weight for oedema or amputations (if charted).  
Body mass 
index (BMI) 
Calculate and indicate the patient’s BMI according to charted weight and height. 
Nutritional 
status 
Indicate the patient’s nutritional status according to the BMI classification system. 
Calculation 
of ideal body 
weight 
Ideal body weight must be calculated for all patients according to the following sex-specific 
guideline: 
 
 
Males: Height2 (m) X 20 – 25 
Females: Height2 (m) X 19 – 24 
 
 
Note: Use the height and weight recorded on the patient’s ICU chart/s. 
The “ideal body weight” does not necessarily refer to the weight used in the calculation of 
nutritional requirements. 
 
 
d. Daily Feeding Prescription 
 
Daily feeding prescriptions are routinely calculated by the Dietitian and or attending physician and charted 
for all ICU patients (charted daily on ICU charts). The daily feeding prescription will be calculated by using 
the method and formulas specified in Appendix IV. The Parenteral Nutrition (ITN 8807 or ITN 8007) will be 
ordered for each patient on the study and the administration rate will be adjusted according to the 
patient’s nutritional requirements. Review each study participant’s daily feeding prescription from the day 
of ICU admission until ICU discharge, discontinuation of specialized nutritional support or death, whichever 
occurred first. Use the patient’s daily feeding prescriptions (as charted on his/her ICU charts) to record the 
following information. Please indicate on the CRF if any particular information was not charted on the 
patient’s records. Remember Asterisk (*) denote required fields. If required data is not charted on the 
patient’s records, exclude this patient and include the next eligible patient. 
 
Person responsible 
for writing daily 
feeding prescription* 
Indicate the person who calculated/wrote the patient’s daily feeding prescription; 
e.g. registered dietician, attending registrar, consultant or chief physician of the 
ICU.  
Nutritional Support 
Initiation Date/Time* 
Enter the date/time PN was initiated in the ICU  
Calculation of 
nutritional 
requirements 
Calculate nutritional requirements according to the method specified in Appendix 
IV. Daily feeding prescriptions may change over time and should be indicated as 
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such.  
Prescribed energy 
intake* 
Enter the total kilocalories provided by the goal regimen (i.e. maximum 
rate/volume) for PN or EN/PN.  Note: If a patient received both EN and PN, please 
record the kilocalories from the combination prescription of EN and PN. If a patient 
received Propofol, enter the prescription before adjusting for Propofol. 
Prescribed protein 
intake* 
Enter the grams provided by the goal regimen (i.e. maximum rate/volume) for PN 
or EN/PN. ote: If a patient received both EN and PN, please record the protein from 
the combination prescription of EN and PN. 
 
e. Retrospective Progress Report 
 
Review the patient’s ICU charts and write down short and concise daily progress reports. 
 
5.  Daily Biochemical Data 
Use Appendix III to retrospectively record the daily biochemical data of each study participant, from ICU 
admission until discharge, discontinuation of specialized nutritional support or death, whichever occurred 
first. Retrospective review of ICU charts should be done on consecutive days following ICU admission. If a 
patient remained in ICU for more than 6 days data should only be collected until day 6 in ICU. Use 
additional pages of the flow chart as necessary.   
 
Routine blood samples will be taken on admission to ICU (Day 0), immediately prior to starting the PN 
(Study day 1). 24 hours after initiating PN (Day 2), 48 hours after initiating PN (Day 3) and five days after 
initiating PN (Day 6). (Study Day 1 is after ICU admission and inclusion into the study, prior to the 
administration of Parenteral Nutrition until 07:00am the next morning. This might be less than 24 hours. 
Day 2 and subsequent days are when the patient is receiving PN and labelled according to ICU chart days 
(i.e. 07:00am to 06:59am). This will ease data collection. 
 
Blood samples should be collected the same time each day via an arterial line. Use the specimen bags 
provided for each day for the routine bloods as well as special laboratory measurements, which will be 
kept in the patient file. 
Blood gases should be done daily at midday.  
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Person responsible 
for taking daily  
routine bloods 
Indicate the person who was responsible for taking routine blood samples e.g. 
nursing sister, attending registrar 
Person responsible 
for taking blood 
samples for 
additional laboratory 
measurements 
Indicate the person who was responsible for taking additional blood samples e.g. 
attending registrar, consultant 
 
Routine blood 
measurements 
Enter the values of the routine blood measurements, namely; PCT, FBC, U&E, 
Triglycerides, blood glucose and Liver function tests according to the laboratory 
results in the case report form. 
Additional blood 
measurements 
Enter the values of the additional blood measurements, namely; Plasma Cytokines, 
Plasma EPA, α-tocopherol and Leukotriene B5/LTB4 ratio taken on Study Day 1, 3 
and 6, in the case report form. These will only be tested at the end of the study. 
Daily blood gases Enter the values of the blood gases taken daily at midday on the case report form. 
Other Record any other blood tests done during the study period 
 
6.  Calculating patients nutritional requirements 
 
It is the dietitian or attending physician’s responsibility to calculate the patient’s nutritional requirements.  
 
The nutritional requirements need to be calculated for each study participant on a daily basis, according 
Appendix IV. 
 
The dietitian needs to enter all final calculations into the parenteral nutrition (PN) prescription form 
(Appendix V) and on the patient’s ICU chart. 
 
The PN prescription form needs to be discussed with the clinician and then signed by the dietitian and 
clinician. This form summarises all the patient’s requirements as well as the composition of the PN. 
 
7.  Quality Control Form 
 
The quality control form (Appendix VI) forms part of the quality control checks which is the study 
investigator’s responsibility.  
 
The research assistant needs to complete a copy of the form. This form should be kept separately from the 
screening and CRF. 
 
The pharmacists at Fresenius Kabi Bloemfontein and Johannesburg, also needs to complete a copy of the 
form. 
 
The information required on the quality control form is: 
 Patient’s research Number 
 Hospital name 
 ICU name 
 Patient’s name 
 Patient’s hospital number 
This form should be completed every time a new patient is entered into the study. 
Stellenbosch University  https://scholar.sun.ac.za
171 
 
8. Additional Laboratory Measurements request form 
 
The additional laboratory measurements request form (Appendix VII) will be a different colour to the 
normal laboratory request form. The form will include the patient’s details as well as the study’s name and 
ethics approval number. All details pertaining to the sample collection are included on the form. 
 
This form will be placed in a specimen bag with all the tubes needed for that particular day and will be 
placed in the patient’s file. 
 
Once the specimen has been taken, label the tube with the patient’s initial and surname and place it in the 
specimen bag.  
 
Complete the form (appendix VII) and place a  in the column to confirm which blood specimens have 
been taken.  
 
Place the form in the specimen bag. 
 
The research assistant at each site will be responsible for the additional laboratory measurement, making 
sure that the measurements are taken according to the study protocol.  
 
At Universitas Hospital she will take all the additional samples to the Haematology research laboratory for 
storage at -800C.  
 
The procedure for collecting additional laboratory measurements on the weekend will be as follows; once 
the samples have been taken, labelled and placed in the specimen bag, they need to be taken to the NHLS 
depot on the 4th floor, where the samples will be centrifuged and stored at -200C. These samples will then 
be collected on the Monday by a staff member and taken to the Haematology research laboratory where 
they will be stored at -800C.  
 
The blood sample taken for the α-tocopherol test needs to be covered in foild before it is frozen at -200C 
and will be stored at the Haematology department until the study is completed. 
At Pelonomi Hospital, the research assistant will then take the specimens to the NHLS laboratory at 
Pelonomi for centrifuging and storage at 40C. These samples will be collected by a courier and taken 
directly to the Haematology research laboratory for storage at -800C. On the weekend the samples will be 
kept at Pelonomi and collected by the courier on Monday morning for delivery to the Haematology 
research laboratory. 
 
At WDGMC, the special laboratory samples will be sent to BARC SA Laboratories to be centrifuged and 
stored at -800C.  
At CHBAH, the special laboratory samples will be taken by the consultant and centrifuged in the ICU by a 
technician, placed in 4, 1.5ml storage tubes and sent to the Robert Lipschitz Research Laboratory for 
storage at -800C . On weekends the samples will be centrifuged in the ICU and stored immediately in the 
freezer at -200C. On Monday morning, the specimens will be delivered to the Research laboratory for 
storage at -800C. 
 
The blood samples need to be centrifuged for 5 minutes at 4000rpm. 
The samples for the fatty acids (plasma EPA) and LTB5/LTB4 will be centrifuged and either taken to the 
Haematology research laboratory or the respective laboratories at each site where they will be stored at -
800C.  
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Appendix AI 
 
Scoring systems 
 
(part of data collection protocol)
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Table 1: The APACHE II Severity of Disease Classification System(1) 
Physiologic 
Variable 
High Abnormal Range                                                      Low Abnormal Range 
  +4 +3 +2 +1 0 +1 +2 +3 +4 Points 
Temperature - 
rectal (°C) 
>41° 39 to 
40.9° 
  38.5 to 
38.9° 
36 to 
38.4° 
34 to 
35.9° 
32 to 33.9° 30 to 
31.9° 
<29.9°   
Mean Arterial 
Pressure - mm 
Hg 
>160 130 
to 
159 
110 to 
129 
  70  109   50 to 69   <49   
Heart Rate 
(ventricular 
response) 
>180 140 
to 
179 
110 to 
139 
  70 to 
109 
  55 to 69 40 to 54 <39   
Respiratory Rate 
(non-ventilated 
or ventilated) 
>50 35 to 
49 
  25 to 
34 
12 to 
24 
10 to 11 6 to 9   <5   
Oxygenation: A-
aDO2 or PaO2 
(mm Hg) 
a. FIO2 >0.5 
record A-aDO2 
b. FIO2 <0.5 
record PaO2 
>500 350 
to 
499 
200 to 
349 
  <200 
  
  
   
PO2>70 
  
  
  
  
PO2 61 to 
70 
    
  
  
  
PO2 55 to 
60 
  
  
  
  
PO2<55 
  
Arterial pH 
(preferred)  
  
Serum HCO3 
(venous mEq/l) 
(not preferred, 
but may use if no 
ABGs) 
>7.7 
  
  
>52 
7.6 to 
7.69 
  
41 to 
51.9 
  7.5 to 
7.59 
  
32 to 
40.9 
7.33 to 
7.49 
 
22 to 
31.9 
  7.25 to 
7.32 
 
18 to 21.9 
7.15 to 
7.24 
 
15 to 
17.9 
<7.15 
 
<15 
  
Serum Sodium 
(mEq/l) 
>180 160 
to 
179 
155 to 
159 
150 to 
154 
130 to 
149 
  120 to 129 111 to 
119 
<110   
Serum Potassium 
(mEq/l) 
>7 6 to 
6.9 
  5.5 to 
5.9 
3.5 to 
5.4 
3 to 3.4 2.5 to 2.9   <2.5   
Serum Creatinine 
(mg/dl) 
Double point 
score for acute 
renal failure 
>3.5 2 to 
3.4 
1.5 to 
1.9 
  0.6 to 
1.4 
  <0.6       
Hematocrit (%) >60   50 to 
59.9 
46 to 
49.9 
30 to 
45.9 
  20 to 29.9   <20   
White Blood 
Count 
(total/mm3) 
(in 1000s) 
>40   20 to 
39.9 
15 to 
19.9 
3 to 
14.9 
  1 to 2.9   <1   
Glasgow Coma 
Score (GCS) 
Score = 15 
minus actual 
GCS 
                    
A. Total Acute Physiology Score (sum of 12 above points)   
B. Age points (years) <44=0; 45 to 54=2; 55 to 64=3; 65 to 74=5; >75=6   
C. Chronic Health Points (see below)   
Total APACHE II Score (add together the points from A+B+C)   
Chronic Health Points: If the patient has a history of severe organ system insufficiency or is immunocompromised as defined below, 
assign points as follows: 
5 points for nonoperative or emergency postoperative patients 
2 points for elective postoperative patients 
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Definitions: organ insufficiency or immunocompromised state must have been evident prior to this hospital admission and conform to 
the following criteria:  
 Liver – biopsy proven cirrhosis and documented portal hypertension; episodes of past upper GI bleeding attributed to portal 
hypertension; or prior episodes of hepatic failure/encephalopathy/coma.  
 Cardiovascular – New York Heart Association Class IV.  
 Respiratory – Chronic restrictive, obstructive, or vascular disease resulting in severe exercise restriction (i.e., unable to climb 
stairs or perform household duties; or documented chronic hypoxia, hypercapnia, secondary polycythemia, severe pulmonary 
hypertension (>40 mmHg), or respirator dependency.  
 Renal – receiving chronic dialysis.  
 Immunocompromised – the patient has received therapy that suppresses resistance to infection (e.g., immunosuppression, 
chemotherapy, radiation, long term or recent high dose steroids, or has a disease that is sufficiently advanced to suppress 
resistance to infection, e.g., leukemia, lymphoma, AIDS). 
Interpretation of Score: 
Score Death Rate (%) 
0-4 4 
5-9 8 
10-14 15 
15-19 25 
20-24 40 
25-29 55 
30-34 75 
>34 85 
 
 
 
 
 
Table 2: Sequential Organ Failure Assessment (SOFA) Score (2) 
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Table 3: RIFLE Classification (3) 
 
 
 GFR Criteria Urine Output Criteria 
Risk Increased SCreat X 1.5 or 
GFR decrease >25% 
UO<5ml/kg/hr X 6 hr 
Injury Increased SCreat X 2 or   
GFR decrease >50% 
UO<5ml/kg/hr X 12 hr 
Failure Increased SCreat X 3 or   
GFR decrease75% or        
SCreat ≥4mg/dl             
Acute rise ≥3.5mg/dl 
UO<3ml/kg/hr X 24 hr or 
Anuria X 12hrs 
Loss Persistent Acute renal failure = complete loss of kidney 
function > 4 weeks 
End stage kidney failure End Stage Kidney Disease (>3months) 
 
 
 
 
 
 
Table 4: ARDS Berlin Definition (4)  
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Appendix AII: 
 
Screening log 
 
(part of data collection protocol) 
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Case Report Form 
 
 
 
A. PATIENT INFORMATION 
 
Sex*:           Male               Female                                         Age* (year & months): __________________           
 
 
ICU Admission Date*: (YYYY-MM-DD):_______________  Time: (HH:MM, 24h): ___________________  
 
Hospital:   Universitas ICUs:  Multi               Surgical              Pelonomi ICU                 WDGMC             CHBAH  
 
Type of admission:              Medical                  Surgical 
 
Primary ICU diagnosis*:________________________________________________________________ 
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_________________________________________________________________ 
 
 
Other comorbidities or medical/nutritional problems: _______________________________________ 
_______________________________________________________________________________________________
___________________________________________________________________________ 
_____________________________________________________________________________________ 
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_______________________________________________________ 
 
Medical history: _______________________________________________________________________ 
 _____________________________________________________________________________________ 
_____________________________________________________________________________________ 
_______________________________________________________________________________________________
_______________________________________________________________________________________________
_________________________________________________________________ 
 
APACHE II SCORE:*____________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
MEDICAL FOLLOW-UP 
 
Medication 
Medication 
e.g. Propofol 
Dose Date 
       
         
         
         
         
         
         
         
         
         
Research number: e.g. R1 
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I.V Fluids administered                                                                                                Date 
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
Date Test/ 
Procedure 
Results 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Monitoring Parameters                                                                                                 Date 
Parameter Normal range        
Blood Pressure         
Temperature         
Heart rate         
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Laboratory blood values  
Parameter Normal range 
 
Date 
       
WCC 4.0 –10X109/L        
Hb 12.0 – 15.0g/dL        
Plt 178-40X109/L        
CRP <10        
PCT <0.5        
Na 135- 145        
K 3.3 – 5.3        
Cl 99 – 113        
CO2 18 – 29        
Urea 2.6 – 7.0        
Creat 60 – 100        
GFR         
Ca 2.05 – 2.56        
Mg 0.65 – 1.1        
P 0.8 – 1.4        
Glucose 3 – 10mmol/L        
Triglycerides         
ALT         
AST         
TNF-α         
IL-1β         
IL-6         
IL-10         
Plasma EPA levels         
LTB5/LTB4 ratio         
Alpha tocopherol         
         
         
         
         
         
         
         
         
 
 
        
Arterial blood gas                                                                                                   Date 
 
pH 7.35 – 7.45        
pCO2 35-45 mm Hg        
pO2 80-100 mmHg         
HCO3 21-28 mEq/L        
BE -4 - +2        
O2 saturation 95% - 100%        
PaO2/FiO2 ratio         
Mean Airway Pressure cm H20        
         
SOFA Score 0        
RIFLE Classification         
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Other parameters 
Fluid 
balance 
Intake*         
Output*         
Balance*         
Gastric aspirates <200mL        
Stools <400mL        
Urine output         
Vomiting         
 
Clinical presentation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. BASELINE NUTRITIONAL ASSESSMENT 
 
 
Date recorded on ICU chart:____________________ (Day of ICU stay: ____) 
 
Height (metres):*____________                       Weight (kg):*_______________                 Actual 
 
                                                                                                                                                           Estimated 
 
 
 
Weight adjusted for oedema?*          Yes             No                Not charted 
 
If yes, indicate degree of oedema:              Mild   Moderate                      Severe              Not charted     
 
If yes, show calculations (if charted): 
_____________________________________________________________________________________________
_________________________________________________________________________ 
 
Dry weight: _________kg              Not charted 
 
 
 
 
Weight adjusted for amputations?*         Yes               No                    Not charted 
 
If yes, indicate body parts amputated: _________________________________            Not charted  
 
If yes, show calculations (if charted): 
_____________________________________________________________________________________________ 
_________________________________________________________________________ 
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Adjusted weight: _________kg              Not charted 
 
 
 
 
Body mass index:*______________kg/m2               Actual Wt    
 
                                                                                       Estimated Wt                                                                                       
 
Nutritional status* (tick the appropriate block): 
 
                                                                                                                                                                                                 
 
 
Calculation of ideal body weight: 
 
Males: Height2 (m) X 20 – 25 
 
Show calculations:______________________________________________________________________ 
 
Females: Height2 (m) X 19 - 24 
 
Show calculations:______________________________________________________________________    
 
                                                                                                                                    
 Undernourished Grade I 17 ≤ BMI < 18.5 
 Grade II 16 ≤ BMI < 17 
 Grade III  BMI < 16 
 Normal 18.5 ≤ BMI < 25 
 Overweight 25 ≤ BMI < 30 
 Obese Class I 30 ≤ BMI < 35  
 Class II 35 ≤ BMI < 40 
 Class III (Morbid obesity) BMI ≥ 40 
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D. NUTRITIONAL PRESCRIPTION 
Date Energy* 
 
PROT* 
 
CHO 
 
Lipid Feeding prescription 
 
Date: 
 
 
Day of ICU stay: 
_____________ 
 
Responsible 
person: 
_____________ 
 
 
   
 
 
 
 
 
 
 
Glucose 
oxidation: 
 
 
 
 
 
 
 
 
Max lipids: 
 
Volume/24hr*: 
________________ 
 
Rate/hr*: 
 
 
Prescribed energy 
intake (kcal/day):* 
________________ 
 
Prescribed protein 
intake (g/day):* 
________________ 
 
 
Date: 
 
 
Day of ICU stay: 
_____________ 
 
Reason for  
changing 
prescription: 
_____________ 
 
Responsible 
person: 
______________ 
   
 
 
 
 
 
 
 
Glucose 
oxidation: 
 
 
 
 
 
 
 
 
Max lipids: 
 
 
Volume/24hr*: 
_______________ 
 
Rate/hr*: 
 
 
Prescribed energy 
intake (kcal/day):* 
________________ 
 
Prescribed protein 
intake (g/day):* 
________________ 
 
 
Date: 
 
 
Day of ICU stay: 
_____________ 
 
Reason for  
changing 
prescription: 
_____________ 
 
Responsible 
person: 
______________ 
   
 
 
 
 
 
 
 
 
Glucose 
oxidation: 
 
 
 
 
 
 
 
 
 
Max lipids: 
 
 
Volume/24hr*: 
_______________ 
 
Rate/hr*: 
 
 
Prescribed energy 
intake (kcal/day):* 
________________ 
 
Prescribed protein 
intake (g/day):* 
________________ 
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Date: 
 
 
Day of ICU stay: 
_____________ 
 
Reason for  
changing 
prescription: 
_____________ 
 
 
 
Responsible 
person: 
______________ 
   
 
 
 
 
 
 
 
 
 
Glucose 
oxidation: 
 
 
 
 
 
 
 
 
 
 
Max lipids: 
 
 
Volume/24hr*: 
_______________ 
 
Rate/hr*: 
 
 
Prescribed energy 
intake (kcal/day):* 
________________ 
 
Prescribed protein 
intake (g/day):* 
________________ 
 
 
 
Date: 
 
 
Day of ICU stay: 
_____________ 
 
Reason for  
changing 
prescription: 
_____________ 
 
 
 
Responsible person: 
______________ 
   
 
 
 
 
 
 
 
 
 
Glucose 
oxidation: 
 
 
 
 
 
 
 
 
 
 
Max lipids: 
 
 
Volume/24hr*: 
_______________ 
 
Rate/hr*: 
 
 
Prescribed energy 
intake (kcal/day):* 
________________ 
 
Prescribed protein 
intake (g/day):* 
________________ 
 
 
 
 
Prescribed energy 
intake (kcal/day):* 
________________ 
 
Prescribed protein 
intake (g/day):* 
________________ 
 
E. PROGRESS REPORT 
 
Date Follow-up notes 
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Appendix AIV 
 
Calculation of Nutritional Requirements 
 
(part of data collection protocol) 
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Calculation of Nutritional requirements: 
 
It is very important that the dietitian follows the procedure below in calculating patient’s nutritional 
requirements to make sure that the same procedure is used on every patient. 
 
 
The following procedure should be followed to calculate the patient’s nutritional requirements: 
 
1. Record the patient’s actual or estimated weight according to the CRF (Appendix III) 
 
2. Record the calculated BMI for the patient. 
 
3. Use the table below as a guide to which body weight should be used for the calculations of  
 energy 
 
 
 
For Example 1: Patient R20 has a BMI of 22 and estimated body weight = 68kg.  
Use 68kg in all the calculations. 
 
Example 2: Patient R25 has a BMI of 29 and actual body weight = 82kg and height of 1.68m 
Use IBW based on BMI of 24.9 (upper range of normal) = 70 kg  
 
4.  To calculate energy, use the equation below. Only non-protein energy (NPE) is going to be used in 
the calculation  
 
The carbohydrate (CHO) and lipid requirements are then calculated from the NPE. Carbohydrates 
usually provided as 50 – 60% of the NPE and lipid, 40 – 50% NPE. 
 
When calculating your grams of CHO and lipid remember that 1g CHO provides 4kcal and 1g lipid 
provides 9kcal. 
 
Calculate the patient’s maximum glucose oxidation rate at 4-5mg/kg/min, as well as the initial rate 
at 2.5mg/kg/min. Make sure that your total amount of CHO does not exceed this limit. This will 
enable you to cross check your calculations and make sure that you do not overfeed the patient. 
 
Calculate the patient’s maximum lipid intake: 1-2g/kg/day. 
 
 
Weight 
 
Indication for use 
 
Actual BW 
 
Underweight  
(at risk of refeeding syndrome) 
 
 
 
(ActuaI BW + ideal BW based on a BMI 18.5 kg/m2) X 0.5 
 
Underweight  
(no risk of refeeding syndrome) 
 
 
Actual BW 
 
 
 
Normal weight 
 
 
Ideal BW based on a BMI of 24.9 (upper range of normal) 
 
Overweight 
 
 
(Actual BW – ideal BW based on a BMI of 24.9 kg/m2) X 0.25} + ideal BW 
 
Obese  
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Nutritional requirement Calculation Example 
Energy Requirements as 
NPE: 
 
25 – 30kcal/kg/day 
 
Example 1: Patient R20 BMI = 22 and  
estimated weight = 68kg  
NPE = (25 – 30) X 68 
        = 1700 – 2040 kcal/day 
 
Example 2: Patient R25, Use 70kg in calculations 
NPE: = (25 – 30) X 70 
         = 1750 – 2100kcal/day 
CHO Requirements 
(expressed as g/day) 
 
Maximum glucose oxidation 
rate 
 
Initial glucose oxidation rate 
 
 
 
 
 
 
 
50 – 60% NPE 
 
 
4-5mg/kg/min 
 
 
2.5mg/kg/min 
Example 1: Patient R20  
NPE = 1700 – 2040 kcal/day 
 
CHO req = 50-60% NPE 
                = 50% (1700-2040) – 60% (1700-2040) 
                = (850-1020) – 1020 – 1224) 
Divide by 4kcal to get grams CHO 
                = (850-1020)/4 – (1020 – 1224)/4 
                = 212 – 306g CHO 
 
Max Glucose oxidation rate: 4-5mg/kg/min 
= [(4 - 5) X 68 X 1440]/1000 
= 391 – 490g glucose 
 
Initial glucose oxidation rate: 2.5mg/kg/min 
= [2.5 X 68 X 1440]/1000 
= 288g 
 
 
Lipid Requirements 
(expressed as g/day) 
 
Maximum lipid intake  
40 – 50% NPE 
 
 
1 - 2g/kg/day 
Example 1: Patient R20  
NPE = 1700 – 2040 kcal/day 
 
Lipid req =40 -  50% NPE 
                = 40% (1700-2040) – 50% (1700-2040) 
                = (680 – 816) - (850-1020) 
Divide by 9kcal to get grams lipid 
                = (680 – 816)/9 - (850-1020)/9 
                = 75g – 113g 
 
Maximum lipid intake: 1-2g/kg/day 
= 68 – 136g/day 
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5. To calculate protein and nitrogen use the equation below. Remember protein requirements are 
always calculated using ideal body weight or actual body weight if the BMI = 19 – 24.9kg/m2 
 
Protein Requirements 
(expressed as g/day). 
Use 1.5 - 2g/kg/day Example 1: Patient R20  BMI = 22 
Estimated weight 68kg 
Protein req = 1.5 – 2g/68kg/day 
                      = 102 – 136g /day 
 
Example 2: Patient R25, BMI = 29  
                     actual body weight = 82kg 
IBW = Ht in m2 X 20 – 25 
         = (1.68)2 X 20 – 25 
         = 2.8224 X 20 – 25 
         = 56.5 – 70.56kg 
         = average 64kg 
Protein req = 1.5 – 2g/64kg/day 
                     = 96g – 128g/day 
 
 
Nitrogen Requirements 
(expressed in g/day) 
1g Nitrogen = 6.25g 
protein, therefore divide 
the protein requirements 
by 6.25 to get Nitrogen 
requirements 
Example 1: Patient R20 
Protein req = 102 – 136g /day 
Nitrogen req = (102 – 136)/6.25 
                        = 16.32 – 21.76gN 
 
Example 2: Patient R25 
Protein req = 96g – 128g/day 
Nitrogen req = (96 – 128)/6.25g 
                        = 15.36 – 20.48gN 
 
 
 
6. To calculate the fluid requirements, use the equation below. Fluid is always calculated on ideal 
body weight. Remember to take into consideration other I.V fluids that the patient is receiving. You 
must also consider any additional fluid losses, i.e fistula output or additional fluid requirements, i.e. 
raised temperature. Always consult with the attending physician in terms of the fluid availability for 
PN. 
 
Fluid requirements 
(expressed as 
ml/kg/hr) 
 
Add losses due to fever 
 
Take into account 
other losses,e.g.fistula 
output  
1.5ml/kgIBW/hr 
 
 
 
+ 2 – 2,5ml/kg/10C > 
370C 
Example 1: Patient R20  BMI = 22 
Estimated weight 68kg 
 
Fluid req: 1.5 X 68 
                = 102ml/hr 
                = 2448ml/day 
 
Example 2: Patient R25, BMI = 29  
IBW  = 56.5 – 70.56kg 
         = average 64kg 
Fluid reg: 1.5 X (64 – 70) 
               = 96 – 105ml/hr 
               = 2304 – 2520ml 
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7. The final step is to use the above calculations to determine the rate of the PN to be used in the 
study (ITN 8807 or ITN 8007). The composition of ITN 8807 and ITN 8007 is as follows: 
 
Contents of PN ITN 8807 ITN 8007 
Fluid 2390ml 2390ml 
Energy (NPE)* 1800kcal 1800kcal 
Carbohydrates 200g (45% of NPE) 200g (45% of NPE) 
Fat 100g (55% of NPE) 100g (55% of NPE) 
Nitrogen 16.8g 16.8g 
Glutamine 15g 15g 
Vitamins, minerals and 
trace elements 
RDA ** RDA** 
Osmolarity 981mOsm/l 978mOsm/l 
 
 Example 1: Nutritional Requirements for patient R20 
 
Nutritional Requirements Patient R20 requirements 100ml/hr  of ITN 8807/ITN 8007 
provides 
Energy 1700 - 2040 kcal  1800kcal 
CHO 212 – 306g 
Max glucose oxidation: 391 – 490g 
Initial glucose oxidation: 288g 
200g 
Lipid 75 – 113g 
Maximum lipid: 68 – 136g 
100g 
Protein 
Nitrogen 
102 – 136g 
16.32 – 21.76g 
 
16.8g 
Glutamine  15g 
Vitamin, minerals and trace 
elements 
RDA RDA 
Fluid 2448ml 2390 
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Appendix AV 
 
Parenteral Nutrition Prescription Form 
 
(part of data collection protocol) 
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Parenteral Nutrition Prescription form 
 
 
 
 
 
 
 
 
 
 
Nutritional 
Requirements 
Patient ITN 8807/ITN 8007 provides Determined rate of PN to 
meet patient’s 
requirements 
Energy  1800kcal  
CHO  200g  
Lipid  100g  
Nitrogen  16.8g  
Glutamine  15g  
Vitamin, minerals and 
trace elements 
 RDA  
Fluid  2390  
 
 
Additional comments ___________________________________________________________________: 
_____________________________________________________________________________________
_____________________________________________________________________________________
__________________________________________________________________________________ 
 
Signed by: ______________________     Date: ___________________ 
  Dietitian 
 
 
Signed by:_______________________     Date:____________________ 
  Clinician 
 
 
 
 
 
 
 
 
 
 
 
Hospital : 
Patient Hospital No. 
Ward : 
Research No. Patient Name 
Date: 
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Appendix AVI 
 
Quality Control Form 
 
(part of data collection protocol) 
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Quality Control Form 
 
 
Patient 
Research 
Number 
Hospital Name ICU Name Patient Name Patient Hospital Number 
R1         
R2         
R3         
R4         
R5         
R6         
R7         
R7         
R8         
R9         
R10         
R11         
R12         
R13         
R14         
R15         
R16     
R17     
R18     
R19     
R20     
R21     
R22     
R23     
R24     
R25     
R26     
R27     
R28     
R29     
R30     
R31     
R32     
R33     
R34     
R35     
R36     
R37     
R38     
R39     
R40     
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Patient 
Research 
Number 
Hospital Name ICU Name Patient Name Patient Hospital Number 
R41     
R42     
R43     
R44     
R45     
R46     
R47     
R48     
R49     
R50     
R51     
R52     
R53     
R54     
R55     
R56     
R57     
R58     
R59     
R60     
R61     
R62     
R63     
R64     
R65     
R66     
R67     
R68     
R69     
R70     
R71     
R72     
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Appendix AVII 
 
Additional Laboratory Measurements Request Form 
 
(part of data collection protocol) 
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Specialised Haemostasis 
Research Laboratory 
 
Please do not register at NHLS     WDGMC 
These are research samples 
 
Test request form 
Patient details / sticker                Ethics approval No  
 
Patient Name: 
 
 Clinical and project details: To 
investigate the effect of a fish oil 
containing parenteral lipid 
emulsion on inflammatory 
markers, gas exchange and 
clinical outcomes in septic 
patients 
Patient Research 
Number: 
 
 
 
Blood Sample Place a √ to confirm the 
sample has been taken 
TNF-α  
IL-1β  
IL-6  
IL-10  
EPA  
LTB5/LTB4 ratio  
 
 
1. Spin yellow top tubes for 5 minutes at 4000rpm 
2. Pour into 4  1,5ml Send-away tubes 
3. Paste a small number on every Send-away tube as well as on the form 
4. DO NOT REGISTER!! 
5. Put corresponding form with specimens immediately in a plastic bag into the basket provided in the  
    walk-in freezer at -200C 
6. These specimens will fetched  and taken to the BARC Laboratory 
 
Name of Study Leader /  
Research assistant 
Contact no: 
Date: 
Time: 
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Screening Information Leaflet and Consent Form 
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SCREENING INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT: 
To investigate the effect of a fish oil containing parenteral lipid emulsion on inflammatory 
markers, gas exchange and clinical outcomes in septic patients 
REFERENCE NUMBER:  M14111090 
PRINCIPAL INVESTIGATOR: Mrs Veronique Donoghue 
ADDRESS:   7 Third Avenue,  
Parktown North 
  Johannesburg  
CONTACT NUMBER: 0833864001 
Hello, my name is ____________. I am a research assistant helping out with a research project, 
which is part of a Masters degree in Human Nutrition at the University of Stellenbosch. This ICU is 
participating in the above research project.  This study aims to compare the difference between 
two fats (oils) as part of specialized feeding directly into the patient’s veins.  
Do you or your relative have any objection to me reviewing your ICU chart to determine if you fit 
the criteria to be involved in this study?             Yes              No 
If you are a suitable candidate, I will explain all the information about the study to you or your 
relative. Your participation or your relative’s participation, is entirely voluntary and you are free to 
decline to participate.  If you say no, this will not affect you negatively in any way whatsoever 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2016. 
 
 ...............................................................  ............................................................  
Signature of participant or relative Signature of witness 
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PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM FOR 
WDGMC 
 
TITLE OF THE RESEARCH PROJECT: 
To investigate the effect of a fish oil containing parenteral lipid emulsion on inflammatory 
markers, gas exchange and clinical outcomes in septic patients 
REFERENCE NUMBER:  M14111090 
PRINCIPAL INVESTIGATOR: Mrs Veronique Donoghue 
ADDRESS:   7 Third Avenue,  
Parktown North 
  Johannesburg  
CONTACT NUMBER: 0833864001 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study staff 
or doctor any questions about any part of this project that you do not fully understand.  It is very 
important that you are fully satisfied that you clearly understand what this research entails and 
how you could be involved.  Also, your participation is entirely voluntary and you are free to 
decline to participate.  If you say no, this will not affect you negatively in any way whatsoever.  You 
are also free to withdraw from the study at any point, even if you do agree to take part. 
This study is part of my Masters degree in Human Nutrition at the University of Stellenbosch. I am 
a registered dietitian with the BSc Dietetics and a Post Graduate Degree in Hospital Dietetics.  
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University, Free State University and  University of the Witwatersrand and will be conducted 
according to the ethical guidelines and principles of the International Declaration of Helsinki, South 
African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) Ethical 
Guidelines for Research. 
 
 
What is this research study all about? 
The study will be conducted in Intensive Care Unit (ICU) at Wits Donald Gordon Medical Centre in 
Johannesburg. 
A total of 66 participants will be recruited. 
This study aims to compare the difference between two fats (oils) as part of specialized feeding 
directly into the patient’s veins. This is called intravenous feeding. This specialized feeding is used 
in the intensive care when the patients are extremely ill, i.e. they are unable to eat and sometimes 
can’t breathe on their own (on a ventilator). This specialized feeding is used when the patient is 
unable to tolerate any other form of feeding and is used quite safely all over the country and the 
world. There has been some promising new information about providing intravenous fats that 
contain fish oil to intensive care patients, showing that they can reduce the risk of infection and 
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improve the patient’s outcome. This study will be comparing two types of intravenous fats and 
assessing the outcome. 
You have been asked to be part of this study because you are an adult (>18 yrs) male or female, 
who have been admitted to the ICU with infections (sepsis) and you are unable to eat on your own 
and will be given intravenous (parenteral) nutrition (PN) for more than 5 days.  
If you agree to participate in the study the following will happen: 
1. The research staff would need access to your ICU chart and records for your blood results 
and information regarding your treatment. 
2. Extra bloods would need to be taken from you on Day 1, 3 and 6 of the study. These bloods 
will be taken at the same time as the usual bloods needed for your treatment. 
3. You will be requested to read and complete the consent form.  
Once you have consented, you will be allocated a research number to make sure that all your 
records will be treated with strict confidentiality. Only then will the research assistant start 
collecting information about you. The dietitian will be consulted to do a nutritional assessment on 
you and will calculate your nutritional requirements to make sure you receive the correct nutrition. 
This nutrition will be administered directly into your veins according to the procedures in the 
hospital intensive care units. The randomization to decide which PN bag you will receive, will take 
place at the facility that dispenses the PN to the hospitals. 
You will be receiving a PN prescription either containing a soybean based oil (Intralipid ® ITN 
8007) or a fish oil-containing oil (SMOFlipid® ITN 8807). Both of these PN solutions are used 
regularly in the ICUs. By following the above procedure it is clear that there will be no deviation 
from usual standardized prescription techniques. The only exception being the specific PN bag 
that you will receive based on the fat composition thereof. 
 
The study period is 5 days on PN, after this period your treatment will continue, however the PN 
prescription will no longer be blinded. You will be monitored throughout the study period according 
to the study protocol as well as the ICU protocol. 
 
Why have you been invited to participate? 
You have been invited to participate in the study because you are over the age of 18 years. You 
have been admitted to the ICU at Wits Donald Gordon Medical Centre.  You have been diagnosed 
with sepsis, you are unable to eat on your own and you will require PN for more than 5 days.  
If you were unable to give consent initially to participate in the study, your closest relatives will be 
asked to give consent. Once you are able you will be asked again for your consent. If you then do 
not want to participate or you do not want your information to be used, all the documents will be 
destroyed immediately. The results of the study will be published. Feedback on the results and 
outcome of the study will be made available on request by yourself or your closest relative. 
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Will you benefit from taking part in this research? 
Taking part in the study will not provide any personal benefit to you whilst being in ICU, however it 
will provide more information on specialized intravenous fats as part of PN and future ICU patients 
requiring this nutritional support will benefit  from the knowledge gained. 
 
Are there any risks involved in your taking part in this research? 
There are minimal risks involved in participating in the study. All the products being used have 
been registered and have been available on the market and used successfully for a substantial 
amount of time. You will be monitored closely throughout your stay in the ICU. 
 
If you do not agree to take part, what alternatives do you have? 
If you do not agree to participate in the study, you will continue to receive treatment according to 
the ICU protocol. It will not affect your medical management in any way. 
 
Who will have access to your medical records? 
Your ICU doctor and staff will have access to all your records. However confidentiality is protected 
within the hospital at all times. In terms of the study, you will remain completely anonymous. A 
research number will be allocated to you at the beginning of the study. This number will be used 
on all the data collections sheets, by the research assistant. The primary investigator will receive 
all the forms with your  research number and no other personal details . The form linking your 
name to your research number will be kept in a locked cabinet at the respective hospitals with only 
one person having access to the key. 
 
What will happen in the unlikely event of some form of injury occurring as a direct result of 
your taking part in this research study? 
Throughout the study standard procedures will be used, to make sure that there are minimal 
errors. However, all patients participating in this study will be covered by an insurance policy. 
 
Will you be paid to take part in this study and are there any costs involved? 
 
No, you will not be paid to take part in the study, because you are already admitted to the ICU. 
With regard to the nutritional treatment (PN) there will be no costs involved for you, if you do take 
part. This study does not affect the rest of your usual management and thus you will still be 
responsible for the payment of that section as per usual. 
 
Is there anything else that you should know or do? 
 You can contact Dr Schleicher at telephone no. 011 726 7403 if you have any further 
queries or encounter any problems or Veronique Donoghue at 0833864001. 
 You can contact the Health Research Ethics Committee at 011 7171252 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
 You will receive a copy of this information and consent form for your own records. 
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research study entitled 
“To investigate the effect of a fish oil containing parenteral lipid emulsion on inflammatory markers, gas 
exchange and clinical outcomes in septic patients” 
I declare that: 
 
 I have read or have had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised to take 
part. 
 I may choose to leave the study at any time and will not be penalised or prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor or researcher feels it 
is in my best interests, or if I do not follow the study plan, as agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2016. 
 
 ...............................................................  ............................................................  
Signature of participant Signature of witness 
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Declaration by family member on behalf of participant (if applicable) 
 
By signing below, I …………………………………..…………. agree to let my family member 
(name)………………………………….. take part in a research study entitled “To investigate the effect of a 
fish oil containing parenteral lipid emulsion on inflammatory markers, gas exchange and clinical outcomes 
in septic patients”. 
I declare that: 
 
 I have read or have had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately answered. 
 I understand that letting my family member take part in this study is voluntary and I have not 
been pressurised to let them take part. 
 My family member may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 My family member may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in his/her best interests, or if he/she does not follow the study plan, as 
agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2016. 
 
 ...............................................................  ............................................................  
Signature of family member Signature of witness 
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Declaration by Clinical Head (if applicable) 
 
By signing below, I …………………………………..…………. agree to let the patient 
(name)……………………………………………………. take part in a research study entitled “To investigate 
the effect of a fish oil containing parenteral lipid emulsion on inflammatory markers, gas exchange and 
clinical outcomes in septic patients”. 
 
I declare that: 
 
 I have read the study protocol with the inclusion and exclusion criteria and agree that the patient 
is eligible to participate in the study. 
 I have had a chance to ask questions and all my questions have been adequately answered. 
 I understand that letting the patient take part in this study is voluntary and I have not been 
pressurised to let them take part. 
 The patient may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
 The patient may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in his/her best interests, or if he/she does not follow the study plan, as 
agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2016. 
 
 
 ...............................................................  ............................................................  
Signature of Clinical Head Signature of witness 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as discussed 
above 
 I did/did not use an interpreter.  (If an interpreter is used then the interpreter must sign the 
declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2016. 
 
 
 ...............................................................  ............................................................  
Signature of investigator Signature of witness 
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Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to explain the information 
in this document to (name of participant) ……………..…………………………….. using the 
language medium of Afrikaans/Sotho. 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....………2016 
 
 
 
 ...............................................................  ............................................................  
Signature of interpreter Signature of witness 
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PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM FOR 
RELATIVES WITH FAMILY AT WDGMC 
 
TITLE OF THE RESEARCH PROJECT: 
To investigate the effect of a fish oil containing parenteral lipid emulsion on inflammatory 
markers, gas exchange and clinical outcomes in septic patients 
REFERENCE NUMBER:  M14111090 
PRINCIPAL INVESTIGATOR: Mrs Veronique Donoghue 
ADDRESS:   7 Third Avenue,  
Parktown North 
  Johannesburg  
CONTACT NUMBER: 0833864001 
Your relative has being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please ask the study 
staff or doctor any questions about any part of this project that you do not fully understand.  It is 
very important that you are fully satisfied that you clearly understand what this research entails 
and how your relative could be involved.  Also, your relative’s participation is entirely voluntary 
and you are free to decline to participate, on behalf of your relative.  If you say no, this will not 
affect your relative negatively in any way whatsoever.  You are also free to withdraw your relative 
from the study at any point, even if you do agree for them to take part. 
This study is part of my Masters degree in Human Nutrition at the University of Stellenbosch. I am 
a registered dietitian with the BSc Dietetics and a Post Graduate Degree in Hospital Dietetics.  
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University, Free State University and University of the Witwatersrand and will be conducted 
according to the ethical guidelines and principles of the International Declaration of Helsinki, South 
African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) Ethical 
Guidelines for Research. 
 
 
What is this research study all about? 
The study will be conducted in Intensive Care Unit (ICU) at Wits Donald Gordon Medical Centre in 
Johannesburg. 
A total of 66 participants will be recruited.  
This study aims to compare the difference between two fats (oils) as part of specialized feeding 
directly into the patient’s veins. This is called intravenous feeding. This specialized feeding is used 
in the intensive care when the patients are extremely ill, i.e. they are unable to eat and usually 
can’t breathe on their own (on a ventilator). This specialized feeding is used when the patient is 
unable to tolerate any other form of feeding and is used quite safely all over the country and the 
world. There has been some promising new information about providing intravenous fats that 
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contain fish oil to intensive care patients, showing that they can reduce the risk of infection and 
improve the patient’s outcome. This study will be comparing two types of intravenous fats and 
assessing the outcome. 
Your relative has been asked to be part of this study because they are an adult (>18 yrs) male or 
female, who has been admitted to the ICU with infections (sepsis) and is unable to eat on their 
own and will be given intravenous (parenteral) nutrition (PN) for more than 5 days.  
If you agree for your relative to participate in the study the following will happen: 
4. The research staff would need access to your relatives ICU chart and records for their 
blood results and information regarding their treatment. 
5. Extra bloods would need to be taken from your relative on Day 1, 3 and 6 of the study. 
These bloods will be taken at the same time as the usual bloods needed for their treatment. 
6. You will be requested to read and complete the consent form on behalf of your relative. 
Once you have consented, your relative will be allocated a research number to make sure that all 
their records will be treated with strict confidentiality. Only then will the research assistant start 
collecting information about your relative. The dietitian will be consulted to do a nutritional 
assessment on your relative and will calculate their nutritional requirements to make sure they 
receive the correct nutrition. This nutrition will be administered directly into your relative’s veins 
according to the procedures in the hospital intensive care units. The randomization to decide 
which PN bag your relative will receive, will take place at the facility that dispenses the PN to the 
hospitals. 
. 
Your relative will be receiving a PN prescription either containing a soybean based oil (Intralipid ® 
ITN 8007) or a fish oil-containing oil (SMOFlipid® ITN 8807). Both of these PN solutions are used 
regularly in the ICUs. By following the above procedure it is clear that there will be no deviation 
from usual standardized prescription techniques. The only exception being the specific PN bag 
that you will receive based on the fat composition thereof. 
The study period is 5 days on PN, after this period your relatives treatment will continue, however 
the PN prescription will no longer be blinded. Your relative will be monitored throughout the study 
period according to the study protocol as well as the ICU protocol. 
Why has your relative been invited to participate? 
Your relative has been invited to participate in the study because your relative is over the age of 
18 years. Your relative has been admitted to ICU at Wits Donald Gordon Medical Centre. They 
have been diagnosed with sepsis, are unable to eat on their own and will require PN for more than 
5 days. 
If your relative was unable to give consent initially to participate in the study, you will be asked to 
give consent. Once your relative is able they will be asked again for their consent. If your relative 
then does not want to participate or does not want their information to be used, all the documents 
will be destroyed immediately. The results of the study will be published. Feedback on the results 
and outcome of the study will be made available on request by yourself or your relative. 
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Will your relative benefit from taking part in this research? 
Taking part in the study will not provide any personal benefit to your relative whilst being in ICU, 
however it will provide more information on specialized intravenous fats as part of PN and future 
ICU patients requiring this nutritional support will benefit  from the knowledge gained. 
Are there any risks involved in your relative taking part in this research? 
There are minimal risks involved in participating in the study. All the products being used have 
been registered and have been available on the market and used successfully for a substantial 
amount of time. Your relative will be monitored closely throughout your stay in the ICU. 
If you do not agree to take part, what alternatives do you have? 
If you do not agree to let your relative participate in the study, they will continue to receive 
treatment according to the ICU protocol. It will not affect their medical management in any way. 
Who will have access to your relative’s medical records? 
Your ICU doctor and staff will have access to all your relative’s records. However confidentiality is 
protected within the hospital at all times. In terms of the study, your relative will remain completely 
anonymous. A research number will be allocated to them at the beginning of the study. This 
number will be used on all the data collections sheets, by the research assistant. The primary 
investigator will receive all the forms with your relative’s research number and no other personal 
details . The form linking your relatives name to their research number will be kept in a locked 
cabinet at the respective hospitals with only one person having access to the key. 
What will happen in the unlikely event of some form of injury occurring as a direct result of 
your relative taking part in this research study? 
Throughout the study standard procedures will be used, to make sure that there are minimal 
errors. However, all patients participating in this study will be covered by an insurance policy. 
 
Will your relative be paid to take part in this study and are there any costs involved? 
 
No, your relative will not be paid to take part in the study, because they are already admitted to the 
ICU. With regard to the nutritional treatment (PN) there will be no costs involved for your relative, if 
they do take part. This study does not affect the rest of your relative’s usual management and thus 
they will still be responsible for the payment of that section as per usual. 
 
Is there anything else that you should know or do? 
 You can contact Dr Dr Schleicher at telephone no. 011 726 7403 if you have any further 
queries or encounter any problems or Veronique Donoghue at 0833864001. 
 You can contact the Health Research Ethics Committee at 011 7171252 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
 You will receive a copy of this information and consent form for your own records. 
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Declaration by family member on behalf of participant (if applicable) 
 
By signing below, I …………………………………..…………. agree to let my family member (name)………………………………….. 
take part in a research study entitled “To investigate the effect of a fish oil containing parenteral lipid emulsion on 
inflammatory markers, gas exchange and clinical outcomes in septic patients”. 
I declare that: 
 
 I have read or have had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately answered. 
 I understand that letting my family member take part in this study is voluntary and I have not been 
pressurised to let them take part. 
 My family member may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
 My family member may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in his/her best interests, or if he/she does not follow the study plan, as agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2015. 
 
 ...............................................................  ............................................................  
Signature of family member Signature of witness 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as discussed above 
 I did/did not use an interpreter.  (If an interpreter is used then the interpreter must sign the declaration 
below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2015. 
 
 
 ...............................................................  ............................................................  
Signature of investigator Signature of witness 
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Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to explain the information in this document 
to (name of participant) ……………..…………………………….. using the language medium of Afrikaans/Sotho. 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed consent document and 
has had all his/her question satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....………2015 
 
 
 
 ...............................................................  ............................................................  
Signature of interpreter Signature of witness 
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Appendix C 
Sample size calculation 
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1-Way ANOVA: Sample Size Calculation 
1-Way ANOVA: Sample Size Calculation
1-Way ANOVA (Fixed Effects)
N vs. Power (RMSSE = 0.55, Groups = 2, Alpha = 0.05)
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Sample Size Calculation ([No active dataset]) 
Sample Size Calculation ([No active dataset])
ANOVA, 1-Way
Fixed Effects
Value
Number of Groups
RMSSE
Noncentrality Parameter (Delta)
Type I Error Rate (Alpha)
Power Goal
Actual Power for Required N
Required Sample Size (N)
2.0000
0.5500
3.0250
0.0500
0.9000
0.9022
36.0000
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Published Review article 
 
Stellenbosch University  https://scholar.sun.ac.za
222 
 
 
Stellenbosch University  https://scholar.sun.ac.za
223 
 
 
Stellenbosch University  https://scholar.sun.ac.za
224 
 
 
Stellenbosch University  https://scholar.sun.ac.za
225 
 
 
Stellenbosch University  https://scholar.sun.ac.za
226 
 
 
Stellenbosch University  https://scholar.sun.ac.za
227 
 
 
Stellenbosch University  https://scholar.sun.ac.za
228 
 
 
Stellenbosch University  https://scholar.sun.ac.za
229 
 
 
Stellenbosch University  https://scholar.sun.ac.za
230 
 
 
Stellenbosch University  https://scholar.sun.ac.za
231 
 
 
Stellenbosch University  https://scholar.sun.ac.za
232 
 
 
Stellenbosch University  https://scholar.sun.ac.za
233 
 
 
Stellenbosch University  https://scholar.sun.ac.za
234 
 
 
Stellenbosch University  https://scholar.sun.ac.za
